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Limiting RNA polymerase II (Pol II) at various stages of the transcription 
cycle is critical for gene regulation, which often occurs during the elongation stage at 
promoter proximal pause sites and in gene bodies. To determine the distribution of Pol 
II along genes, I used nascent transcript analysis as a general method. First, I identified 
the precise positions of Pol II pausing near promoters using a genome-wide nuclear 
run-on, called Precision Run-On sequencing (PRO-seq) in Drosophila embryonic 
cells. Using this, I revealed how the position of pausing is associated with initiation 
and promoter DNA elements. To further dissect the precise dynamics of paused Pol II, 
I probed the stability of paused Pol II and its termination by analyzing steady-state 
turn-over of the nascent transcript associated with Drosophila Hsp70 promoter. This 
shows that paused Pol II on Hsp70 is stable for around 5 min and can either terminate 
or elongate into the gene body, which is consistent with optical measurements of 
paused Pol II. I also examined how Pol II elongates during the time course of rapid 
and robust inhibition of pause escape in mouse embryonic stem cells. The analysis of 
the elongation rates in nearly 1,000 genes showed tight interplay between promoter 
proximal pausing, early elongation rates, and co-transcriptional splicing at the 
beginning of the genes. Finally, I demonstrate that the nascent transcriptome analysis 
methods can be directly extended into mammalian tissues, and show possibility of 
linking the study of the fundamental mechanism of Pol II into biomedical applications.
 iii 
 
BIOGRAPHICAL SKETCH 
 
Hojoong Kwak was born in a middle class family in Seoul, Korea. He was a 
curious young boy who liked to play sports outside. As he grew up, he showed interest 
in science and mathematics, and went to the Seoul Science High School, where he met 
more of his kind who shared their visions as future scientists. He was particularly 
interested in physics, and even won a gold medal in International Physics Olympiad 
for the first time from Korea, but still too young to commit himself as a scientist. 
Instead he went to the medical school. 
During the medical school, he started to realize that he still wanted to do 
something more than a clinical practice. After graduating from the medical school, he 
spent a year in a hospital for intern training, during the time when he met Yoona Lee, 
a beautiful wise young woman who did not discourage him from pursuing science. 
He then went to do a master’s degree in the biochemistry department of the medical 
school in Seoul National University, finish the military service at Korea Food and 
Drug Administration, and applied for a graduate school in the U. S. and was finally 
admitted to Cornell University. 
At Cornell, he met Dr. John Lis, a passionate scientist who is a pioneer of the 
transcription field. Hojoong still remembers the first day when he met John 
enthusiastically explaining the newest GRO-seq data one by one. He eventually joined 
the Lis Lab, and started his early scientific career learning the cutting edge 
technologies, and developing solid background in molecular biology. He believes his 
graduate study at the Lis lab has been very successful, and looks forward to his next 
steps. 
 iv 
 
ACKNOWLEDGMENTS 
 
First of all, I would like to thank John, my advisor for his mentorship during 
my graduate study. He is a great teacher, and a role model as a scientist to me. He is 
also a wonderful person, always enthusiastic and optimistic about everything, caring 
for everyone. Having him as my teacher was the luckiest thing and really changed my 
life. I also thank my committee members, Dr. Roberts and Dr. Pleiss, for their advices 
and supports. 
Members of the Lis lab have been the greatest supporters throughout my stay 
in Cornell in every aspect. I thank Martin and Iris for sharing their data and allowing 
me to take a role in their fantastic projects. Nick was always there when someone 
needed his help. Most of all, I thank Leighton Core, who first mentored me during the 
rotation and guided me all throughout my graduate study. 
Finally, I thank my family, my parents and especially my wife Yoona, and our 
princess Enhu Claire for their patience, trust, and everlasting love. 
 v 
 
TABLE OF CONTENTS 
 
 
Biographical Sketch         iii 
 
Acknowledgments         iv 
 
Table of Contents         v 
 
List of Figures          viii 
 
List of Tables          x 
 
 
Chapter 1. Introduction : Control of Transcriptional Elongation   1 
 
Summary         1 
 
Introduction         1 
 
Identification of the Regulatory Step During Early Elongation  3 
 
Mechanisms of Promoter Proximal Pausing     11 
 
Escape Into Productive Elongation      17 
 
Elongation Through the Nucleosome and Gene Body   23 
 
Conclusion         30 
 
References         31 
 
 
Chapter 2. Precise Maps of RNA Polymerase Reveal How Promoters Direct 46 
 Initiation And Pausing        
 
Summary         46 
 
Introduction         46 
 
Development of PRO-seq and Validation of the Pausing Sites  47 
 
Pausing Sites Are Not Fixed, but Linked to Initiation Sites   52 
 
Promoter DNA Elements Shape the Pausing Pattern    56 
 
Testing the Positional Association of the DNA Elements in Hsp70  59 
 vi 
 
Conclusion         62 
 
Materials and Methods       63 
 
References         75 
 
 
Chapter 3. RNA Polymerase II Pausing and Termination Kinetics at the  78 
Drosophila Hsp70 Promoter In Vivo       
 
Summary         78 
 
Optical Measurement of Pol II Stability in Hsp70    79 
 
Biochemical Measurement of Pol II Stability by Nascent RNA  83 
Fractionation 
 
Both Pause Escape and Termination Can Be Optically Measured  87 
Separately. 
 
Conclusion         89 
 
Materials and Methods       89 
 
References         96 
 
 
Chapter 4. Genome-Wide Transcription Dynamics Reveal the Interplay of 99 
Pausing and Elongation Rates On Pre-mRNA Splicing 
 
Summary         99 
 
Introduction         100 
 
Generation of GRO-seq Libraries Treated with transcription inhibitors 102 
 
P-TEFb Dependent Escape from the Pause Occurs at All Active TSSs 106 
 
Measurement of the Elongation Rates and the Acceleration of Elongating 110 
Pol II in the Gene Body 
 
Modeling Acceleration of Pol II in the Gene Body    116 
 
Correlations between elongation rates and transcription factors, histone 117 
marks and modifiers 
 
Elongation Rates and Splicing      121 
 vii 
 
Pausing Increases Splicing Efficiency     125 
 
Discussion         126 
 
Material and methods        130 
 
References         145 
 
 
Chapter 5. Analysis of Organ Specific Nascent Transcriptome from Solid  151 
Tissues 
 
Summary         151 
 
Introduction         151 
 
The Chromatin Run-On Method      153 
 
Analysis of the Tissue Specific Nascent Transcriptome Data  157 
 
Discussion         160 
 
Materials and Methods       163 
 
References         166 
 
 
Chapter 6. Conclusion        168 
 
An integrative model of Pol II elongation     168 
 
Perspective         170 
 
References         171 
 
 
 
 viii 
 
LIST OF FIGURES 
 
 
Figure 1.1. Structure of the promoter and Pol II before and during early  9 
elongation 
 
Figure 1.2. Models of promoter proximal Pol II pausing    12 
 
Figure 1.3. Productive transcription elongation complex    20 
 
Figure 1.4. Pol II transcribing through gene body nucleosomes   24 
 
Figure 2.1. Accumulation of Pol II at promoters, 3’ ends, 3’ splice sites, and 48 
nucleosomes. 
 
 
Figure 2.2. PRO-seq compared with other genome-wide transcription assays 51 
 
Figure 2.3. Comparison of the PRO-seq , PRO-cap, and permanganate footprint 52 
average profiles in selected genes and their individual profiles. 
 
Figure 2.4. Variations of the pause sites and TSSs     53 
 
Figure 2.5. PRO-seq relative to nucleosomes     55 
 
Figure 2.6. DNA elements in different pausing subsets    57 
 
Figure 2.7. Relationship between promoter DNA elements and Pol II pausing 58 
 
Figure 2.8. Association between the strength or the position of promoter DNA 60 
elements and Pol II pausing or initiation 
 
Figure 2.9. Disruption in the position of downstream DNA elements in Hsp70 61 
promoter 
 
 
Figure 3.1. Schematics of Pol II kinetics at the pause site    80 
 
Figure 3.2. Imaging the stability of paused Pol II at uninduced Hsp70 transgene 81 
in living cells. 
 
Figure 3.3. Biochemical analysis of steady state paused Pol II kinetics  84 
 
Figure 3.4. Estimation of the rate constant of elongation (kel) from pausing 85 
 
Figure 3.5. Optical measurement of the termination rate of paused Pol II  88 
 ix 
 
at Hsp70 transgene in living cells. 
 
Figure 3.7. Half life estimation after background correction of FDAP  93 
 
Figure 4.1. GRO-seq time-course after Flavopiridol and Tripolide treatment 103 
 
Figure 4.2. Heatmap density plot of Flavopiridol and Triptolide treatments 107 
near promoters 
 
Figure 4.3.  Analysis of the effects of Flavopiridol and Triptolide near promoters  108 
 
Figure 4.4. Genome-wide analysis of the elongation rates    111 
 
Figure 4.5. Validation of the elongation rate analysis    112 
 
Figure 4.6. Two alternative hypotheses for the apparent increase in elongation 114 
rate. 
 
Figure 4.7. Modeling of the acceleration and the termination hypotheses  115 
 
Figure 4.8. Analysis of the chromatin marks or factors and the elongation rates 118 
 
Figure 4.9. Association between the elongation rate and the chromatin landscape 119 
at the first intron. 
 
Figure 4.10. Linkage between pausing, elongation rates and exon counts or 122 
splicing efficiencies. 
 
Figure 4.11. Characteristics of the splicing sites and introns/exons associated 123 
with elongation rates. 
 
 
Figure 5.1. Scheme of the Chromatin Run-On method    153 
 
Figure 5.2. Correlation between the ChRO-seq libraries    154 
 
Figure 5.3. Examples of differential ChRO-seq profiles on selected genomic 156 
positions 
 
Figure 5.4. Gene ontology analysis based on the expression levels   157 
 
Figure 5.5. Scheme of the de-novo transcription unit calling using HMM  158 
 
Figure 5.6. Identification of tissue specific re-annotated de-novo transcription 159 
units 
 
Figure 5.7. Identification of an un-annotated de-novo transcription unit  161 
 x 
 
LIST OF TABLES 
 
 
Table 1.1. A growing list of the factors participating in transcriptional elongation 4 
 
 
Table 2.1. 3’ end uniformity in PRO-seq sequence reads.    49 
 
Table 2.2. Enrichment of Dist pausing group among constitutive genes.  63 
 
 
Table 3.1. Rate constants for the kinetics of promoter proximal Pol II  87 
 
Table 3.2. DNA and RNA sequences for nascent RNA fractionation.  95 
 
 
Table 4.1. Sequencing statistics report of Flavopiridol and Triptolide treated 104 
time-course. 
 
Table 4.2. Number of genes with significant changes in Flavopiridol and  110 
Triptolide GRO-seq profiles 
 
 
Table 5.1. Sequencing and alignment statistics for ChRO-seq in mouse tissues 154 
 
 
1 
 
CHAPTER 1a 
 
INTRODUCTION : CONTROL OF TRANSCRIPTIONAL ELONGATION 
Summary 
Elongation is becoming increasingly recognized as a critically controlled step 
in transcriptional regulation. While traditional genetic and biochemical studies have 
identified major players of transcriptional elongation, our understanding of the 
importance and roles of these factors is evolving rapidly through the recent advances 
in genome-wide and single-molecule technologies. Here we focus on how elongation 
can modulate the transcriptional outcome through the rate-liming step of RNA 
polymerase II pausing near promoters, and how the participating factors were 
identified.  Among the factors we describe are NELF and DSIF, the pausing factors, 
and P-TEFb, the key player in pause release.  We also describe non-exclusive models 
for how pausing is achieved by making use of high resolution genome-wide mapping 
of paused Pol II relative to promoter elements and the first nucleosome. We also 
discuss Pol II elongation through the bodies of genes and the roles of FACT and Spt6, 
the factors that allow Pol II to move through nucleosomes.  
 
Introduction 
Advances in genome-wide, high-throughput technology have taken our 
analysis of transcriptional elongation into a new era. The distribution of RNA 
polymerases and their regulatory or auxiliary factors are being examined on all genes 
under steady-state cellular conditions or in response to regulatory signals and 
systematic perturbations. Computational analyses of these massive data sets along 
                                                
a This chapter has been submitted to and is in press at Annual Review of Genetics, Volume 47 
© Annual Reviews, http://www.annualreviews.org. 
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with more traditional genetic and biochemical analyses are transforming our 
understanding of transcription and its control. With all these advances, transcriptional 
elongation is becoming more widely recognized as a significant step in gene 
regulation. In this review, we describe and connect the ideas from traditional studies 
with results from newer methodologies, and we provide high-resolution models of 
how transcription is controlled at elongation. 
 We begin by illustrating one classic example of how traditional genetics have 
contributed to the study of transcriptional elongation. In early 80’s, Winston and 
colleagues selected genes that are critical for the transcription of a retrotransposon 
element called Ty in yeast1,2. These Suppressor of Ty (Spt) genes turned out to be 
essential elements in Pol II transcription in general. In particular, a group of Spt genes 
characterized by genetic complementation patterns later turned out as genuine 
elongation factors acting directly on elongating Pol II using biochemical analyses2. 
Through this convergence between genetics and biochemistry, some of the key players 
of elongation have been identified, and are currently being extensively studied using 
the newest methods such as genome-wide or single-molecule technologies. 
To further discuss the control mechanisms of transcriptional elongation in 
depth, we divided the stages of elongation into two parts, ‘early elongation’ and 
‘productive elongation’. After initiation, Pol II starts the iterative incorporation of 
nucleotides at its 3’ end to extend the nascent RNA. This elongation by Pol II is not 
uniform throughout the gene. During the early elongation stage, Pol II first transcribes 
the initial 20~60 nucleotides (nt) of RNA and pauses3.  Progressing beyond this point 
is rate-limiting for approximately half of all active Drosophila and mammalian genes, 
and the escape beyond the pause into productive elongation is often regulated. 
 Once Pol II makes the transition from the paused state into productive 
elongation, it then progresses through the body of the gene. In the gene body, Pol II 
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still faces other barriers and requires additional elongation factors to overcome them4. 
Finally, Pol II transcribes through the 3’ end of the gene, where nascent RNA cleavage 
and poly-adenylation defines the end of the mRNA transcript. The termination of a 
transcribing Pol II takes place on average 8 kb downstream of the 3’ end of the gene in 
human cells5. This 3’ end processing of the nascent RNA and Pol II termination can 
add extra dimensions to the co-transcriptional and post-transcriptional6. 
 In this review, we will focus on the distinct stages of early elongation and the 
productive elongation and discuss the factors and their control mechanisms (Table 1.1).  
Other recent reviews deal with complementary aspects of transcription elongation 
control including the functions of promoter-proximal pausing, conflicts between 
transcription and DNA replication, and co-transcriptional RNA processing. 
 
Identification of the Regulatory Step During Early Elongation 
Early elongation can be defined as the transition of Pol II between promoter 
escape and fully productive elongation, and is often accompanied by an intermediate 
step of promoter proximal pausing4. This transition of initiated Pol II to paused occurs 
as nascent RNA with a length from ~10 nucleotides (nt) is extended to 20-60 nt, as 
measured most precisely in Drosophila3,7,8, and the bulk of this paused Pol II in 
mammalian genes occurs in a similar position9. When the RNA chain is less than 10 nt 
long, Pol II is still considered to be within the initiation stage; it is associated with 
TFIIB and can terminate prematurely (abortive initiation), which may provide 
checkpoints for promoter control10. Once the RNA grows longer than 12 nt and TFIIB 
is displaced, the Pol II elongation complex is stably engaged11 and is now in the early 
elongation stage. Early elongation is not a simple smooth transition of Pol II but 
involves critical regulatory steps as observed in a plethora of evidence from the 
earliest to most recent studies. 
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Table 1.1. A growing list of the factors participating in transcriptional elongation 
 
Factor Function Related factors and notes 
GAGA-factor Generate nucleosome free region12 and promoter 
structure for pausing13 
NURF14 
GTFs TFIID  Generate promoter structure for pausing13  
TFIIF Increase elongation rate15,16 Near promoters17 
TFIIS Rescue backtracked Pol II15,18 Pol III19 
Pausing factors NELF Stabilize Pol II pausing20,21  
DSIF Stabilize Pol II pausing22/ facilitate elongation23,24  
P-TEFb Phosphorylates NELF25 , DSIF26, Pol II CTD27 for 
pause release 
 
Processivity 
factors 
Elongin Increase elongation rate28  
ELL Increase elongation rate29 AFF430  
SEC Contains P-TEFb and ELL30 Mediator31, PAF32 
Activator c-Myc  Can directly recruit P-TEFb33  
NF-κB Can directly recruit P-TEFb34  
Coactivator Brd4 Recruits P-TEFb35,36  
Mediator Recruits P-TEFb via SEC31  
Capping 
machinery 
CE Facilitates P-TEFb recruitment37, counters 
NELF/DSIF38 
 
RNMT a Methylates RNA 5’ end to complete capping Myc39 
Premature 
termination factors 
Dcp2  De-caps nascent RNA for Xrn2 digestion40 Dcp1a / Edc3 40 
Microprocessor Cleaves hairpin structure for Xrn2 digestion41 Tat, Senx 
Xrn2 ‘Torpedo’s Pol II with RNA 5’-3’ exonucleation40,41  
TTF2 Release Pol II from DNA40,41  
Gdown1 Anti-termination and stabilize paused Pol II42-44 TFIIF44, Mediator42 
Histone chaperone FACT H2A/H2B eviction and chaperon45,46 Tracks with Pol II47 
Nap1 a H2A/H2B chaperon48 RSC49, CHD50 
Spt6 H3/H4 chaperon51 Tracks with Pol II47 
Asf1 a H3/H4 chaperon52 H3K56ac53 
Chromatin 
remodeler 
RSC a SWI/SNF remodeling in gene body54 H3K14ac55  
Chd1 a Maintain gene body nucleosome organization56 FACT, DSIF50 
NURF ISWI remodeling at promoter14 GAGA factor12 
PARP Transcription independent nucleosome loss57 Tip6058 
PAF complex Loading dock for elongation factors59 SEC32, FACT60 
Histone tail 
modifiers 
MOF H4K16ac, recruit Brd461 H3S10ph, 14-3-361 
Tip60 H2AK5ac, activate PARP58  
Elongator a Acetylates H3, facilitate nucleosomal elongation62 Also in cytoplasm62 
Rpd3C (Eaf3) a Deacetylates and inhibit spurious initiation in gene 
body63 
H3K36me363 
Set1 a H3K4me364,65 MLL/ COMPASS 
Set2 a H3K36me366, regulate acetylation-deacetylation 
cycle63 
Rpd3C63 
PIM1 H3S10ph, recruit 14-3-3 and MOF67  
RNF20/40 H2BK123ub1, facilitate nucleosomal DNA 
unwrapping60 
UbcH6, PAF 
a Not covered in the main text
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Evidence suggesting a mode of transcription regulation in eukaryotes occurs early 
after initiation 
Peaks of paused Pol II on proximal promoters. Studies of transcription regulation have 
for decades focused primarily on how regulatory signals and key transcription factors 
act at the level of the recruitment of Pol II to promoters or the initiation step of 
transcription68. This model gained strong support for all genes that were closely 
examined in S. cerevisiae.  Activation of transcription generally produced a 
recruitment of general transcription factors (GTFs) and Pol II to promoters, and the 
recruited Pol II then began transcribing and produced full gene-length transcripts and a 
relatively even distribution of Pol II across each gene69.   
 One set of observations that seemed at least partially at odds with all 
transcription being controlled at initiation was that genes in chicken70, Drosophila heat 
shock genes3,71  and human c-Myc and c-Fos72-74, appeared to have much higher levels 
(peaks) of Pol II near their promoters - at levels that dwarf that on gene bodies. 
Moreover, this promoter-proximal Pol II was transcriptionally engaged, that is, it had 
already initiated transcription and had progressed beyond the point of known abortive 
initiation.  These Pol II molecules were also shown to associate with melted DNA 
found in elongation complexes75 and could elongate efficiently in nuclear run-on 
reactions if inhibitory factors were removed by high salt or sarkosyl treatments (both 
of which block new initiation)76.  These results indicated that a ‘paused’ Pol II 
elongation complex can accumulate to high levels at least on some genes without 
efficiently entering into productive elongation. 
 Whereas promoter-proximal pausing of Pol II was first characterized in a 
handful of genes, it turns out to be a general mechanism for other genes across species. 
Pol II ChIP experiments using genome-wide methods77-79 and GRO-seq5,9,80 have 
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shown that Pol II pausing is widespread near promoters. Furthermore, similar to 
Hsp70, other genes in Drosophila are sensitive to nuclear run-on with sarkosyl 
treatment, indicating that the promoter proximal Pol II in other genes are also 
physically tethered at the paused state by inhibitory factors81.  
 Genes that have paused Pol II are also highly regulated and the escape of Pol II 
from the pause into productive elongation can be activated in the cases of heat shock 
genes by stress and in c-Myc by serum stimulation4. Thus, regulation of these genes 
was not solely at Pol II recruitment or initiation, but rather, a main component 
appeared to be at the escape of the paused Pol II into productive elongation. 
  
In vitro transcription systems needed pausing factors and a kinase to recapitulate full 
regulation seen in metazoans in vivo. The early in vitro transcription systems derived 
from human whole nuclear extracts were shown to initiate properly and elongate on 
model DNA templates.  All that seemed to be required to produce transcripts was the 
recruitment of GTFs and Pol II to promoters.  Therefore, reconstituted systems 
composed of GTFs and Pol II were used, and many regulatory transcription factors 
were shown to facilitate the production of transcripts indicating a mode of regulation 
at the level of recruitment of GTFs and Pol II82. 
 Interestingly, these early reconstituted transcription systems were insensitive to 
an inhibitor of transcription in mammalian cells, DRB22.  DRB is a kinase inhibitor, 
and was postulated to act at the elongation stage to reduce the production of full length 
transcripts83. The search for factors that make a transcription system responsive to 
DRB inhibition led to the discovery and characterization of protein complexes that act 
to stabilize paused Pol II and a kinase that overcame this rate limiting pausing by 
phosphorylating the pausing complexes20,22,84 
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 Wada et al. purified a complex from HeLa nuclei that conferred DRB 
sensitivity to the human in vitro transcription system22. This complex, DSIF, consists 
of two subunits, and remarkably, they were the homologs of yeast Spt4 and Spt5 genes 
identified from the early genetic studies by Winston and colleagues22.  
 Studies by Price and colleagues helped clarify the mechanism by which DSIF 
inhibits elongation. Results from Drosophila nuclear extract suggested that Pol II is 
tightly associated with negative transcription elongation factor (N-TEF), and a positive 
transcription elongation factor (P-TEF) relieves the effect of N- TEF85. A series of 
biochemical complementation analyses showed that DRB inhibits P-TEF, and that N-
TEF is epistatic to P-TEF inhibition84,85. Therefore, it was concluded that DSIF plays 
the role of N-TEF.  However, in the presence of recombinant DSIF alone, 
transcription was not fully sensitive to DRB inhibition. Handa and colleagues purified 
an additional N-TEF protein factor that conferred complete DRB sensitivity and was 
named NELF20. NELF is a multiprotein complex composed of four subunits - A, B, C 
or D, and E21 - and has been shown to physically interact with DSIF and Pol II20. 
 In summary, the discovery of Pol II pausing near promoters and identifying 
several pausing factors that are essential for full regulation of transcription has 
revealed another critical layer of transcription control that occurs during early 
elongation. 
 
Sequence of events leading to promoter proximal pausing 
Follow-up on these pioneering studies revealed many factors and promoter features 
that are part of early elongation control. Additionally, the mechanisms of early 
elongation were found to be connected both temporally and spatially to that of 
initiation and the promoter structure. 
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 The promoter is a dynamic structure that can direct transcription initiation and 
pausing. In Drosophila, promoter DNA sequences by themselves often have a 
tendency to position a nucleosome at the TSS86, and these promoter regions are 
typically packaged by nucleosomes under repressed conditions87 (Figure 1.1A). On the 
other hand, many yeast or human promoters have DNA features such as the A-T 
richness or CpG islands that can intrinsically favor an accessible chromatin structure88. 
In either case, for a gene to be poised for activation, the accessibility of the promoter 
to transcription factors is critical87. Transcription activators or other DNA binding 
proteins such as GAGA factor in Drosophila 12 can recruit chromatin remodelers to 
produce an open promoter structure87 (Figure 1.1B). Importantly, prolonged 
transcription factor binding (35) and Pol II pausing itself86 contribute to the 
maintenance of this open promoter structure . 
 General transcription factors (GTFs) are assembled on core promoters87, and 
direct the recruitment and transcriptional initiation of Pol II (Figure 1.1C). The TFIID 
complex binds provides a strong foundation for binding to the promoter region. The 
interaction between the TATA box and TATA box binding protein (TBP), a major 
subunit of TFIID, as well as interactions of TFIID-associated proteins with elements 
downstream of the TSS contribute to TFIID binding in many promoters. TFIIA and 
TFIIB also associate with TBP to facilitate TFIID binding and Pol II recruitment89. Pol 
II in complex with TFIIF binds to the promoter followed by TFIIE and TFIIH. TFIIH 
contains the XPB DNA helicase subunit that melts the DNA and generates the open 
Pol II complex to expose the template strand of DNA and allow initiation of 
transcription90.   
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-1 nuc 
+1 nuc (+120) 
+2 nuc (+300) 
TSS 
TFIID 
+1 nuc 
+2 nuc 
TFIID TFIIB 
TBP 
TFIIA 
TFIIH 
TFIIE 
TFIIF 
Pol II TFIIS DSIF 
NELF TFIID 
Pol II 
+1 nuc 
PIC assembly Promoter proximal pausing 
Open promoter Closed promoter 
a b 
c d 
A B! A  
C D 
Figure 1.1. Structure of the promoter and Pol II before and during early elongation 
(A) The promoter is occupied by a nucleosome in a closed configuration. This 
conformation represents a Drosophila promoter unbound by Pol II before priming86. 
The nucleosome (nuc) positions are the distance between the dyad axes and the TSS 
in base-pairs (bp), based on the average micrococcal nuclease sequencing profile86. 
(B) The promoter is in an open configuration, unbound by nucleosome and occupied 
by general transcription factors87. (C) The pre-initiation complex (PIC) is assembled 
(zoomed in relative to other panels). Part of the TFIID structure is removed to 
visualize the assembly of other general transcription factors. TBP is a subunit of the 
TFIID structure but is not removed to illustrate its binding to the promoter DNA and 
Pol II. (D) Pol II is paused between the promoter and the first nucleosome (+1 nuc). 
The pausing position is at +40 from TSS, which is typical in Drosophila promoters. Pol 
II bound NELF, DSIF, and TFIIS are also shown. TFIID may or may not be present at 
the promoter depending on its residency in a re-initiation scaffold91. The illustrated 
molecules are based on crystal89,92-94 and cryo-electron microscope95,96 structures 
except for NELF (structure not available), and are scaled proportional to their actual 
dimensions. The length of each DNA turn is about 10 bp or 3.4 nm. 
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Another important function of TFIIH is to phosphorylate the C-terminal 
domain (CTD) of the Pol II Rpb1 subunit90,97. Pol II CTD is composed of a species-
specific number of 7 amino acid repeats, Tyr-Ser2-Pro-Thr-Ser5-Pro-Ser7, ranging 
from 26 in yeast up to over 50 in mammals. A cyclin-dependent kinase Cdk7 subunit 
of TFIIH phosphorylates the fifth residue (Ser5)27. Ser2 and Ser7 can also be 
selectively phosphorylated later on, which allows the interaction of accessary 
elongation factors with Pol II. 
 After the very early elongation of nascent RNA (up to ~10 nt), Pol II escapes 
this initiation stage. Some GTFs are dissociated, but part of the initiation complex 
such as TFIID, TFIIA, and TFIIH may remain associated with the promoter providing 
a scaffold for re-initiation91. Moreover, TFIIF can remain associated with the Pol II as 
an elongation factor15,16. During the course of early elongation, Pol II is prone to 
arrests in a backtracked position, where TFIIS binds to Pol II facilitating the cleavage 
of protruded nascent RNA and rescue from the arrested state15,94. 
 In higher eukaryotes, after transcribing the initial 20-60nt of RNA, Pol II 
becomes paused between the promoter and the first (+1) nucleosome (Figure 1.1D). 
Pausing factors NELF and DSIF can bind to paused Pol II and stabilize it in vivo98. 
However, the mechanistic details for these complexes are still being determined. A 
possible mechanism by which these pausing factors mediate their function could be 
related to their RNA binding property. NELF contains the subunit NELF-E which 
contains an RNA recognition motif21,25, and DSIF has been shown to bind shorter 
nascent RNA as it emerges from the elongating Pol II complex99. Consistent with this, 
the crystal structure of DSIF bound to archaeal RNA polymerase (RNAP) shows that 
DSIF binds near the active center cleft and RNA exit channel93 where it may interact 
with the transcription bubble and modulate the processivity of the RNA polymerase. 
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Mechanisms of Promoter Proximal Pausing 
To better understand proximal pausing and its role as a rate-limiting step of 
transcriptional regulation, we need to review in detail the mechanics of early Pol II 
elongation. In addition to what is known about the factors involved, we need to 
consider how DNA sequence elements and nucleosomes influence Pol II pausing and 
its escape. In this section, we discuss the mechanisms of how elongating Pol II can 
become paused near promoters and what the fate of the paused Pol II is. Also, we 
describe genomic approaches to identify the properties of promoter that determine the 
extent and the pattern of promoter proximal pausing. 
 
Molecular models of promoter proximal pausing 
After initiation, the early elongating Pol II meets its first roadblock and pauses. 
The identity of this first roadblock is very important, because it provides the strongest 
rate-limiting step in the course of Pol II elongation along the gene. Various in vitro 
studies have identified many different components that comprise this stop sign. The 
mechanisms for establishing the pause in vivo can be summarized into three models 
that are not mutually exclusive (Figure 1.2A). The actual promoter environment may 
be a blend of these individual models, and different promoters may use different 
blends. 
 The first can be described as the kinetic model, where the balance between 
early elongation and the recruitment of pausing factors determines Pol II pausing. 
Intrinsic features of Pol II such as the early elongation rate, and DNA and RNA 
sequence specific features such as the DNA-RNA hybrid energy will affect the  
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Figure 1.2. Models of promoter proximal Pol II pausing (A) The driving force for 
establishing the position and the extent of Pol II pausing near promoter is 
summarized in 3 models. (left) In the Kinetic model, the recruitment of the pausing 
factors competes with the elongation of Pol II. (middle) In the Barrier model, physical 
barriers such as nucleosomes impede with elongating Pol II. (right) In the Interaction 
model, a tethering factor that binds to DNA and Pol II at the same time drives Pol II 
pausing. (B) Promoter DNA elements in Drosophila are shown100,101. Protein factors 
such as GAGA-factor(GAF), TBP, and TFIIB can bind to their DNA elements. TFIID 
complex can make specific contacts with the DNA elements at multiple positions that 
are relatively downstream. (C) In promoters with stronger DNA elements, Pol II is 
more proximal to the TSS within the contact range of the promoter complex8, and the 
interaction between the promoter and Pol II can drive the pause. Pausing is stronger 
in these promoters and the first nucleosome may be absent86. (D) In promoters with 
weaker DNA elements, Pol II is closer to the dyad axis of the first nucleosome8, and is 
more compatible with pausing driven by nucleosome barriers. The interaction with the 
promoter complex and the downstream DNA is weaker and may generate less 
resistance to the Pol II. The illustrations in (C) and (D) are based on actual structures 
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kinetics and the energy landscape of elongating Pol II complexes103. In regions with a 
higher energy state, Pol II may spontaneously backtrack, and need to be rescued from 
this backtrack by TFIIS, which is associated with paused Pol II104. These kinetic 
processes along with rate of pausing factor binding and the rate and energetics of Pol 
II will determine the level and the position of promoter proximal pausing7. 
 Second is the barrier model where a physical barrier on the chromatin blocks 
Pol II elongation. Nucleosomes have long been known to provide barriers to Pol II 
elongation in vitro105. In Drosophila, it was shown that the first nucleosomes make 
contacts with paused Pol II and can be cross-linked together in vivo106. However, in 
some highly paused genes, the first nucleosome barriers may not be present, for 
example, the nucleosome free region around the Drosophila Hsp70 promoter extends 
to +250 bp from TSS86,87.  
 Third is the interaction model where sequence specific binding factors interact 
with elongating Pol II and determine pausing. This has been an underappreciated 
model in higher eukaryotes, but for bacteria, it successfully explains the sequence 
specific pausing by DNA or RNA binding factors that interact with RNAP. For 
instance, RNA secondary structure at the leader pause site of the E. coli his gene was 
shown to interact with Pol II107, and at other genes, the initiation factor σ70 induces 
pausing by interacting with the downstream DNA elements during its retention within 
Pol II after the initiation event108 . In higher eukaryotes, there is evidence that pausing 
may be determined by RNA binding of NELF or DSIF99,109. Additionally, a testable 
hypothesis is that like σ70, the components of the initiation complex may remain 
bound to the promoter DNA and tether Pol II to induce pausing. Therefore, the general 
features of E. coli pausing may provide a framework of a molecular model for the 
promoter proximal pausing of Pol II. 
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High-resolution mapping allows integration of pausing models 
Advances in the genome-wide approaches have made it possible to define the status of 
Pol II at the promoter for thousands of genes. In mammalian cells, GRO-seq identified 
about 40-46% of active genes as paused5,9. Likewise in a Drosophila embryonic cell 
line, 70%-89% of active promoters contained paused Pol II81. However, although a 
large fraction of the active genes are paused, the degree of pausing and distribution of 
pause sites within a promoter varies between genes depending on the features of the 
promoter8, and here we consider two types of cis-acting elements: promoter DNA 
elements and the nucleosome. 
 The promoter region around a TSS contains several conserved sequence motifs 
recognized by the general transcription factors (GTFs) and Pol II (Figure 1.2B). In 
Drosophila, these include the TATA box, initiator (Inr), TFIIB recognition element 
(BRE), downstream promoter element (DPE)100, and motif-ten element (MTE)101 
(Figure  1.3B). The extent to which promoter DNA elements contribute to GTF 
binding does not simply rely on true or false type of matching to the consensus motif 
but on the strength and the quality of the elements110. The search for the DNA motifs 
in paused genes in Drosophila embryo have shown the enrichment of some of the core 
promoter elements such as Inr and DPE, and more upstream GAGA element111,112. 
These elements were also found to be required for pausing in Hsp70 in assays of 
transgenic mutant promoters13. A novel GC rich element bearing sequence similarity 
to DPE was also identified as enriched on paused genes and called the ‘Pause Button’ 
112. In addition, the strength of these and other core promoter DNA elements at the 
consensus position strongly correlated with the extent of pausing8. Therefore, the 
strength of a promoter complex as a whole may be a determinant of pausing as well as 
initiation86. 
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 The precise position of pausing also relates to the strength of the promoter 
DNA elements. In Drosophila, promoters with stronger DNA elements tend to have 
more proximal pausing (+40), while promoters with weaker elements have more distal 
dispersed pausing (up to +80)8. Since the average position of the center of the first 
nucleosome is around +120 from TSS86, the distal pause position is more consistent 
with the nucleosome barrier mechanism8,105,113. 
 These findings lead us to propose an amalgam of molecular models of pausing 
for different promoters that involves distinct inputs and mechanisms for a proximal, 
promoter driven pausing (Figure 1.2C) and for a distal, nucleosome driven pausing 
(Figure 1.2D).  For the ‘kinetic’ model, the energy landscape and rates are defined not 
only by the DNA-RNA sequences but also by features of the ‘interaction’ and the 
‘barrier’ models. Simply put, the ‘kinetic’ model is an integral part of the ‘interaction’ 
and ‘barrier’ models. For a promoter with stronger DNA elements, the ‘interaction’ 
model dominates the energy landscape and the output is a more proximal, promoter 
driven pausing (Figure 1.2C). On the other hand, for a promoter with weaker DNA 
elements, the nucleosome barrier defines the energy landscape more dominantly and 
the result is a more distal, nucleosome driven pausing (Figure 1.2D). The interaction 
and barrier models can even co-exist within a single promoter, and often one may 
mask the other depending on the balance between the two principal components. 
  
Fate of paused Pol II 
Promoter proximal paused Pol II can resume the NTP catalysis and enter 
productive elongation. It has been shown that the vast majority of paused genes have 
detectable levels of elongating Pol II in the gene bodies9,81. Measuring the ratio 
between paused and elongating Pol II will make it possible to estimate how frequently 
Pol II escapes into productive elongation and assess the activity of the promoter. 
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However, confounding this calculation is the loss of paused Pol II though termination 
at or near the pause site. 
 Premature termination from the pause or arrest has been extensively 
documented in the bacterial Rho dependent termination mechanism, but this 
mechanism usually comes into play downstream of any promoter-associated pause. In 
eukaryotic cells, stalled Pol II at DNA damage sites can be remove by the 
ubiquitination mediated degradation pathway during transcription coupled nucleotide 
excision repair114,115. This is not necessarily dependent on the DNA damage itself but 
is a response to prolonged Pol II stalling116. 
 In mammals, mRNA de-capping and 5’→3’ exonuclease Xrn2 mediated 
termination, similar to the torpedo-like mechanism at the 3’ end of the gene, can take 
place in promoter proximal region. RNAi depletion of de-capping proteins or the 
termination factors result in the redistribution of Pol II from the proximal region into 
the gene bodies40. Although it is technically challenging to assess the balance between 
termination and pause escape, it will be critical to quantify the extent of each in order 
to understand their roles in the regulatory mechanism. 
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Escape Into Productive Elongation 
Productive elongation is defined here as the efficient progression of Pol II 
through the gene body, and the ‘escape into productive elongation’ refers to the 
transition of the paused Pol II into this productive mode. During Pol II’s residence in 
the promoter proximal region, two important modifications to the major components 
of transcription elongation complex take place. One is the 5’ capping of nascent RNA, 
and the other is the phosphorylation of the paused Pol II complex. The latter is 
mediated by protein kinase complex P-TEFb that also phosphorylates the pausing 
factors DSIF and NELF. At this stage, Pol II and its associated nascent RNA are 
modified so as to allow recruitment of additional elongation and RNA processing 
factors that help polymerase overcome further barriers in the gene body and couple 
transcription and RNA processing4. 
 
5’ capping as a checkpoint for productive elongation 
Transcription is coordinated with other essential events that lead to proper 
processing of RNA6. This requires the loading Pol II with an entourage of proteins that 
facilitate the RNA processing and help Pol II navigate properly through chromatin. 
RNA capping has been regarded as a mechanism dependent on early elongation, but 
accumulating data suggests that it may also have an active role as a control point. 
 Capping the 5’ end of the nascent RNA requires three enzymatic activities: 
digestion of the 5’ triphosphate of RNA, addition of a guanine base in 5’ to 5’ linkage, 
and methylation of the added guanine base6. In yeast, these activities depend on three 
different genes, whereas in metazoans, a single Capping Enzyme (CE) performs the 
first two activities. CE can be recruited to Pol II when the nascent RNA is about 30 nt 
long through the interaction with phosphorylated Ser5 and DSIF38. Recruitment of CE 
can relieve the action of NELF and provide a platform for P-TEFb loading37,38. 
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 Examination of the capped state of Pol II-associated RNAs at high resolution 
in the pause region of heat shock genes under non-heat shock conditions showed that 
capping occurs progressively as Pol II moves through the pause region – the most 
proximal paused RNAs are largely uncapped and the more distal (beyond +30) are 
completely capped3.  Thus, capping could be required for escape into productive 
elongation, but given the low rate of escape in non-HS conditions, it appears that 
capping may not be sufficient on its own to drive this escape. 
 
Major role of P-TEFb in pause escape 
Identification of P-TEFb. As described previously, biochemical analysis of the 
elongation activity in Drosophila Kc nuclear extract showed that the majority of Pol II 
complexes were only able to produce short, paused transcripts. However, a fraction of 
the Pol II complexes were able to produce full-length transcripts from the template in 
a DRB sensitive manner85. This fraction was postulated to contain positive 
transcription elongation factor (P-TEF), and later a homogenous fraction was purified 
that contained P-TEFb84. 
 P-TEFb is a heterodimer complex of Cyclin T (CycT) and Cyclin-dependent 
kinase 9 (Cdk9) subunits117. Its major role is to phosphorylate Ser2 of Pol II CTD27, 
and the pausing factors DSIF24,26 and NELF25. However, there is partial redundancy 
and non-specificity in Pol II CTD phosphorylation by P-TEFb. P-TEFb can also 
phosphorylate Ser5 in vitro27, and Cdk12118 or Brd4119 can also perform Ser2 
phosphorylation. Nevertheless, inhibition of P-TEFb kinase activity with another 
potent inhibitor flavopiridol resulted in a 5’ to 3’ clearing of Pol II within the gene 
body in Drosophila Hsp70120 and globally in mouse embryonic stem cells121. Upon 
this inhibition, Pol II molecules that are already elongating at the time of inhibition 
continue elongation through the gene body and still maintain a high level of Ser2 
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phosphorylation level near the 3’ end of Hsp70120. Therefore, P-TEFb plays a role in 
pause escape by phosphorylating the pausing factors and releasing NELF, but it is less 
clear whether Ser2 phosphorylation itself is required for pause escape.   
 The recruitment of active P-TEFb is a critical step in controlling gene 
expression, and is regulated at multiple stages. In human cells, the free form of P-
TEFb is sequestered by 7SK snRNP in an inactive state122,123 (Figure 1.3A). Upon 
activation, P-TEFb is released from the sequestration and recruited to the promoter in 
a variety of ways (Figure 1.3B). After completing its function, P-TEFb can be 
sequestered again by 7SK snRNP, but in some highly active genes, it remains bound 
with the elongating Pol II in Super Elongation Complexes (SECs)124 (Figure 1.3C). 
 
Recruitment of P-TEFb by activator, Brd4, and Mediator. There are several ways for 
P-TEFb to be recruited to paused Pol II. The first is directly by activators. It has been 
shown that c-Myc can physically interact with the CycT subunit of P-TEFb during 
transcriptional activation33,125. Treating mouse ES cells with the chemical inhibitor of 
c-Myc/Max complex resulted in a decrease of pause release preferentially in known c-
Myc targets121. Similarly, the RelA subunit of NF-κB also binds to CycT and recruits 
P-TEFb to TNF-α target genes34. Finally, the HIV Tat transactivator can bind CycT 
and directly recruit P-TEFb to the 5’ LTR region through Tat binding to TAR hairpin 
RNA, adjacent to where Pol II is paused117.  
 A second way that P-TEFb is recruited is through the co-activator Brd435,36. 
Brd4 is a bromodomain protein that can recognize acetylated histone tails, and can 
also bind to the CycT subunit of P-TEFb once it is released from 7SK snRNP35. 
Recruitment of Brd4 may also require a ‘histone crosstalk’61 triggered by PIM1  
20 
 
Paused Pol II 
P-TEFb 
P 
P 
NELF 
DSIF 
BRD4 
Ac 
P 
NELF 
DSIF 
P 
P 
P P-TEFb 
Pol II 
P 
NELF 
DSIF 
7sk RNP 
P-TEFb P 
NELF 
DSIF 
m
yc
 
P 
NELF 
DSIF 
Act 
Mediator SEC 
P-TEFb 
ELL 
P-TEFb recuitment 
by activator 
by Brd4 
by Mediator 
Elongation 
TSS 
NELF 
P 
DSIF 
P 
P P SEC 
ELL 
P-TEFb 
PAF 
a b c 
Highly active genes 
Figure 1.3. Productive transcription elongation complex (A) Paused Pol II is bound by 
NELF and DSIF. The CTD is phosphorylated at Ser5. P-TEFb is held inactive by 7SK 
RNP. (B) P-TEFb is activated and recruited to the paused Pol II by various 
mechanisms. The first is directly by activator that binds to the DNA. Recruited P-TEFb 
can phosphorylate NELF, DSIF, and Ser2 of Pol II CTD. The second is through Brd4 
that binds to acetylated histone tails. In human cells, Brd4 can bind to H4K16 
acetylation which is dependent on H3S10 phosphorylation through the ‘histone 
crosstalk’61. The third is indirectly through the Mediator complex, which links the 
activator (Act) and Pol II. A Mediator subunit MED26 can recruit SEC, which also 
contains P-TEFb31. (C) Pol II escapes pausing. Phosphorylated NELF is dissociated 
from Pol II, and DSIF turns into a positive elongation factor after being phosphorylated 
by P-TEFb. Alternatively, P-TEFb can remain bound to Pol II by SEC that also 
interacts with PAF in genes with highly active elongation124. P-TEFb can continuously 
phosphorylate Ser2, and a SEC component ELL can facilitate elongation. PAF can 
also recruit additional elongation factors. RNA is not shown for the clarity of viewing 
the complexes. 
 
C A
 
B
21 
 
kinase to phosphorylate H3Ser10 (H3S10ph)67. 14-3-3 adaptor protein recognizes 
H3S10ph and recruits histone acetyl-transferase complex MOF to acetylate H4Lys16 
which serves as a binding platform for Brd461. Brd4 was also identified as a 
therapeutic target of acute myeloid leukemia that can control the expression of Myc at 
the elongation level126. Thus Brd4-mediated recruitment of P-TEFb may be a key 
mechanism of gene regulation. 
 P-TEFb can also be recruited through the Mediator complex. Human Mediator 
subunit MED26 can serve as a binding platform for SEC, which contains P-TEFb. 
During initiation and pausing, MED26 is associated with TFIID, but MED26 can be 
switched to recruit SEC instead31. Recruitment of P-TEFb through Mediator is 
believed to be more sensitive in a subpopulation of Pol II that contains a tightly 
associated factor Gdown142. Gdown1 can compete with TFIIF and therefore might 
reduce the efficiency of initiation44. In contrast, after Pol II initiates, Gdown1 
stabilizes Pol II in a paused configuration43. In addition to P-TEFb recruitment, an in 
vitro study also showed that Mediator helps Pol II overcome the +1 nucleosome 
barrier on a mononucleosomal template127, further strengthening its positive function 
during the early elongation steps of the transcription cycle. 
 
Factors required for more efficient elongation 
There is a set of factors associated with elongating Pol II that is critical for its 
efficient transcription. Historically, some of these factors were discovered from a class 
of frequent genetic mutations involving mixed lineage leukemia (MLL) gene in a type 
of hematopoietic malignancy128. More surprisingly, all of these factors turned out to be 
associated with each other to form a single complex, both functionally and physically 
124. 
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 The first factor discovered among these is Elongin. Elongin was purified from 
a fractionation of rat liver nuclear extract that enhanced the in vitro transcription rate 
of Pol II from the adenovirus 2 major late promoter (AdML) template, composed of 
three subunits A, B, and C. Elongin’s function in transcription elongation was further 
confirmed when an Elongin related gene in humans, eleven-nineteen lysine-rich 
leukemia 1 (ELL1), was found to be a frequent fusion partner MLL in translocation 
t(11;19)(q23;p13.1)29. Functional characterization showed that the Elongin and ELL 
family of proteins increase the net catalytic rate of Pol II, presumably by reducing the 
transient pauses in gene bodies124. 
 ELL can interact with the elongating Pol II as a part of a multi-protein complex 
named super elongation complex (SEC). SEC consists of AFF1 or AFF4 (AF4/FMR2 
family member 1 and 4), ENL (eleven-nineteen leukemia) or AF9 (ALL fused gene 
from chromosome 9), ELL1 or ELL2, and active P-TEFb30,124. The possible 
combinations of the factors generate diverse subtypes SECs that can activate distinct 
sets of genes under various physiological contexts124. In addition, AFF1, AF9, and 
ENL also are frequent translocation partners of MLL128. MLL can bind to Menin and 
LEDGF (lens epithelial-derived growth factor), and these two factors are responsible 
for the aberrant tethering of MLL-fused SEC to promoters of Hox genes, resulting in 
misregulation at the elongation stage and disease progression into leukemia124.  
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Elongation Through the Nucleosome and Gene Body 
Even after pause escape, Pol II still has to break further roadblocks in the gene 
body, most of which are nucleosomes (Figure 1.4). Genes can use general mechanisms 
to remove or weaken the nucleosome barriers, such as nucleosome remodeling, 
exchange of histone variants, and histone tail modifications. Elongating Pol II can 
make use of an entourage of its associated chaperones to overcome the nucleosome 
barriers, which can be detected by assaying pausing of Pol II or the loss of the evicted 
barriers.  
 
Overcoming the nucleosome barrier 
FACT. Nucleosomes provide a barrier to elongation. In vitro assembled nucleosomal 
templates strongly inhibit the generation of full-length transcripts by Pol II45,105. 
However, adding HeLa nuclear extract allowed transcription through these 
chromatinized templates, and FACT was identified from the biochemical fraction that 
allowed Pol II to overcome the nucleosome barriers45. FACT has 2 subunits, Spt16 
and SSRP1129. It functions to disassemble an H2A-H2B dimer from nucleosomes and 
Pol II can transcribe through the remaining histone hexamer without being displaced46. 
Afterwards, the disassembled H2A-H2B dimer can be re-deposited by FACT, leaving 
the reassembled histone octamer in a more dynamic state130. FACT’s in vivo 
association with chromatin was also confirmed on Drosophila Hsp70, and it showed 
localization and recruitment kinetics that are consistent with elongating Pol II47. 
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Figure 1.4. Pol II transcribing through gene body nucleosomes. Pol II may use 
multiple mechanisms to get through a nucleosome, and not all the steps are used. 
Step 1, Pol II approaches and makes contact with a nucleosome. Step 2, the outer 
wrap of nucleosomal DNA can be easily unwrapped, and Pol II moves into the 
nucleosome near the dyad axis. Pol II active site is at around -40 from the dyad 
axis8,105,113. The nucleosome binding is strong at this point and Pol II often pauses 
transiently. Step 3, H2A/H2B dimer is dissociated from the DNA and the nucleosome 
is now a hexamer. A dissociated dimer can still remain through its association with 
FACT and be re-deposited later46. Step 4, H3/H4 core nucleosomal particle is evicted 
from DNA. H3 can remain associated and be re-deposited by Spt6 or Asf151,52. Step 
5, nucleosome hexamer transfers upstream of Pol II while Pol II transcribes into 
downstream region. A looping intermediate may form during the transfer. Step 6, 
nucleosome octamer transfers upstream of Pol II, which can be facilitated by histone 
chaperones. Step 7, Pol II evicts the nucleosome by transcribing through it. Step 8, 
Pol II transcribes through the nucleosome leaving a hexamer. Step 9, Pol II 
transcribes through the nucleosome leaving an octamer. 
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Spt6. Spt6 was initially identified from the Suppressor of Ty genetic screen in yeast1,2. 
Spt6 can physically interact with histones H3 and H4 directly, and has histone 
chaperone activity51. Spt6 travels with Pol II, as it shows an in vivo association with 
chromatin on Drosophila Hsp70 that is consistent with elongating Pol II47. Its function 
is proposed to displace the nucleosome in front of Pol II and reassemble it in the back, 
allowing Pol II to transcribe through51. However, Spt6 can also increase the elongation 
rate of Pol II on naked DNA in vitro131 and independent of the nucleosomes in 
vivo57,132. Depletion of Spt6 by RNAi decreases the elongation rate on Drosophila 
Hsp70 under heat-shock conditions132, when the nucleosomes on Hsp70 are already 
lost57,58. Therefore, Spt6 may both increase the intrinsic elongation rate of Pol II and 
remove nucleosome barriers at the same time. 
 
PAF complex. PAF complex is another Pol II associated complex that has a role in 
elongation, and was first identified from the immuno-precipitating yeast whole cell 
extract using an antibody to the Pol II CTD59. Like Spt6, PAF also is associated with 
elongating Pol II in vivo47, suggesting that it travels with Pol II. PAF complex by itself 
is not known to contain any enzymatic activity, but serves as a platform for recruiting 
elongation factor complexes such as SEC1,2,32, FACT60, and histone modifying 
enzymes to elongating Pol II133. In particular, PAF complex was required for 
H2BK123 monoubiquitination by RNF20/40 (Rad6) and UbcH6 in vitro, and this H2B 
modification shows a cooperative effect with FACT to allow Pol II to transcribe 
through nucleosomes60.   
 
PARP. All the factors above in this section relieve the nucleosome barriers in 
transcription-dependent manner, associated with elongating Pol II. However, recent 
studies suggested that PARP (poly(ADP-ribose) polymerase) can achieve this in a 
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transcription-independent way57,58. PARP is required for chromatin loosening at 
transcriptionally active puffs in Drosophila polytene chromosomes134 and is bound to 
the promoters of active genes in a pattern that is reciprocal to histone H1135. On 
Drosophila Hsp70, heat shock factor (HSF) response recruits Tip60 histone acetyl-
transferase complex to acetylate H2AK5 and subsequently activate PARP. This results 
in a creation of poly(ADP-ribose) chains and rapid nucleosome loss that precedes the 
elongation of Pol II through the gene body58. 
 
Single molecule studies provide insights to mechanism 
Using biochemical experiments, it was shown that SP6 RNAP can transcribe 
into partially unwrapped DNA that rewraps on the same nucleosome as soon as the 
polymerase has transcribed through, and the nucleosome ‘steps around’ (~ 50 bp 
upstream) the polymerase136. However, Pol II is about 1.7 times larger than SP6 
RNAP in dimension, and in other in vitro studies, most Pol II molecules were unable 
to overcome the nucleosome barrier by itself136. The precise mechanism could be 
assessed by examining the Pol II molecules individually to characterize their 
elongation movements and by defining the conditions under which Pol II can 
transcribe through the nucleosomes. 
 Using optical tweezers, it was shown that Pol II could transcribe through the 
nucleosome under higher ionic strength conditions. The kinetics of Pol II movements 
were consistent with the model that Pol II transcribes into locally unwrapped DNA137, 
similar to SP6 RNAP. Atomic force microscopy made it possible to identify the 
intermediate structure with locally unwrapped DNA containing Pol II looping back to 
the same nucleosome. Also, some nucleosomal particles have lost H2A/H2B dimers to 
become hexamers, and even the whole octamers were lost when the Pol II elongation 
rates were faster under higher NTP concentrations138.  
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 When the histones were modified, the kinetics of Pol II through the 
nucleosomes change. The position of Pol II pausing relative to the nucleosome could 
be at the entry, central, and exit regions, but reached the maxima at the central region 
(-35 to +5bp from dyad)15,137,139. This is consistent with in vitro105 and in vivo8,113 
positions of Pol II relative to gene body nucleosomes (not the first nucleosome) where 
the pause is on average ~ 30 bp inside the upstream margin and ~ -40 bp relative to the 
dyad of the nucleosomes. When the histone tails are acetylated or absent, the pause 
density at the entry region is decreased, indicating that the unacetylated tails normally 
interact with the outer turn of the DNA surrounding the nucleosome. When the core 
histone H3 and H4 are mutated, the pause density in the central region is decreased 
indicating that the relaxed interaction near the dyad allows Pol II to transcribe through 
better139. 
 One limitation of these methods is that the experiments were carried out under 
ionic strengths that are higher than the physiological conditions137,139. However, by 
adding reconstituted elongation factors to the system and reproducing in vivo 
conditions, these sets of single molecule methods will be powerful tools to define 
precisely how Pol II overcomes the nucleosome barrier and how elongation factors 
cooperate with this process. 
 
Elongation rates 
The elongation rate of Pol II is an important property of the transcriptional 
machinery that can direct the level, timing, and the processing of nascent RNA into 
mature mRNA. It has two components: the pause-free velocity and the 
frequency/duration of the pauses. The catalytic rate of Pol II sets up the pause-free 
velocity. It depends on the translocation of the catalytic active site, and this rate is 
known to be governed by the ‘trigger loop’ structure of Pol II around the active site140. 
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Therefore, elongation factors that can bind to this region of Pol II may affect the 
trigger loop structure and alter the translocation rate. The net elongation rate of Pol II 
would then be a composite of this pause-free velocity and the frequency/duration of 
pausing or arrests due to underlying sequences and nucleosomes. 
 The in vitro assays that were used to identify factors related to elongation were 
basically net elongation rate assays over time courses to determine how long it takes to 
transcribe the full-length templates. These rates do not represent the true elongation 
rates in vivo, since rate can be affected by limiting NTP concentrations and the 
presence of additional elongation factors. To measure the elongation rate in vivo, the 
traditional approach was to use a rapid induction or shut-down of a gene and measure 
the time for the “first wave” or the “last wave” of Pol II to reach a certain position on 
the gene141. A collection of these rates from yeast to Drosophila and mammals range 
anywhere between 1-5 kilobases per minute (kb min-1)141. However these 
measurements are limited in numbers and types of genes examined, and a systematic 
comparative analysis between the genes was difficult. 
 Another approach to measuring the elongation rate is by fluorescence recovery 
after photobleaching (FRAP). Upon photobleaching fluorescently tagged Pol II, the 
time for full recovery is the time it takes for the newly initiated polymerase to finish 
transcribing the whole gene. In Drosophila, salivary gland polytene chromosomes 
were used to identify the endogenous Hsp70 locus under heat shock condition for the 
FRAP142. Similarly, nascent RNA synthesis rate can be measured by FRAP using 
fluorescently labeled RNA binding proteins. In diploid cells, transgenic genes were 
used that had structured RNA regions to recruit fluorescently tagged RNA binding 
proteins143,144. 
 Spt6 was the first among known elongation factors for which the role in 
elongation rate was robustly confirmed in vivo. Using ChIP, it was shown that 
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depletion of Spt6 in Drosophila embryonic cells delayed the traversal of the first wave 
of heat shock response in Hsp70 gene132. In addition, FRAP in Drosophila polytene 
chromosomes showed that the elongation rates on induced Hsp70 in Spt6 knock-down 
animals is more than two fold slower than the wild type132,142. 
 More recently, GRO-seq is being used as a tool to measure elongation rates at 
a large number of genes simultaneously145. This was made possible because the 
resolution and the sensitivity of GRO-seq allow the detection elongating Pol II in gene 
bodies. By stimulating human cells with estrogen or TNFα and measuring the time-
course of Pol II induction wave in longer genes, the elongation rates of over 160 
responsive genes could be determined. Elongation rates differed between cell types 
and genes, ranging from 0.4-3.6 kb min-1 in estrogen responsive genes145. Also genes 
with higher levels of Pol II in the gene body had faster elongation rates consistent with 
the in vitro model where cooperative Pol II interactions help rescue arrested Pol II145-
147. 
 Although the use of stimulus responsive genes yielded elongation rates in one 
to two hundred genes, using a more general inhibitor of elongation may greatly 
expand the number. For example, a DRB washout strategy has been used to induce an 
artificial first wave of Pol II and pre-mRNA level at various positions were detected to 
measure the elongation rate in several long human genes148. Applying genome-wide 
technology to this type of inhibitor approach will be highly informative in determining 
the rates and the role of elongation factors in vivo141. 
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Conclusion 
 Traditional genetic and biochemical studies have revealed that elongation is as 
critical as initiation in transcriptional regulation of some genes. Recent genome-wide 
analyses of the distribution of transcription complexes reveal that on many genes in 
metazoans significant regulated barriers to elongation exist, most prominently near 
promoters.  This promoter-proximal pausing and its regulated escape to productive 
elongation are being better understood with the advent of high resolution methods for 
precisely mapping Pol II relative to promoter elements and nucleosome barriers.  The 
pausing intensity and position depend both on core promoter complex interactions 
with Pol II and the first nucleosome barrier, both appear to contribute to differing 
extents on different promoters.  New single molecule technologies are also providing 
unprecedented views of individual RNA polymerases during elongation and are 
providing further insights to the mechanics of elongation and the transit of Pol II 
through nucleosome barriers during elongation. Further studies in the field will be 
directed towards testing how mechanistically the promoter-proximal pausing is 
regulated by transcription factors and the how factors influence the efficiency and rate 
of elongation in cells. 
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CHAPTER 2b 
 
PRECISE MAPS OF RNA POLYMERASE REAVEAL HOW PROMOTERS 
DIRECT INITIATION AND PAUSING 
Summary 
Transcription regulation occurs frequently through promoter-associated 
pausing of RNA polymerase II (Pol II). We developed a Precision nuclear Run-On and 
sequencing assay (PRO-seq) to map the genome-wide distribution of transcriptionally-
engaged Pol II at base-pair resolution. Pol II accumulates immediately downstream of 
promoters, at intron-exon junctions that are efficiently used for splicing, and over 3' 
poly-adenylation sites. Focused analyses of promoters reveal that pausing is not fixed 
relative to initiation sites nor is it specified directly by the position of a particular core 
promoter element or the first nucleosome. Core promoter elements function beyond 
initiation, and when optimally positioned they act collectively to dictate the position 
and strength of pausing. We test this ‘Complex Interaction’ model with insertional 
mutagenesis of the Drosophila Hsp70 core promoter. 
 
Introduction 
Tracking the accumulation of Pol II along genes reveals potential points of 
regulation1. For example, a rate limiting step in early elongation, known as promoter-
proximal pausing, has revealed a major regulatory block in the transition to productive 
elongation in Drosophila and mammals2-8.  Also, less extensive, but significant 
accumulation of Pol II over the 3’ cleavage/polyA region of genes is proposed to 
facilitate 3’ processing and transcription termination9,10.  Finally, the interplay of 
                                                
b From Kwak et al., Precise Maps of RNA Polymerase Reveals How Promoters Direct 
Initiation and Pausing, Science 339, 950-953 (2013). Reprinted with permission from AAAS. 
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transcription rate and splicing efficiency11 might be reflected in the selective 
accumulation of Pol II at splice junctions. 
Promoter-associated Pol II pausing is a culmination of intrinsic interactions 
between Pol II and the underlying DNA, as well as extrinsic stabilization by protein 
complexes12. Protein factors such as Negative Elongation Factor (NELF) and DRB 
Sensitivity Inducing Factor (DSIF)3,13, DNA elements14,15, DNA sequence 
composition16, nascent RNA processing16, and nucleosomes17 can influence pausing. 
Understanding how these elements and factors function mechanistically requires a 
high resolution view of their spatial relationship. Current tools for precise tracking of 
the location and status of Pol II in vivo have distinct limitations18. ChIP-based methods 
that collect Pol II or associated RNAs do not distinguish paused Pol II from other Pol 
II-RNA complexes16,18,19. The genome-wide nuclear run-on approach (GRO-seq 
method)6-8 circumvents these issues by enriching nascent transcripts only associated 
with actively engaged polymerase with high sensitivity, but it has a resolution of only 
30-50 bases16. 
 
Development of PRO-seq and Validation of the Pausing Sites 
We developed a genome-wide, nuclear run-on assay called PRO-seq that has 
the sensitivity of GRO-seq, but maps Pol II with base-pair resolution. PRO-seq uses 
biotin-labeled ribonucleotide triphosphate analogs (biotin-NTP) for nuclear run-on 
reactions, allowing the efficient affinity purification of nascent RNAs for high 
throughput sequencing from their 3’ ends (Figure. 2.1A). Supplying only one of the 
four biotin-A/C/G/UTP restricts Pol II to incorporate a single or at most a few 
identical bases, resulting in sequence reads that have the same 3’ end base within each 
library (Table 2.1). Moreover, the incorporation of the first biotin-base inhibits further 
transcript elongation, ensuring base-pair resolution (data not shown). 
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Figure 2.1. Accumulation of Pol II at promoters, 3’ ends, 3’ splice sites, and 
nucleosomes. (A) Schematic of PRO-seq. (B) Average PRO-seq profile of non-
overlapping genes (n=6,309) for the sense strand.  Gene body regions (+1 kb from 
the 5’ end to -1 kb from the 3’ end) are scaled to 4 kb. Read counts are adjusted to 
per kilobase per million mapped (RPKM). Shaded margins surrounding the average 
plot show standard errors of the means. (C) High resolution PRO-seq profile from the 
TSS to +150 bp (n=16,746). (D) Heatmap visualization of PRO-seq profile of the 
annotated genes. Genes are arranged by their increasing PRO-seq density. (E) 
Average PRO-seq profile at 3’ splicing sites of less used and their flanking exons 
(n=242 each). Less used exons have RNA-seq densities less than 5% of their 
flanking exons. (F) Average PRO-seq profile relative to the dyad centers of gene body 
and first nucleosomes. Region occupied by nucleosome is in grey shades. 
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Table 2.1. 3’ end uniformity in PRO-seq sequence reads. For each of the 4 libraries, 
we counted the number of sequences reads ending in each of the 4 bases. Then we 
calculated the percentage of the reads ending in the same base as the nuclear run-on 
substrate. High substrate base percentage indicates that the majority of 3’ ends of the 
sequences were at the active sited of engaged polymerases. 
Libraries 
3’ end base Substrate 
base 
percentage A C G T 
PRO-seqATP 11,198,117 270,067 831,090 314,045 88.8% 
PRO-seqCTP 765,809 11,760,234 402,994 423,382 88.1% 
PRO-seqGTP 1,447,593 439,723 9,900,845 275,139 82.1% 
PRO-seqUTP 1,965,563 1,903,897 465,259 8,915,790 67.3% 
 
 
The average profile of PRO-seq density (Figure 2.1B) reveals pausing of Pol II 
immediately downstream of the transcription start site (TSS) (Figure 2.1C, Figure 
2.1D), and accumulation of Pol II at 3’ cleavage/PolyA sites, consistent with previous 
studies20,21. Interestingly, Pol II also accumulates near 3’ splicing sites at spliced 
exons, but less often at skipped exons (Figure 2.1E), suggesting that splicing decisions 
are connected to differential rates of Pol II elongation through splice junctions11. 
Although we have insufficient sequencing coverage to quantify Pol II accumulation at 
particular 3’ splice sites, our composite analyses support a functional coupling 
between elongation and splicing. 
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The highest density of PRO-seq reads map within +30 to +60 from the TSS (Figure 
2.1C, Figure 2.1D), providing a higher resolution view of paused Pol II mapped by 
GRO-seq21(Figure 2.2D). Moreover, the pattern of pausing by PRO-seq is consistent 
with the positions and levels of short nuclear-capped RNAs (scRNAs, Figure 2.2A)16. 
Additionally, we demonstrate that PRO-seq maps correspond precisely to positions of 
engaged Pol II observed in intact cells seen by previous permanganate footprints of 
transcription bubbles (Figure 2.3). 
Nucleosomes are known to act as barriers to Pol II12. In the bodies of genes 
(nucleosomes at position +2 and greater), the average PRO-seq density shows a 
relative increase at ~ -40 from the previously mapped22 nucleosome centers (Figure 
2.1F). This is consistent with measurements of strong DNA-nucleosome interactions23 
and measured impediments to Pol II transcription through nucleosomes measured in 
vitro and in yeast19,24. However, the PRO-seq density relative to the first (+1) 
nucleosome is different (Figure 2.1F), with the average PRO-seq density at a 
maximum ~ -80 from the nucleosome centers. Thus, the bulk of promoter-proximal 
pausing is inconsistent with a standard nucleosome barrier model, and is more 
consistent with tethering of polymerases near the promoter21.  
 
Pausing Sites Are Not Fixed, but Linked to Initiation Sites 
Whereas the average promoter-associated pause location is approximately at 
+40 from the TSS, pausing is far from uniform. Some genes have more proximal and 
focused pausing, while others have distal and dispersed pausing (Figure 2.4A). We 
systematically assessed genome-wide pausing positions relative to the TSS and their 
dispersion to identify two characteristic groups of promoters: focused-proximal 
(Prox), and dispersed-distal (Dist) promoters (Figure 2.4B). 
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Figure 2.2. PRO-seq compared with other genome-wide transcription assays. 
(A) High resolution heatmap of short capped nuclear RNA-seq (scRNA-seq) and PRO-
seq profiles near the TSS. Each profile is sorted by the sum of the reads in the region for 
each gene. (B,C) Scatterplots of promoter-proximal densities between PRO-seq and 
scRNA-seq (B) or GRO-seq (C). Promoter-proximal densities are the read densities from 
-50 to + 150 around TSS, RPKM normalized. (D) High resolution heatmap of GRO-seq 
and PRO-seq profiles near TSS. (E) PRO-seq and GRO-seq density correlations in gene 
body regions. (F) PRO-seq and poly-A RNA-seq (modENCODE_3138; GSM461182) 
densities in exons. The upward concave curvature of the distribution suggests the 
possibility of elongation rate, nascent RNA processing efficiency, or mRNA stability 
being positively correlated with density of transcribing polymerases. 
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Figure 2.3. Comparison of the PRO-seq , PRO-cap, and permanganate footprint 
average profiles in selected genes and their individual profiles. 
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Figure 2.4. Variations of the pause sites and TSSs. (A) Examples of highly paused 
genes with different pausing patterns. Initiation sites from PRO-cap mapping are 
shown in grey. (B) Distribution of paused genes (n=3,225) by the pausing position 
and dispersion percentiles. Focused-proximal (Prox, n=848) and dispersed-distal 
(Dist, n=846) groups are indicated and axis units in base-pairs are also shown. (C) 
Heat map of initiation (PRO-cap) and pausing (PRO-seq) for Prox and Dist genes. 
(D) Association between initiation and pausing patterns. ‘TSS focusing’ in Prox vs 
Dist genes (left) and ‘Pausing proximity’ in focused vs dispersed initiation genes 
(right). The fraction of PRO-cap reads at (±1 bp) the TSS over the sum of reads 
around (±50 bp) the TSS represents the ‘TSS focusing’22. Focused and dispersed 
initiation genes are the quartiles of the paused genes with the highest and the 
lowest TSS focusing respectively. Pausing Proximity Index is defined by the 
average of pausing position and dispersion percentiles. Boxes represent 25th, 
50th(median), and 75th percentiles; whiskers are 5th and 95th percentiles. Asterisks 
(*) indicate p<0.001 by Kolmogorov-Smirnov(KS) test. 
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The Prox and Dist pausing patterns could arise from a fixed length of 
elongation from initiation sites that have the same dispersion, or from variable lengths 
of elongation from more focused initiation sites. Distinguishing between these 
possibilities requires precise mapping of the initiation sites using the same pool of Pol 
II-engaged nascent RNAs. Therefore, we modified the PRO-seq method to detect 
initiation sites (PRO-cap) and compared the degree of variation in the initiation and 
the pause sites. We observed that both Prox and Dist genes have relatively focused 
initiation in general (Figure 2.4A, Figure 2.4D), and that pausing is overall more 
dispersed than initiation. Nonetheless, the degree of the focused initiation, the fraction 
of initiation arising exactly at a single TSS, is higher for Prox genes, and genes with 
more focused initiation also have more proximal pausing (Figure 2.4D). These 
findings indicate that although pausing is not fixed to initiation, the mechanisms that 
produce focused initiation affect the resulting pattern of pausing. 
In an effort to otherwise explain the differential patterns of pausing, we first 
compared the nucleosome occupancy around Prox and Dist promoters. Prox 
promoters have less nucleosome occupancy than Dist promoters (Figure 2.5A, Figure 
2.5B), and some Pol II at Dist promoters appear to have more intimate contact with the 
first nucleosome (Figure 2.5C).  These results (and Figure 2.1F) support a nucleosome 
independent mechanism of pausing for Prox promoters, whereas a subset of Dist 
promoters could have a component of pausing that is established by direct nucleosome 
barriers.  Because nucleosome position and occupancy does not explain the bulk of 
Pol II pausing, we investigated the underlying DNA elements around promoters.  
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Figure 2.5. PRO-seq relative to nucleosomes. (A) Micrococcal nuclease (MNase)-
seq profile relative to nucleosome centers in gene body and the first nucleosome. 
Nucleosome centers were defined from a local Gaussian fit of the MNase-seq 
data22 within 175 bp windows. Nucleosome center positions that were more than 2 
kb downstream of the TSS were considered gene body, and those that are 
between 0 to +200 bp from the TSS were considered the first nucleosomes. 
Regions of the nucleosome occupancy are shaded in grey. (B) MNase-seq profile 
relative to TSS in Prox and Dist genes. (C) Average PRO-seq profile relative to the 
first nucleosome center in Prox and Dist genes. Fit curves with broken strokes for 
the Dist genes show possible combination of the Prox fit and the gene body 
nucleosome fit (Figure 2.1F) that are centered at -83 and -44 from nucleosome 
centers, respectively. 
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Promoter DNA Elements Shape the Pausing Pattern  
Critical DNA sequence elements within the core promoter direct the position, 
direction and efficiency of transcription initiation25. These include the TATA box, 
Initiator (Inr), Motif Ten Element (MTE), the Downstream Promoter Element (DPE)25 
and a recently discovered element implicated in pausing, the Pause Button15 (Figure 
2.6A). Core promoter elements are more enriched on Prox than on Dist promoters 
(Figure 2.7A, Figure 2.6B-D). Additionally, when we searched within the extended 
promoter regions of Prox and Dist groups for the presence of 232 additional functional 
DNA elements26 (Figure 2.6E), only the GAGA element, residing ~80 bp upstream of 
the TSS15,27 shows strong associations with Prox genes (Figure 2.7B), as does the 
level of GAGA-factor binding. Thus, core promoter elements and GAGA-factor 
appear to play a significant role in the mechanism of pausing. 
Promoter DNA elements could be causing the variable pausing positions 
through direct tethering of elongating Pol II to the elements. Alternatively a ‘Complex 
Interaction’ model - where pausing is mediated through protein complexes that 
function best when cognate elements are located at specific positions in the core 
promoter. Thus, if we examine the association of the positions of the DNA elements 
and the pausing sites in this model, we expect a ‘V’-shaped plot of association rather 
than a simple linear correlation: displacement of the element from the optimal position 
will weaken the interactions within the core complex, resulting in downstream 
scattering and reduced level of pausing (Figure 2.7C). To test this, we examined genes 
where a particular promoter DNA element occurs only once, and divided genes into 
three subsets: the optimal consensus position, upstream and downstream. Genes with 
the DNA elements nearest to the consensus positions have more proximal pausing. 
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Figure S8. DNA elements in different pausing subsets 
(A) Structure of promoter DNA elements(24). GAGA element, TATA box, Initiator element (Inr), Motif Ten 
Element (MTE), Downstream Promoter Element (DPE), and Pause Button (PB)(26) are shown at the positions 
of their peak occurrences. Sequence logo(20) representation of each element is also shown. (B, C, D) 
Frequency of the core promoter elements in gene subsets of Prox or Dist pausing. Inr, MTE and DPE are 
shown respectively as described in Fig. 3B,C,D. (E) Heatmap of the difference in the occurrence of sequence 
elements between Prox and Dist groups. 232 regulatory DNA elements in two sub-panels from Stark et al.(25) 
were examined. The elements are ordered according to a hierarchical clustering. TE63 and ME137, both of 
which match the consensus for GAGA element, are the only elements showing noticeable enrichments.
Figure 2.6. DNA elements in different pausing subsets 
(A) Structure of promoter DNA elements. GAGA element, TATA box, Initiator element 
(Inr), Motif Ten Element (MTE), Downstr am Promoter Element (DPE), and Pause 
B tton (PB)1 a e shown at the positions of their peak occurre ces. Sequ ce logo 
representation of each element is also shown. (B, C, D) Frequency of the core 
promoter elements in gene subsets of Prox or Dist pausing. Inr, MTE and DPE are 
shown respectively. (E) Heatmap of the difference in the occurrence of sequence 
elements between Prox and Dist groups. 232 regulatory DNA elements in two sub-
panels from Stark et al.1 were examined. The elements are ordered according to a 
hierarchical clustering. TE63 and ME137, both of which match the cons sus for 
GAGA element, are the only elements showing noticeable enrichments. 
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Figure 2.7. Relationship between promoter DNA elements and Pol II pausing. (A) 
Frequency of TATA box and Pause Button (PB) in Prox and Dist subsets. The 
average frequency per gene is shown. (B) Frequency of GAGA element (lines) and 
GAF binding (shades) in Prox and Dist subsets. (C) ‘Complex interaction model’ 
between DNA elements and paused Pol II. The DNA elements (blue) are at their 
consensus (Strong) or slightly upstream (Weak) positions and the expected changes 
of the pausing positions are plotted. (D) Pattern of the positional association between 
DNA elements and pausing positions. Pausing position percentiles are shown for 
gene subsets by the element positions (Cs: optimal consensus position, Up: 
upstream, Dn: downstream). Asterisks indicate p-values for the KS test(***: p<0.002, 
**: p<0.06, *: p<0.14). (E) Association of promoter DNA element strength at 
consensus positions with Pausing Index(6). Active genes (n=5,471) are divided into 
three subsets according to the distance-weighted p-values of the DNA elements to 
the consensus positions. Asterisks indicate p-values for the KS test 
(**:p<0.001,*:p<0.01) 
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Genes with TATA at around -30 have more proximal pausing than the genes with 
TATA at positions of -40 or more, showing a ‘V’-shaped association (Figure 2.7D). 
This ‘V’ pattern was observed in both the upstream elements TATA and Inr (Figure 
2.8A), and the downstream elements PB (Figure 2.7D) and MTE (Figure 2.8B). Also, 
pausing tends to be stronger in genes with the elements at the optimal positions 
(Figure 2.8D). Furthermore, the extent of pausing shows strong dependency on the 
match of the DNA elements to their consensus sequence and consensus positions (data 
not shown). Together, these association patterns between core promoter elements and 
pausing support the ‘Complex Interaction’ model, and explain the strong and focused 
pausing on Prox promoters. 
 
Testing the Positional Association of the DNA Elements in Hsp70 
The ‘Complex Interaction’ model depends on both the presence and the correct 
positioning of core promoter elements. We disrupted the positional relationship of 
core elements in the well-studied Drosophila gene Hsp701. Transgenic fly lines were 
generated that carry mutant Hsp70 promoters with spacers inserted at the +15 position 
between the upstream and downstream promoter elements (Figure 2.9A), and analyzed 
by PRO-seq. The initiation sites remain constant in these mutant promoters, indicated 
by the 5’ ends of the PRO-seq reads (Figure 2.9B). The transgenic Hsp70 without 
spacers inserted shows a strong pause peak mainly at +31 (Figure 2.9C). When 5 bp 
are inserted, the pause peak is shifted 5-7 bp downstream from the original site. The 
additional bases transcribed before pausing again demonstrates that the position of 
pausing is not predetermined by elongation distance. When 10 bp are inserted, pausing 
sites become scattered between +20 to +60 (Figure 2.9D) and have fewer reads 
(Figure 2.9C). 
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Figure 2.8. Association between the strength or the position of promoter DNA 
elements and Pol II pausing or initiation (A) Pattern of positional association 
between Inr and pausing. Inr positions are -24 to -4 from TSS for upstream genes 
(Up, n=111), -4 to +1 from TSS for consensus positioned genes (Cs, n=131), +1 to 
+21 for downstream genes (Dn, n=110). (B) Pattern of positional association 
between MTE and pausing. Genes were divided based on the position of MTE in 
bins of 10 bp from TSS to +60 (n=56, 90, 70, 64, 52, 51). (C) Pattern of positional 
association between DPE and pausing. Genes were divided based on the position 
of DPE in bins of 10 bp from TSS to +60 (n=148, 102, 142, 105, 101, 97). Asterisks 
indicate p-values for the Kolmogorov-smirnov (KS) test (*** - p<0.0022, ** - 
p<0.021, * - p<0.066). (D) Pausing indices in genes with DNA elements at Up, Cs, 
and Dn positions. TATA and PB ge e subsets are the same sets used in Figure. 
2.8E; Inr subsets are the same sets used above; for MTE subsets, subsets 
containing MTE at 20’s, 30’s, and 40’s were used for Up, Cs, and Dn subsets 
respectively. 
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Collectively, these results support the core interaction model and suggest that the 
interaction complex can accommodate a small change (5 bp) in the positional context 
of the DNA sequences, but a larger change (10 bp) results in reduced and dispersed 
pausing. 
 
Conclusion 
The advances in resolution provided by PRO-seq enabled the precise and 
genome-wide assessment of the relationship between promoter-proximal pausing and 
the core promoter structure. For the strong and tightly clustered pausing of the Prox 
genes, we provide support for a ‘Complex Interaction’ model involving the promoter 
initiation complex which can extend up to 30 bp from the TSS28, physically contacting 
and tethering the pausing complexes. This may share a kinship with bacterial initiation 
factor σ that is retained within the early elongation complex and interacts with 
promoter proximal DNA during transcription pausing in E. coli29. Interestingly the 
Prox genes are expressed on average at a lower level but show a broader range of 
expression, and the Dist genes are enriched in constitutively active genes (Table 2.2). 
These results suggest that the mechanistic distinctions have regulatory consequences. 
A well-structured core promoter may strongly recruit Pol II; however, it can also 
effectively retain Pol II in a paused configuration close to the TSS, until activation 
signals allow its escape into productive elongation. 
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Table 2.2. Enrichment of Dist pausing group among constitutive genes. A list of 
constitutive genes from a developmental transcriptome study30 was examined for the 
number of genes in each Prox and Dist pausing groups. As defined in the original 
study, genes with short poly(A)+ RNA-seq levels greater than 1.0 FPKM in all 30 
developmental conditions were considered constitutively active30. In addition, genes 
that have significant PRO-seq reads from upstream genes were removed and only 
the ‘upstream clear’ genes were selected as the ‘active’ genes. Expected counts of 
the constitutive genes are derived from the proportions of each group in all genes. 
Asterisk (*) indicate p-value < 0.0043 by χ2 test. 
 All genes Constitutive genes (expected count) 
Active 5,471 3,557 
Paused 3,225 2,022 (2,097) 
Prox 848 492 (532) 
] * Dist 846 583 (530) 
 
 
Materials and Methods 
Cell culture and nuclei isolation 
Drosophila S2 cells were maintained in Shields and Sang M3 insect medium 
supplemented with 10% Fetal Bovine Serum, Bacto-Peptone and Yeast Extract at 
30°C. At 16~20 passages, nuclei were isolated as described previously with 
modifications6,20,21. All temperatures were at 4°C or ice cold unless otherwise 
specified. Briefly, cells were washed in PBS and resuspended in Buffer S (10 mM 
Tris-HCl pH 7.5, 10% glycerol, 3 mM CaCl2, 2 mM MgCl2 , 0.5 mM DTT, protease 
inhibitors cocktail (Roche), 4 u/ml RNase inhibitor (SUPERaseIN, Ambion) at the cell 
density of 2×107 cells/ml. After 5 min of incubation, 9× volume of Buffer L was 
added and immediately homogenized using a tight fitting pestle until over 90% of the 
nuclei were released. Nuclei were fractionated by centrifugation at 1000 g for 4 min 
and recovered from the pellet fraction. Recovered nuclei were washed twice in Buffer 
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L and once in Buffer D (50 mM Tris-HCl pH 8.0, 25% glycerol, 5 mM MgAcetate2, 
0.1 mM EDTA, 5 mM DTT). Washed nuclei were finally resuspended in Buffer D at a 
density of 2×107 nuclei/100 µl) and immediately frozen in liquid nitrogen. Nuclei 
were stored in -80˚C until usage. 
 
PRO-seq and PRO-cap library preparations 
Four parallel run-on reactions of PRO-seqATP, PRO-seqCTP, PRO-seqGTP and 
PRO-seqUTP were carried out as follows. 2×107 nuclei were added to the same volume 
of 2× Nuclear Run-On (NRO) reaction mixture (10 mM Tris-HCl pH 8.0, 300 mM 
KCl, 1% Sarkosyl, 5 mM MgCl2, 1 mM DTT, 500 µM biotin-11-A/C/G/UTP (Perkin-
Elmer), 0.8 u/µl RNase inhibitor) and incubated for 3 min at 30˚C. Alternatively, 375 
µM of each of all 4 biotin-11-NTPs were supplemented in the reaction for an 
abbreviated protocol (PRO-seq4NTP) or PRO-cap. Nascent RNA was extracted using 
Trizol and precipitated in 75% ethanol. Extracted nascent RNA was fragmented by 
base hydrolysis in 0.2 N NaOH on ice for 10~12 min, and neutralized by adding 1× 
volume of 1 M Tris-HCl pH 6.8. For PRO-cap, the fragmentation step was omitted. 
Excessive salt and residual NTPs were removed by using P-30 column (Bio-rad). 
Fragmented nascent RNA was bound to 30 µl of Streptavidin M-280 magnetic beads 
(Invitrogen) following the manufacturer’s instructions. The beads were washed once 
in high salt (2 M NaCl, 50 mM Tris-HCl pH 7.4, 0.5% Triton X-100), once in medium 
salt (300 mM NaCl, 10 mM Tris-HCl pH 7.4, 0.1% Triton X-100), and once in low 
salt (5 mM Tris-HCl pH 7.4, 0.1% Triton X-100). Bound RNA was extracted from the 
bead using Trizol (Invitrogen) in two consecutive extractions, and the RNA fractions 
were pooled, followed by ethanol precipitation. 
For the first ligation reaction, fragmented nascent RNA was redissolved in 
H2O and incubated with 10 pmol of reverse 3’ RNA adaptor (5'p-rGrArUrCrGrUrCrG 
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rGrArCrUrGrUrArGrArArCrUrCrUrGrArArC-/3’InvdT/) and T4 RNA ligase I (NEB) 
under manufacturer’s condition for 6 hr at 20˚C. For PRO-cap, the standard 3’ RNA 
adaptor (Illumina) was used. Ligated RNA was enriched with biotin-labeled products 
by another round of Streptavidin bead binding and extraction. To repair 5’ ends, the 
RNA products were treated with Tobacco Acid Pyrophosphatase (TAP, Epicentre) and 
Polynucleotide Kinase (PNK, NEB). Each reaction was followed by an ethanol 
precipitation step. For PRO-cap, PNK treatment step was omitted, and Antarctic 
phosphatase (AP, NEB) was used to treat the RNA preparation prior to TAP treatment 
to enrich for 5’ capped RNA. Since these procedures repair 5’ ends after the 3’ 
ligation, self-circularized products were not expected during the first ligation step. 
5’ repaired RNA was ligated to reverse 5’ RNA adaptor (5'-rCrUrGrArArCrArArGrC 
rArGrArArGrArCrGrGrCrArUrArCrGrA-3' or 5'-rCrCrUrUrGrGrCrArCrCrCrGrArG 
rArArUrUrCrCrA-3’ for using TruSeq barcodes (Illumina)). Standard 5’ RNA 
adaptors were used for PRO-cap. Ligated RNA products were further enriched for 
biotin-labels by the third round of streptavidin bead binding and extraction. Adaptor 
ligated nascent RNA was reverse transcribed using 25 pmol RT primer (5’-AATGAT 
ACGGCGACCACCGACAGGTTCAGAGTTCTACAGTCCGA-3’(GX2 primer, 
Illumina) or 5’- AATGATACGGCGACCACCGAGATCTACACGTTCAGAGTTCT 
ACAGTCCGA-3’ for TRU-seq barcodes (RP1 primer, Illumina). Standard Illumina 
RT primers were used for PRO-cap. 
A portion of the RT product was removed and used for trial amplifications to 
determine the optimal number of PCR cycles. For the final amplification, 12.5 pmol of 
GX1 primer (Illumina) or RPI-index primers (for TRU-seq barcodes, Illumina) was 
added to the RT product with Phusion polymerase (NEB) under standard PCR 
condition. Excess RT primer served as one primer of the pair used for the PCR. The 
66 
 
product was amplified 12~18 cycles and PAGE purified before being analyzed by 
Illumina’s GenomeAnalyzer 2 or HiSeq 2000 machines. 
 
Processing raw sequence data for polymerase active site mapping 
Raw sequences were preprocessed using FASTX-Toolkit. Adaptor sequences were 
removed from the raw sequences using ‘fastx_clipper’, and the first 26 bases were 
trimmed with ‘fastx_trimmer’. Sequence reads shorter than 16 bases were removed. 
The first bases, which were the reverse complements of 3’ end bases, were counted for 
each library to verify that the 3’ ends represent the polymerase active sites (Table 2.1). 
Indeed, the majority of the sequences had the same 3’ end base as the biotin-NTP that 
was added in the run-on reaction, indicating that the identified sequences define the 3’ 
ends that are exactly at or near the Pol II active sites.   
Reverse complements of the sequence reads, which were the sense sequences of 
nascent RNA, were generated using ‘fastx_reverse_complement’. Each of the 4 biotin-
NTP libraries was aligned to the Drosophila melanogaster (Dm3) reference genome 
using Bowtie31 allowing 2 mismatches and excluding any non-uniquely aligned reads. 
The histograms of the 3’ end positions in base pair resolution were generated in the 
‘bedgraph’ format.  
 For the normalization of the 4 biotin-NTP libraries to generate a composite 
profile, we first assumed that the probability of finding polymerase on difference bases 
in the bodies of the genes (GB) were uniform. Under this assumption, a normalization 
factor should be multiplied to a library such that the sum of the normalized reads 
mapped to the gene body divided by the corresponding base counts in the gene body 
regions becomes uniform throughout different base libraries. The normalization factor 
for each library is calculated as follows, 
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, where GB is the set of all gene body positions (table S4). 
Using the normalization factors, composite PRO-seq histogram (in bedgraph format) 
was generated. 
 
 
This composite PRO-seq dataset was used for the downstream analysis unless 
specified otherwise. 
 
Analysis of pausing level and gene activity 
 For the analysis of pausing level and gene activity, we first generated a list of 
genes for which the PRO-seq densities could be measured without having interference 
from other genes. From the scRNA-seq based re-annotated gene list16, we defined 
promoter upstream, promoter downstream, and 5’ genic regions as -300 to -100 bp, 
+300 to +500 bp, and 0 to +500 bp from TSS respectively. For each region of the 
individual genes, we calculated ‘active site coverage’, which is the fraction of 
positions covered by 3’ end of PRO-seq reads within each region. Because of the 
normalization, some positions have read counts less than 1 and we considered these 
positions partially covered. Active site coverage can be formulated as follows. 
We called genes ‘upstream clear’ if promoter upstream region had the active 
site coverage of less than 0.01, or less than one fourth of the downstream region active 
site coverage (n=11,584). This was intended to filter out genes that have polymerase 
transcribing through from the upstream genes that can interfere with the downstream 
Normalization factorbase =
Readsmapped toGBi
BasecountsinGBii=A,C,G,U
∑ 4 Readsmapped toGBbaseBasecountsinGBbase
PROseq(pos) = Normalization factorbase ⋅PROseqbase(pos)
base=A,C,G,U
∑
Activesitecoverage(region) = max PROseq(pos),1( )
pos∈region
∑ lengthof theregion
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levels. Among the ‘upstream clear’ genes, we called genes ‘active’ if the active site 
coverage in 5’ genic regions was greater than 0.01 (n=5,471). 
To calculate the pausing level, PRO-seq read counts per million normalized 
mapped reads (RPM) from -50 to +150 relative to TSS were obtained and the sum of 
the read count was divided by the length of the region (0.2 kb) to generate RPM per 
kb, or RPKM which equivalent to the commonly used definition of RPKM in RNA-
seq. For the consistency of the unit usage, we also used RPKM to describe PRO-seq 
profiles for individual genes along the positions on the genome, regarding that a RPM 
read count on a single base position can be considered as a RPKM density for a 0.001 
kb region. 
For the gene body activity, we used active site coverage instead of read counts 
to minimize the effects of unexpected spikes or unannotated transcription initiation 
within the gene body region. This modified PRO-seq density was calculated by 
multiplying a conversion factor to the active site coverage from +300 from the TSS to 
the 3’ end of the gene and RPKM normalized. For genes that contain another 
annotated TSS within the gene body, we truncated their gene body region to -300 bp 
from any downstream annotated gene starts. The conversion factor is given below. 
 
 
All the densities were adjusted by the mappability of 26 bp sequence uniquely to the 
genome. 
 
Conversion factor =
PROseq(pos)
pos∈GB∑
Activesitecoverage(GB) ⋅lengthof GB
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Data visualization using scatterplots, average profiles and heatmaps 
The scatterplots were generated using in-house scripts. Briefly, on a 
1,000×1,000 pixel bitmap, each data-point was represented as filler circles with 11 
pixel diameter on log axes. For each pixel, data-point counts were stackable. After 
plotting all the data-points, the counts in each pixel was converted to a color code, and 
the image was anti-aliased. The scale-bars for the color code were shown together 
with the colored scatterplot images. Pearson coefficients were presented on the 
scatterplots 
Average profiles relative to position lists were generated using modified 
bootstrap methods and permutation tests. Briefly, position lists of N genes were 
randomly partitioned into [N/100] subsets (integer part of N/100) each containing 
~100 members. The average profile of each subset was calculated removing 2 greatest 
and least outliers per relative positions. The average and the standard error of the 
subset profiles were calculated and usually plotted together respectively as a line and 
margins surrounding the line in shades. Gaussian smoothing was applied to the 
profiles if necessary using the formula below, 
smoothed profile(pos) = φ(2i / b) ⋅raw profile(pos+ i)
i=−3b/2
3b/2
∑ φ(2i / b)
i=−3b/2
3b/2
∑  
where ϕ(x)=exp(-x2/2) is the Gaussian density function, and b is the bandwidth of 
smoothing which is twice the standard deviation of regular Gaussian distribution. A 
data value is smoothed over 3 bandwidths around the data point. For most profiles, 
smoothing bandwidth of 2 bp was used unless specified otherwise. 
Scaled ‘metagene’ profile was generated as described previously20, with 
modification to the scaled region of the gene body being TSS +1 kb to 3’ end −1 kb of 
the gene. A smoothing bandwidth of 200 bp was used. 
Heatmaps were generated using in-house scripts. Briefly, a data matrix of 
PRO-seq read counts, with genes on the rows and relative position to each TSS on the 
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columns, was scaled to a 200×1,000 matrix with an algorithm that uses incremental 
accumulators for each pixel. The data values were converted to color codes and the 
image was anti-aliased. Typically, this generated moderately averaged profiles for 
gene lists containing more than 10,000 genes, but represented individual genes 
relatively well for comparing gene subsets containing up to 1,000 genes. 
 
Pause peak identification and paused gene clustering by pausing pattern 
With the ‘active’ genes (n=5,471) listed above, we defined PRO-seq peaks using a 
clustering algorithm. Briefly, for each gene, we scaled the number of reads to 1,000 
pseudo-reads maintaining their relative positions in the promoter proximal region (-50 
to +150 from TSS), and applied a k-means clustering algorithm by their positions to 
identify the peaks. The number of clusters (k), i.e. the number of peaks, was 
determined by taking the minimum k for which the variance to the cluster centroid 
was less than 5 (bp×bp). The k value was modified within ±1 range to have the local 
maximum of the average silhouette. For each peak, the total read count of the actual 
reads was calculated, and major peaks greater than one fourth of the maximum peak of 
the region were selected. Each peak is assigned with two parameters, average position 
and total read count. We repeated the same peak calling algorithm in promoter 
downstream regions (+300 to +500), and called a gene ‘paused’ if the total read count 
of the maximum peak at promoter proximal region is greater than 4 times the read 
count of the maximum peak at the promoter downstream region (n=3,225). These cut-
offs are chosen for the purpose of relative comparison between groups, but they do not 
necessary define pausing per se6. For each paused gene, we calculated the median 
position of the peaks and the average dispersion of the peaks weighted by the read 
counts. We calculated the percent rank of the median position and the average 
71 
 
dispersion within the paused genes subset and defined them as ‘position percentile’ 
and ‘dispersion percentile’ of the peaks respectively for each gene. 
For the 2D heatmap representation of the pausing pattern on the position-
dispersion axes, we used an in-house script (Fig. 2.4B). Briefly, each gene was added 
as a 2D Gaussian peak, 
 
where x and y are the relative position to the position vs dispersion percentile 
coordinate of the gene on a 2D space [0,1]×[0,1], and b is the bandwidth of the peak 
(20%). The overall density on the 2D space was normalized by dividing by the total 
gene number. Therefore, the integral over an area reflects the probability of finding a 
gene in the corresponding position-dispersion range, and the integral over the whole 
2D space, which is the probability of finding a gene over the whole region, equals 1. 
To further identify the two apparent clusters of the genes- ‘Clustered proximal’ (Prox) 
on the lower left quadrant and ‘Dispersed distal’ (Dist) on the upper right quadrant- in 
Fig. 2B, we employed an Expectation-Maximization algorithm. This was done using 
the ‘Mclust’ package in R software. Briefly, we performed Mclust on the position-
dispersion dataset with the prior specification of 2 clusters with ellipsoidal model 
(variable volume, shape, and orientation of covariance matrix: ‘VVV’ model), and 
initialization of a Poisson noise model (p=0.25). This was done iteratively and a 
representative set was chosen. Two clusters were generated allowing outliers, and we 
determined the cut-offs for their z-scores (Prox: 0.15, Dist: 0.08) to have maximum 
number of non-overlapping elements and least difference in cluster sizes. Genes were 
assigned to Prox or Dist clusters if their z-scores were smaller than the cut-offs 
(n=848, 846 respectively). The average profiles show similar pausing distributions as 
anticipated by individual cases. Since the majority of the genes lie on the diagonal of 
φ(x, y) = 12π (b / 2)2 e
−(x2+y2 )/2(b/2)2
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the position-dispersion space, we defined the Pausing Proximity Index (PPI) as the 
average of the pausing position percentile and the pausing dispersion percentile. 
 
Analysis of the initiation from PRO-cap 
PRO-cap results were processed in the same way as PRO-seq, except that the 5’ ends 
of non-reverse complemented sequence reads were used and the promoter proximal 
window was set to be -100 to +100 from the TSS. Average relative profile was 
generated by first dividing the read counts by total number of reads in the promoter 
proximal window for each gene, and then calculating the average plots afterwards. 
This allowed us to examine the average pattern of initiation at the TSS without having 
the pattern be overly affected by genes with the highest read counts. 
To compare the dispersion pattern of initiation and pausing, we used the identical 
script to identify the initiation peaks. For a direct comparison, the dispersions were 
shown in the actual number of base pairs instead of the percentiles in boxplots. 
To assess the focusing of initiation, we defined the ‘read fraction at TSS’ 
parameter (frTSS) for each gene as described previously with modifications22. 
  
 
 
Scoring the positions and the strengths of the DNA elements 
Promoter DNA elements were identified from promoter proximal regions using 
existing position weight matrices (PWM) or consensus sequences by a fast permutated 
string-match algorithm. First we extracted a sequence substring from the promoter 
proximal sequence of each gene on every position, and calculated the PWM score. The 
score was compared to a cumulative distribution function (CDF) of the scores of 
100,000 permutated sequences that were randomly generated using the same 
frTSS =
PROcap(pos)
pos∈TSS±1bp∑
PROcap(pos)
pos∈TSS±25bp∑
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background letter frequencies. From the CDF, p-values were obtained for every 
position on the promoter proximal region of a gene. When the PWM was not 
available, we built a PWM from the log-likelihood of the consensus match at matched 
letters and 0 at non-matched letters.  
We identified the positions and the strengths of DNA elements by generating a 
log likelihood array (-log p-value) for each gene at every position (Figure 2.6B-D). 
The array was smoothed with a modified Gaussian smoothing, 
Smoothed logL (pos) =max φ(2i / b) ⋅ logL (pos+ i);− 32 b < i < 32 b( )  
where Smoothed logL(pos) is the smoothed profile for relative position pos, logL(pos) 
is the log likelihood profile at position pos, b is the bandwidth of the Gaussian curve 
for smoothing, and ϕ(x)=exp(-x2/2) is the Gaussian density function. This type of 
smoothing reports the strongest element nearby that is modified by a distance factor 
dependent on the bandwidth, and reflects the probability of finding a factor binding at 
the position within the bandwidth. A bandwidth of 10 bp was used for core promoter 
elements and 40 bp for GAGA elements. 
 
Generation of the fly lines with sequence modified Hsp70 promoter transgenes (This 
part was done by Dr. Nick Fuda) 
Adult flies carrying sequence modified Hsp70 promoter transgenes (Figure 2-
9A) were made as described below. First, the Hsp70 gene was amplified and cloned 
into pBluescriptII KS+. The 5 bp insert and 10 bp insert transgene were created using 
site-directed mutagenesis with the following primer sets; +5 bp forward: 5’-CGACGG 
AGAGTCAATTCAATTCAAACAAAACAAGCAAAGTGAACACATCG C-3’; +5 
bp reverse: 5’-GCGATGTGTTCACTTTGCTTGTTTTGTTTGAATTGAATTGACT 
CTCCGTCG-3’; +10 bp forward: 5’-CGACGGAGAGTCAATTCAATTCAAACAA 
74 
 
TGAGTCACAAGCAAAGTGAACACATCGC-3’; +10 bp reverse: 5’-GCGATGTG 
TTCACTTTGCTTGTGACTCATTGTTTGAATTGAATTGACTCTCCGTCG-3’.  
The gene was cut out of the wild type (Hsp70wt), 5 bp insert (Hsp70+5), and 
10 bp insert (Hsp70+10) plasmids with XbaI to yield a fragment from -245 to +1863 
(relative to the TSS), and cloned into a modified pCasper4 containing the attB site32. 
The ΦC31-mediated transformation was performed by Best Gene Inc. to insert each 
transgene into 22A3 (PBac{yellow[+]-attP-3B}VK00037). The lines were balanced 
and crossed to Hsp70 null flies33 (Bloomington 8841: w1118; Df(3R)Hsp70A, 
Df(3R)Hsp70B) to create homogenous stocks.  
 
PRO-seq and the analysis of transgenic Hsp70 promoter fly lines 
The nuclear isolation from adult flies was adapted as described previously27. One gram 
of flies were homogenized in 15 ml cold Buffer A (10 mM Tris-HCl pH 8.0, 30 0mM 
sucrose, 3 mM CaCl2, 2 mM MgOAc2, 0.1% TritonX-100, 0.5 mM DTT) for 1 minute 
using the Omni-mixer, the homogenate was filtered through 100 um nylon mesh into a 
40 ml Dounce homogenizer. After 40 strokes in the homogenizer, the homogenate was 
filtered through 35 um nylon mesh and mixed with an equal volume of Buffer B (10 
mM Tris-HCl pH 8.0, 2 M sucrose, 5 mM MgOAc2, 0.5 mM DTT). The homogenate 
was then layered over 10 ml Buffer B in 35 ml Ultracentrifuge tube, and centrifuged 
through the Buffer B cushion at 12 krpm for 25 minutes at 4˚C in a SW28 swinging 
bucket rotor. The supernatants were removed, and the nuclei were resuspended to the 
density of 1×108 nuclei/ml in 1 ml buffer C (50 mM Tris-HCl pH 8.0, 25% glycerol, 5 
mM MgOAc2, 0.1 mM EDTA, 5 mM DTT).  
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CHAPTER 3c 
 
RNA POLYMERASE II PAUSING AND TERMINATION KINETICS AT THE 
DROSOPHILA HSP70 PROMOTER IN VIVO 
Summary 
Many metazoan promoters have a high occupancy of transcriptionally engaged 
RNA polymerase II (Pol II) relative to their gene bodies1-5. Although it is widely 
accepted that Pol II is paused near promoters, this accumulation could also be a 
consequence of polymerases that are rapidly initiating and then terminating 
prematurely similar to some prokaryotic and viral promoters6,7.  Notably, in addition 
to pausing factors, termination factors are also enriched at metazoan promoters, and 
the depletion of each can alter the distribution of Pol II8.  These findings raise the 
possibility that polymerases might undergo cycles of initiation and non-productive 
elongation.  However, current Pol II occupancy measurements are insufficient to 
define the fate of promoter proximal Pol II in vivo. Here we show the kinetic status of 
the promoter proximal Pol II through a combination of complementing optical and 
biochemical strategies in Drosophila.  By tracking the fate of photo-activatable-GFP 
tagged Pol II at the Hsp70 locus on polytene chromosomes, we found that Pol II is 
stably paused and has a half-life of 5 minutes on the uninduced gene.  Biochemical 
analysis of short nascent RNA from Hsp70 showed that this half-life is composed of 
Pol II that has the both probabilities of escaping into productive elongation and non-
productively terminating.  We further confirm this termination rate using optical 
                                                
c Works in this chapter was done in collaboration with Dr. Martin S. Buckley. Extents 
of contributions are noted in the figure legends.  
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measurements after blocking the productive elongation with a chemical inhibitor, 
Flavopiridol9.  These findings show that the competing fates of paused Pol II to 
termination and to escape into productive elongation can modulate transcription levels. 
 
Optical Measurement of Pol II Stability in Hsp70 
The Drosophila Hsp70 heat shock gene possesses a promoter-proximal Pol II 
that has been extensively characterized10.  Notably, many of the features of the paused 
Pol II at uninduced Hsp70 are similar to the large number (70% of active Drosophila 
genes) containing paused Pol II11.  In addition, many of the proteins identified to be 
involved in Hsp70 gene regulation have corresponding activities at other genes in 
various organisms10.  These findings indicate that the mechanisms governing Hsp70 
gene regulation are general.  Therefore, in order to gain insights into the status of the 
promoter-proximal paused Pol II, we focused our efforts on measuring the stability of 
paused Pol II at Drosophila Hsp70 (Figure 3.1).  
To address this, we first made use of an optical approach to measure the 
stability of photoactivatable GFP (paGFP)-tagged Pol II at the Hsp70 locus on 
Drosophila salivary gland polytene chromosomes (Figure 3.2A).  These interphase-
like giant chromosomes have been used as a platform for high-resolution imaging12.  
Dynamics of Pol II and other transcription factors can be measured by optical pulse-
chase experiments such as fluorescence recovery after photobleaching (FRAP) at 
induced Hsp70 gene loci (87A and 87C) in living cells13-15.  These FRAP studies rely 
on the fact that the activated 87A/C heat shock (HS) loci can be unambiguously 
localized using a distinctive puff doublet pattern formed by fluorescently labeled Pol 
II subunits such as eGFP-Rpb313-15.  However, under basal conditions, identifying the 
Hsp70 gene loci is technically challenging, since paused eGFP-Rpb3 signal from 
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Hsp70 is too weak to reliably identify from other bands and perform photobleaching 
analysis. 
To circumvent this problem, we engineered a transgenic fly line that contains 
the full length Hsp70 gene marked with 256 repeats of Lac operator sites (LacO), that 
when bound by the mCherry tagged-Lac repressor (mCherry-LacI), allows us to easily 
identify the uninduced Hsp70 loci in salivary gland nuclei (Figure 3.2A). 
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Supplementary Figure 1. Schematics of Pol II kinetics at pause site.  Pol II near TSS can be 
described by a mixture of multiple first order kinetics.  The half-life of paused Pol II can be 
directly measured by the decay of photoactivated Pol II (green) on the polytene chromosome.  
This paused Pol II can elongate into the gene body with a rate constant of kel or terminate with a 
rate constant of kt.  The short nascent RNA associated with paused Pol II or terminated Pol II 
can represent the amount of Pol II molecules themselves. Under the assumption that the short 
nascent RNA at the free fraction is at steady-state, the production rate of free nascent RNA, 
kt[RNA]ch should be equal to the decay rate of the free nascent RNA, kd[RNA]fr.  kd can be 
directly calculated by inhibiting the initiation with Triptolide, and measuring the time-course of 
the nascent RNA decrease.  From these values, kt could be determined as kd([RNA]fr / [RNA]ch). 
Figure 3.1. Schematics of Pol II kinetics at the pause site.  Pol II near TSS can be 
described by a mixture of multiple first order kinetics.  The half-life of paused Pol II 
can be directly measured by the decay of photoactivated Pol II (green) on the 
polytene chromosome.  This pau ed Pol II can elongate into the gene body with a 
rate con tant of kel or terminate with a rate constant of kt.  The short nascent RNA 
associated with paused Pol II r termi ated Pol II can represent the amount of Pol 
II molecules themselves. Under the assumption that the short nascent RNA at the 
free fraction is at steady-state, the production rate of free nascent RNA, kt[RNA]ch 
should be equal to the decay rate of the free nascent RNA, kd[RNA]fr.  kd can be 
directly calculated by inhibiting the initiation with Triptolide, and measuring the 
time-course of the nascent RNA decrease.  From these values, kt could be 
determined as kd([RNA]fr / [RNA]ch). 
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Figure 3.2. Imaging the stability of paused Pol II at uninduced Hsp70 transgene in 
living cells.  (A) Schematic diagram of live-cell imaging experimental set-up.  The 
transgenic construct contains 256 LacO repeats followed by Hsp70 sequence which 
is flanked by the insulator elements scs and scs’.  (B) During NHS, images of Hsp70 
transgene marked with mCherry-LacI before and after photoactivation of Rpb9-
paGFP and the time course that follows.  The strongest paGFP-Pol II signal is 
outlined in white.  (C) During HS, images of mCherry-LacI, Rpb9-paGFP, and merge 
at Hsp70 transgene.  (D) Normalized fluorescence intensities of Rpb9-paGFP 
flourescence decay after photoactivation (FDAP within outlined region in b) under 
NHS conditions; n=9.  Error bars indicate SD.  Scale bar, 10 µm. Data for this figure 
was generated by Dr. Martin S. Buckley. 
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HS induction of the transgene leads to a response similar to the native HS loci 
(decondensation and additional recruitment of Pol II)15, indicating that it is functional.  
Using this system, we designed an optical pulse-chase experiment by photoactivating 
Pol II subunits instead of photobleaching16, at the marked Hsp70 locus, using a 
transgenic fly that expresses a paGFP tagged subunit of Pol II (Rpb9-paGFP) in the 
salivary gland nuclei.  Rpb9-paGFP distributes on chromosomes bands in a pattern 
identical to the fluorescently tagged Rpb3 subunit (RFP-Rpb3), under basal conditions 
and HS conditions.  Moreover, like Rpb3, Rpb9-paGFP reliably locates to the 
mCherry-LacI tagged Hsp70 transgene before and after HS. 
Rpb9-paGFP is fluorescently inert at the Hsp70 transgene before 
photoactivation (Figure 3.2B).  In order to directly assay the dynamics of paused Pol II 
at the Hsp70 loci, laser scanning confocal microscopy (LSCM) was used to 
specifically photoactivate Rpb9-paGFP (~14 fold increase in fluorescence) at the 
mCherry-LacI marked Hsp70 transgene under non-heat shock (NHS) conditions (Fig. 
1a).  We then obtained a time series of the fluorescence decay of Rpb9-paGFP at the 
Hsp70 transgene (Figure 3.2B).  To validate that the locus examined was the Hsp70 
transgene and not some other gene near the single mCherry-LacI band in nuclei, we 
determined that Rpb9-paGFP signal is specific is heat shock inducible (Figure 3.2C).  
We also demonstrated that the decay of signal is due to loss of the photoactivated 
Rpb9-paGFP from the locus and not photobleaching by showing that photobleaching 
is minimal during the time course of imaging.  The resulting decay plot corresponds 
approximately to a first order kinetics with the half-life of around 5 min (Figure 3.2D).  
This finding indicates that Pol II is relatively stable at this locus.  Because the main 
form of Pol II at the uniduced Hsp70 locus is paused Pol II, this suggests that this Pol 
II is stably associated with a turnover half-life of 5 min. 
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Biochemical Measurement of Pol II Stability by Nascent RNA Fractionation  
 Although paused Pol II at Hsp70 appears to be relatively stable, it does not 
have an infinite lifetime.  We reasoned that the clearance of the paused Pol II would be 
the sum of escape into elongation and premature termination.  To measure their 
contributions to the stability of paused Pol II, we used an independent biochemical and 
kinetic approach in Drosophila S2 cells (Figure 3.3A, Figure 3.1).  First, we evaluated 
the escape into elongation by calculating the kinetic constant of the polymerase 
escaping into the gene body.  The rate of escaping Pol II can be derived from the gene 
body Pol II density and the speed of Pol II elongation.  By dividing this rate by the 
total amount of paused Pol II, the kinetic constant of escape (fraction of paused Pol II 
that escapes into elongation per minute) can be calculated (Figure 3.4). 
For this measurement, we used pre-existing nuclear run-on sequencing (GRO-seq or 
PRO-seq) datasets in S2 cells (Figure 3.3B), and the elongation speed of 1.5 kb/min 
from previous FRAP study in Hsp7013 as independent measurements of the Pol II 
elongation rate on Drosophila genes.  The run-on sequencing results show that at 
Hsp70, about 86% of engaged Pol II are restricted to promoter proximal region on 
average while 13% are distributed in the 2.4 kb gene body region (Figure 3.3C).  From 
these numbers, we calculated that about 9.4% of paused Pol II escapes into elongation 
every minute, or in other words, each Pol II has an escape half-life of 7.3 min.  This 
measurement agrees well with the half-life estimate derived from the density of 
transcribing RNA polymerase at Hsp70 loci in electron micrographs of Miller spreads 
(data not published). Interestingly, this half-life estimate shows minor discordance 
from the optical measurement (5 min), indicating that  Pol II escaping to elongation 
composes a significant fraction, but probably not all of the loss of paused Pol II seen 
optically. 
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Figure 3.3. Biochemical analysis of steady state paused Pol II kinetics.  (A) 
Schematic diagram of paused Pol II and associated short nascent RNA kinetics on 
chromatin and in free fractions.  (B) Average GRO-seq profile on Hsp70 gene.  
Vertical axis is the fraction of GRO-seq read counts in 50 bp bins relative to the 
total read counts across Hsp70 gene (n=14 datasets).  Error bars indicate SD.  (C) 
Fraction of GRO-seq reads mapped to pause peak (-50 to +250 from TSS) and 
gene body (+300 to 3’ end).  (D) Ratio between free and chromatin bound fractions 
of short nascent RNA associated with Hsp70 TSS (n=9).  (E) Time-course of free 
Hsp70 nascent RNA after Triptolide addition (10 µM).  Each time-point is 
normalized to pre-treatment level.  Error bars indicate SEM unless noted otherwise. 
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Supplementary Figure 9.  Estimation of the rate constant of elongation (kel) from pausing.  
By the definition of rate constant, the amount of Pol II escaping during a short time period ∆t is 
kel[Pol II]pr∆t, where [Pol II]pr is the level of Pol II at the promoter.  During ∆t, the first escaped 
Pol II travels a distance of v∆t, where v is the elongation speed of Pol II.  Pol II that escaped 
during ∆t will be distributed within this range, and the amount of escaped Pol II will be v∆t·λ, 
where is λ is the Pol II density in the gene body.  Pol II level at the promoter and gene body is 
obtained from GRO-seq datasets on Hsp70 gene.  From these values, kel could be determined as 
vλ / [Pol II]pr. 
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Figure 3.4.  Estimation of the rate constant of elongation (kel) from pausing.  By the 
definition of rate constant, the amount of Pol II escaping during a short time period 
∆t is kel[Pol II]pr∆t, where [Pol II]pr is the level of Pol II at the promoter.  During ∆t, 
the first escaped Pol II travels a distance of v∆t, where v is the elongation speed of 
Pol II.  Pol II that escaped during ∆t will be distributed within this range, and the 
amount of escaped Pol II will be v∆t·λ, where is λ is the Pol II density in the gene 
body.  Pol II level at the promoter and gene body is obtained from GRO-seq 
datasets on Hsp70 gene.  From these values, kel could be determined as vλ / [Pol II]pr. 
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Next we evaluated the rate of premature termination.  Terminated Pol II is no 
longer associated with chromatin and will be freely released, along with the short 
nascent RNA derived from the same Pol II molecule (Figure 3.3A, Figure 3.1).  The 
ratio between terminated and paused RNAs will then reflect the rate of termination 
(see methods).  We measured the amount of short nascent RNA arising from Hsp70 
TSS in both chromatin-associated (paused) and free (terminated) fractions.  The free 
fraction was on average 41% of the chromatin bound fraction (Figure 3.3D), 
suggesting that a significant amount of Pol II may be terminating from the Hsp70 
pause site. 
To estimate the kinetic constant of termination, we analyzed the flux of short 
nascent RNA in and out of the free fraction (Figure 3.3A, Figure 3.1).  At steady state, 
since free nascent RNA is generated from terminating Pol II, the rate of free nascent 
RNA production should be equal to the rate of the free RNA decay.  In this case, the 
kinetic constant of termination equals the constant for RNA decay multiplied by the 
ratio between free and chromatin bound short nascent RNA levels (Figure 3.3A, 
Figure 3.1).  To estimate the decay constant, we blocked the RNA production at the 
initiation step by using Triptolide, a potent chemical inhibitor of TFIIH helicase17, and 
measured the time-course of free nascent RNA decay.  The time course showed a 
decay half-life around 6 min (Figure 3.3E), and the calculation of the termination 
kinetic constant implies that 4.6% of paused Pol II undergoes termination per every 
minute.  After combining these estimates of termination (4.6%) and elongation (9.4%), 
about 14% of paused Pol II is cleared from the pause site per minute, which 
corresponds to the half-life of 5.0 min.  It is reassuring that the two independent 
methods - biochemical steady-state kinetics and the optical pulse-chase measurements 
- are in such close agreement (Table 3.1).  
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Table 3.1. Rate constants for the kinetics of promoter proximal Pol II 
Method Rate Description Value (min-1) Half life (min) 
Optical puls
e-chase 
k ctrl Overall stability 0.13 5.4 
k FP Elongation blocked by FP 0.072 9.6 
Biochemical
 steady-stat
e 
k el Elongation by GRO-seq 0.094 7.3 
k t Termination in steady-state 0.046 15 
k cl Overall stability (= k el + k t) 0.14 5.0 
 
 
 
Both Pause Escape and Termination Can Be Optically Measured Separately. 
The Pol II CTD-kinase P-TEFb is required for the escape of paused Pol II into 
productive elongation at most genes including Drosophila Hsp703,9,18. Therefore, to 
further confirm the early termination rate of paused Pol II in vivo, salivary glands were 
treated with the P-TEFb kinase inhibitor Flavopiridol to block transcription elongation 
(Figure 3.6A).  The termination rate was then optically measured by assaying the 
fluorescence decay after photoactivation of Rpb9-paGFP at the uninduced Hsp70 
transgene (Figure 3.6B).  The decay curves show the stabilization of Pol II (Figure 
3.6C) and near doubling of the half-life with Flavopiridol treatment (Figure 3.6D, 
Table 3.1), indicating that the elongation and termination can also be distinctly 
measured using optical methods in vivo.  Together, the optical and biochemical 
analyses provide a strong indication that paused Pol II is relatively stable and 
undergoes both productive elongation and termination in vivo. 
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Figure 3.6. Optical measurement of the termination rate of paused Pol II at Hsp70 
transgene in living cells.  (A) Schematic diagram outlining overall logic of using 
Flavopiridol to measure paused Pol II termination kinetics.  (B) Illustration of the 
experimental scheme.  (C) Semi-log plot of normalized fluorescence intensities of 
paGFP-Rpb9 FDAP under NHS condition in the presence (filled circles) and the 
absence (empty circles) of Flavopiridol treatment; n=7 and n=9, respectively.  Data 
corrected for background Pol II signal, see methods.  Error bars indicate SD.  (D) 
Half-lives of paused Pol II decay with Flavopiridol treatment and control using the 
data in panel c.  Error bars indicate SEM. 
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Conclusion 
The prevailing model for regulation of paused Pol II proposes that recruitment 
of elongation factors such as P-TEFb facilitate the escape of Pol II into productive 
elongation19.  This mode of regulation implies that paused Pol II stably associates with 
promoters until factors are recruited to trigger its release.  Here we provide evidence 
that the canonical paused Pol II at the Drosophila Hsp70 gene is dynamic and 
undergoes both termination and elongation.  This raises the intriguing possibility that 
premature termination plays a role in metazoan gene regulation.  Importantly, these 
findings provide a new avenue for future studies to assess the termination status of 
paused Pol II genome-wide and importantly, its potential contribution to gene 
regulation. 
 
 
Materials and Methods 
Generations of the transgenic fly lines 
Fly lines are generated and maintained by Dr. Martin S Buckley in the Lis lab. 
Hsp70 transgenic fly line:  The Hsp70 gene region (-252 to +2439) was PCR 
amplified from the 56H8 plasmid20, and cloned into pBSIIKS vector (Agilent 
Technologies) creating pBSIIKS-Hsp70.  The SCS/SCS’ boundary elements were 
amplified from w1118 flies  and sequentially cloned into pBSIIKS-Hsp70 to generate 
pBSIIKS-SCS-Hsp70-SCS’.  LacO repeats (256x) were digested from the vector 
pps8.32 (ref) and cloned into the pSTBlue-1 (Millipore) using XhoI/SalI sites creating 
pSTBlue-1-LacO.  The SCS-Hsp70-SCS’ fragment was digested from PBSIIKS-SCS-
Hsp70-SCS’ and cloned into pSTBlue-1-LacO using ApaI/SpeI sites to create 
pSTBlue-1-LacO-SCS-Hsp70-SCS’.  Internal restrictions sites for SphI/NotI were 
introduced to pCasperII(attb) vector by inserting annealed oligos between 
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BamHI/BglII sites, creating pCasperII(InsertF/InsertR).   The LacO-SCS-Hsp70-SCS’ 
fragment was digested with pSTBlue-1LacOSCSHsp70SCS’ and cloned into pCasper 
II(InsertF/InsertR) using SphI/NotI sites creating pCasperII(InsertF/InsertR)-LacO-
SCS-Hsp70-SCS’.  The attb fragment was digested from the vector pCasper II(attb) 
and cloned into the pCasperII(InsertF/InsertR)-LacO-SCS-Hsp70-SCS’ using NotI 
sites to generate pCasperII(attb)-LacO-SCS-Hsp70-SCS’.  This final plasmid was 
transformed into the Drosophila genome using the PHiC31 platform line attp16 
(Genetic Services Inc.). 
 
Rpb9-paGFP transgenic fly line:  The paGFP gene was PCR amplified from the 
mPAGFP-pRK5 plasmid16 and cloned into a Gateway (Invitrogen) based UAST P-
element insertion vector, pTWG, creating pTW-paG.  The Rpb9 cDNA was amplified 
from Drosophila cDNA (Open Biosystems) and the Rpb9 coding region was cloned 
into the pDONR221 vector using the Gateway system generating pDONOR221-Rpb9. 
The clone was transferred to pTW-paG generating the construct pT-Rpb9-paG. The 
Rpb9-paGFP fusion construct was introduced into the Drosophila germ line by P-
element mediated transformation (Best Gene Inc.). 
 
mCherry-LacI transgenic fly line:  The minimal Sgs3 promoter (drives gene 
expression in salivary gland) was PCR amplified from w1118 flies and cloned into 
pCaSpeR-4 vector creating pCaSpeR-Sgs3.  mCherry was PCR amplified from the 
pRSET-B-mCherry (Dr. Roger Tsien) and cloned into pAFS144 vector (contains LacI 
ORF) creating pAFS-mCherry-LacI.  The mCherry-LacI fragment was digested from 
the pAFS-mCherry-LacI and cloned into pCaSpeR-Sgs3 using XhoI/XbaI sites 
creating pCaSpeR-Sgs3-mCherry-LacI. The mCherry-LacI fusion construct was 
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introduced into the Drosophila germ line by P-element mediated transformation (Best 
Gene Inc.). 
 
Fluorescence Decay After Photoactivation (FDAP) of polytene nuclei (This 
experiment was carried out by Dr. Martin Buckley) 
Dr. Martin S. Buckley generated the primary imaging data. Briefly, intact 
Drosophila salivary glands were dissected from third instar larvae and transferred to a 
MaTek glass bottom dish (P35G-1.0-14-C) containing Grace’s media (Sigma-Aldrich) 
and a glass coverslip was placed on the sample to reduce movement of the glands.  For 
drug experiments, glands were transferred to 500 nM Flavopiridol (Sigma) diluted in 
media.  Laser scanning confocal microscopy of salivary glands was carried out on a 
Zeiss 710 microscope using a Zeiss 63x C-Apochromat objective (numerical aperture 
1.2, water immersion).  The RFP-LacI tagged Hsp70 transgene was identified using a 
561 nm laser. Samples were photoactivated using a circular region of interest limited 
(ROI) to the dimensions of the RFP-LacI spot using a 405 nm.  The fluorescent of 
both the RFP-LacI and paGFP-Rpb9 was imaged using a 488 nm every 30 sec for 12 
min.  To confirm that the Hsp70 gene was targeted, an objective pre-heated to 37°C 
(Bioptechs) was used to heat-shock samples for 20 min.  The images were analyzed 
with ImageJ. 
 
Correction of background genomic Pol II signal. 
The FDAP measurement within a region of interest (ROI) can have non-Hsp70 
Pol II background signal depending on the resolution and the orientation of the 
polytene chromosome.  To correct for this background, we used a mixed linear decay 
model for Pol II signal from adjacent genes.  For each gene within 300 kb from the 
Hsp70 transgene, Pol II level, gene length, and the distance from Hsp70 transgene 
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were obtained using GRO-seq datasets.  Then assuming that Pol II signals clear from 
the gene bodies with the elongation rate of 1.5kb/min, we derived a linear decay 
function for each gene.  We introduced a resolution parameter, and took the distance-
dependent Gaussian-weighted (exp(-distance2/2/resolution2)) sum of individual decay 
functions as the background signal decay function.  We fitted each FDAP time-course 
curve to a two-component model composed of mixed linear decay with a resolution 
parameter, and an exponential decay with a half-life parameter.  The best fit resolution 
and half-life parameter combination was found using a grid search algorithm (Figure 
3.7).  
 
Biochemical analysis of steady state kinetics. 
The rate constant of elongating Pol II from pausing (kel) was derived from 
GRO-seq and PRO-seq data in Drosophila S2 cells at the Hsp70 gene: 
kel = vλ / [Pol II]pr 
where v = Pol II elongation speed (kb/min), λ = gene body Pol II density (reads/kb), 
[Pol II]pr = level of promoter proximal Pol II (reads) (Supplementary Fig. 9). The 
kinetic constant of Pol II termination (kt) was determined from nascent RNA 
fractionation in S2 cells: 
kt = kd ([RNA]fr / [RNA]ch) 
where [RNA]ch = nascent RNA in chromatin fraction, [RNA]fr = nascent RNA in free 
fraction, kd = free nascent RNA decay constant (min-1) (Figure 3.1). 
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Supplementary Figure 11. Half life estimation after background correction of FDAP.  
FDAP measurements and fits for control and flavopiridol treatment conditions are shown.  The 
grid search algorithm was used to find the resolution and half-life pair applying the least square 
method.  The search space was [5, 100]×[0.05, 50] and the grid size was 0.05×5 (min×kb).  First, 
the parameter pairs were limited to those that have the sum of squares for error (SSE) within the 
+5% margin of the least SSE.  Then, the one with least resolution parameter was selected.  
Finally, the background component of the mixed linear decay model with the resolution 
parameter was subtracted from the FDAP measurement, and was fit to an exponential decay 
model.  The highest and the lowest values from each condition were removed for the half-life 
analysis. 
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Figure 3.7. Half life estimation after background correction of FDAP.  FDAP 
measurements and fits for control and flavopiridol treatment conditions are shown.  
The grid search algorithm was used to find the resolution and half-life pair applying 
the least square method.  The search space was [5, 100]×[0.05, 50] and the grid 
size was 0.05×5 (min×kb).  First, the parameter pairs were limited to those that 
have the sum of squ res for error (SSE) within th  +5% m rgin of the l ast SSE.  
Then, the one with least resoluti n parameter was selected.  Finally, the 
background component of the mixed linear decay model with th  resolution 
parameter was subtracted from the FDAP measurement, and was fit to an 
exponential decay model.  The highest and the lowest values from each condition 
were removed for the half-life analysis. 
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Nascent RNA fractionation. 
Nascent RNA fractionations were performed as described by Wuarin and 
Schibler21, with minor modifications.  Briefly, 0.5~1×107 S2 cell was lysed directly in 
the 1 M urea lysis buffer and fractionated by ultracentrifugation for 20 min at 45,000 
g.  RNA from supernatant fraction was phenol-chloroform extracted.  Chromatin pellet 
was resuspended in Trizol (Ambion) and disrupted by short bursts of sonication, 
followed by RNA extraction.  A short in vitro-transcribed spike-in RNA from an 
Arabidopsis gene (RCP1) sequence (5×10-2 fmol) was added before ethanol 
precipitation as a normalization control.  Each RNA fraction was hybridized to a 
mixture of biotin labeled DNA probes complementary to Hsp70 and RCP1 
sequences22, and specific RNA was enriched.  RNA was sequentially treated with 3’ 
RNA adaptor ligation (T4 RNA ligase I; NEB), 5’ phosphate dependent exonuclease 
(Terminator; Epicentre), Tobacco acid pyrophosphatase (TAP; Epicentre), 5’ RNA 
adaptor ligation, and reverse transcription (Superscript; Invitrogen) following the 
manufacturer’s instructions.  Hsp70 and RCP1 products were quantified by qPCR 
using primers that span across the insert and adaptor junctions.  Hsp70 products of 
different lengths (25 ~ 40 nt) were normalized to RCP1 level and the normalized 
values from different lengths were averaged.  RNA adaptor and DNA primer 
sequences are listed in Table 3.2. 
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Table 3.2. DNA and RNA sequences for nascent RNA fractionation.  (A) RNA 
adaptor sequences.  (B) Organization of Hsp70 qPCR primers.  (C) Hsp70 qPCR 
primers.  (D) RCP1 control sequences.  /idT/ : inverted dT.  /bio/ : 3’-biotin. 
A 
B 
C 
D 
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CHAPTER 4d 
 
GENOME-WIDE TRANSCRIPTION DYNAMICS REVEAL THE INTERPLAY OF 
PAUSING AND ELONGATION RATES ON PRE-MRNA SPLICING 
Summary 
The transcription cycle of RNA polymerase II (Pol II) consists of many 
potentially rate-limiting steps that can be regulated. One major step in regulation is the 
escape of promoter-proximal paused Pol II into productive elongation driven by 
Positive Transcription Elongation Factor (P-TEFb) kinase. To ascertain which genes 
require P-TEFb kinase activity and when during the transcription cycle it is required, 
we inhibited P-TEFb with flavopiridol (FP) and examined the effects on transcribing 
and paused Pol II distributions using the highly sensitive GRO-seq assay. 
Transcription of nearly all genes is dramatically inhibited but the peak of paused Pol II 
often persists or is enhanced, showing that escape from pause is a ubiquitous and 
crucial step in the transcription cycle. Furthermore, we tracked the progression of 
elongating Pol II following inhibition of pause escape by FP and derived elongation 
rates on a genome-wide scale. Systematic analysis of nearly 1,000 genes shows that 
Pol II rates vary between and within genes. Notably, Pol II accelerates as it transcribes 
through genes and slows when splicing occurs.  Furthermore, splicing is less efficient 
in 5’ regions of genes, but its fidelity is enhanced by promoter-proximal pausing, 
revealing the interplay between Pol II elongation and splicing. 
 
                                                
d Works in this chapter was done in collaboration with Dr. Iris H. Jonkers. Extents of 
contributions are noted in the figure legends.  
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Introduction 
Many steps throughout the transcription cycle of RNA polymerase II (Pol II) 
can be regulated, and modulation of each step has the potential to alter the timing, total 
output, and the isoforms of mRNA production. First is initiation, which is mostly 
dependent on the transcription factor recruitment, pre-initiation complex assembly, 
and formation of the transcription bubble1. While initiation is very important, it is by 
no means the only step at which transcription can be regulated. After initiation, Pol II 
can be paused by Negative Elongation Factor (NELF), DRB-sensitivity Inducing 
Factor (DSIF) and components of the core promoter2,3. The escape of paused Pol II 
into productive elongation can be rate-limiting, and is dependent on the positive 
elongation factor P-TEFb, which consists of protein kinases Cdk9 and CyclinT14-6. P-
TEFb is recruited directly or indirectly to the paused Pol II complex by transcription 
activators, where it phosphorylates the CTD, as well as DSIF and NELF to transform 
DSIF into a positive elongation factor and evict NELF7. P-TEFb appears to be both 
necessary and sufficient for paused Pol II escape into productive elongation. 
The importance of transcription regulation at pausing has become increasingly 
evident over the last few years. Genome-wide Run-on sequencing (GRO-seq)8,9, 
sequencing of short capped nascent RNAs10, and Pol II Chromatin 
Immunoprecipitation (ChIP) experiments11,12 all have shown in organisms ranging 
from Drosophila to humans that a large fraction of actively transcribed genes have 
accumulations of paused Pol II within the promoter proximal region, indicating a rate-
limiting step during early elongation that for many genes appears P-TEFb dependent13. 
Also, expressed genes that do not have a peak of paused Pol II in one cell type, may 
acquire one in another9, indicating that many genes have the potential of becoming 
regulated at the step of escape into productive elongation. However, it is unclear if all 
genes undergo this P-TEFb kinase dependent step. 
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Several functions of Pol II pausing have been proposed and have variable 
levels of support in the literature2. One unproven, but attractive hypothesis is that 
pausing might function as a checkpoint to ensure that the elongation complex is fully 
assembled and modified for efficient elongation and co-transcriptional RNA 
processings, i.e. capping and splicing. Capping occurs when the nascent RNA 
protrudes from the paused Pol II located 20-30 nucleotides from the TSS14,15, and the 
cap can promote co-transcriptional splicing by recruitment of splicing factors via Cap 
Binding Complex CBC16-18. Also, increased phosphorylation of the CTD and the 
association of additional RNA processing components coincides with increased Pol II 
escape to productive elongation19. These studies indicate that RNA capping and the 
maturation of Pol II may form a link between pausing and co-transcriptional mRNA 
processing.  
In addition to the maturation of Pol II during pausing, the rate of Pol II 
elongation has also been proposed to influence co-transcriptional processes such as 
transcription splicing20-22, 3’ end processing23, and termination24. Transcription with a 
slow mutant of Pol II promotes alternative splicing in human and yeast cells21,22. 
Slowing of Pol II around exons is thought to facilitate assembly of the spliceosome 
and recognition of the splice site, and thereby, splicing of the associated intron25,26.  
Many studies have measured elongation rates at individual genes in various 
organisms, producing a range from 1 to 4 kb/min27. Recently, elongation rates for over 
one hundred genes were measured simultaneously by following the induction wave of 
Pol II after Estrogen or TNF-α treatment28. Interestingly, this study showed a broad 
range of elongation rates within single cell types and different rates of sets of genes 
responding to different activators. 
Here, we use FP, a specific inhibitor of the P-TEFb kinase29, and the highly 
sensitive GRO-seq assay8 to demonstrate that productive transcription of virtually all 
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Pol II genes in mouse embryonic stem cells (mESCs) requires P-TEFb kinase activity.  
The added sensitivity and transcription orientation information provided by GRO-seq 
confirms and extends earlier results using a ChIP-seq assay of Pol II13.  Thus, P-TEFb 
is generally required for promoter-proximal Pol II to escape into a productive 
elongation, even on genes where the escape of paused Pol II is apparently not a rate-
limiting step. Furthermore, this striking inhibition of Pol II caused a ‘wave’ of 
elongating Pol II that, when assayed as a function of time following FP addition, 
allowed measurement of elongation rates of nearly a thousand genes simultaneously, 
and at various regions within genes. These systematic analyses show that Pol II 
elongation rates increase within the gene body, and decrease during splicing events. 
Finally, we show that proximal pausing correlates with efficient splicing at the 5’ end 
of genes, supporting a model where pausing has a role in allowing the establishment of 
a functionally mature elongation complex that can couple transcription and RNA 
processing.  
 
Generation of GRO-seq Libraries Treated with FP and Trp 
P-TEFb kinase is recruited to promoters and phosphorylates the paused Pol 
II•NELF•DISF complex, thereby allowing the paused Pol II to escape into productive 
elongation. To identify all genes regulated by P-TEFb, we inhibited P-TEFb kinase 
activity with the drug FP, and compared this to inhibition of pre-initiation complex 
formation by Triptolide (Trp), a drug that interferes with the XPB helicase function of 
TFIIH30,31. We isolated replicates of nuclei of untreated mESCs and cells treated for 2, 
5, 12.5, 25 and 50 min. with 300nM FP, as well as nuclei treated for 12.5, 25, and 50 
min. with 500nM Trp (Figure 4.1A). To minimize off target effects, the concentrations 
of drugs are at the lower spectrum of concentrations used in previous experiments29-31. 
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Figure 4.1. (A) Experimental set-up, 300 nM flavopiridol (FP) and 500 nM of triptolide 
(Trp) were used to block pause escape or transcription initiation in mES cells.  Nuclei 
were isolated at timepoints after treatment as specifiied, control nuclei were untreated 
for the FP samples, and treated for 50 min with DMSO for the Trp samples. (B) 
Screenshot of genes Pkp4 and Ppp2r5e with or without Trp or FP treatment for 12.5, 
25 or 50 min, with sense reads in red and antisense reads in blue. Inset numbers are 
the number of normalized reads per kb per unit area for each gene and treatment 
timecourse. (C) Composite profile of GRO-seq read density of all genes >12.5 kb (top 
panel) or >150 kb (bottom panel) after treatment with Trp for various durations of 
time. The middle panel is a zoom-in of the top panel of the region downstream of the 
TSS. (D) As C, but after treatment with FP for various periods of time. The 
experimental design, GRO-seq experiments were performed by Dr. Iris Jonkers. 
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Sequencing results Total reads % trimmed % ribosomal aligned % aligned Spike-In % Spike-In
Control #1 39054383 23.3% 29.5% 5016163 12.8% 219906 0.6%
12.5min Trp #1 35515502 24.6% 24.3% 5152395 14.5% 338370 1.0%
25min Trp #1 34107998 51.2% 13.9% 613603 1.8% 73777 0.2%
50min Trp #1 37503054 22.3% 40.0% 1824854 4.9% 253943 0.7%
Control #2 74380410 20.3% 31.7% 13074860 17.6% 393978 0.5%
12.5min Trp #2 45737802 20.4% 25.1% 9147442 20.0% 358560 0.8%
25min Trp #2 76937683 24.0% 33.2% 8798933 11.4% 805210 1.0%
50min Trp #2 40672137 21.0% 39.7% 2639097 6.5% 304272 0.7%
Sequencing results Total reads % trimmed % ribosomal aligned % aligned Spike-In % Spike-In
untreated #1 104889824 16.2% 34.8% 25539711 24.3% 3046032 2.9%
2min FP #1 92103568 16.1% 34.7% 22843152 24.8% 2627811 2.9%
5min FP #1 82094962 16.7% 30.0% 24548283 29.9% 2454930 3.0%
12.5min FP #1 84600449 15.3% 34.2% 21607659 25.5% 2980280 3.5%
25min FP #1 94235237 16.7% 41.1% 17356268 18.4% 3055098 3.2%
50min FP #1 101614542 14.0% 49.1% 15403548 15.2% 2721538 2.7%
untreated #2 63997320 15.4% 33.5% 17869848 27.9% 1295280 2.0%
2min FP #2 41265136 12.4% 35.5% 12447634 30.2% 901113 2.2%
5min FP #2 50758538 14.9% 36.9% 12912212 25.4% 1286001 2.5%
12.5min FP #2 54675137 10.4% 35.4% 16926587 31.0% 1873970 3.4%
25min FP #2 74393287 9.6% 48.6% 15992442 21.5% 2544132 3.4%
50min FP #2 83154700 9.2% 55.2% 14019123 16.9% 2124287 2.6%
Pearson correlation promoter gene body Spearman correlation promoter gene body
Control replicates 1.000 0.994 Control replicates 0.958 0.986
12.5min Trp  replicates 0.999 0.972 12.5min Trp  replicates 0.937 0.988
25min Trp replicates - - 25min Trp replicates - -
50min Trp replicates 1.000 0.999 50min Trp replicates 0.772 0.964
Pearson correlation promoter gene body Spearman correlation promoter gene body
untreated replicates 0.999 0.992 untreated replicates 0.976 0.993
2min FP replicates 0.998 0.997 2min FP replicates 0.975 0.991
5min FP replicates 0.993 0.944 5min FP replicates 0.973 0.990
12.5min FP replicates 0.999 0.993 12.5min FP replicates 0.977 0.990
25min FP replicates 0.999 0.998 25min FP replicates 0.976 0.986
50min FP replicates 1.000 0.999 50min FP replicates 0.971 0.980
Table 4.1. Sequencing statistics report. The GRO-seq library and sequencing data 
was generated by Dr. Iris Jonkers. 
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Nuclear run-on and library preparation was performed, and replicates were sequenced 
(Table 4.1). Biological replicates correlated extremely well and were combined for all 
further analysis. Because inhibition of escape from elongation and initiation were 
anticipated to have large genome-wide effects on Pol II transcription, we chose to 
normalize treated and control libraries using spike-in controls of in-vitro transcribed 
Arabidopsis thaliana RNA added during the run-on.  
Two long genes, Pkp4 and Ppp2r5e (Figure 4.1B), illustrate the effects of 
inhibition of P-TEFb kinase or PIC formation on the kinetics of Pol II distribution. 
Clearly these genes show a distinct time dependent wave of Pol II leaving the body of 
the gene after either FP or Trp treatment, while the effects at the promoter were 
opposite for the two drugs. The Pol II pause peaks increased after FP treatment, but 
disappeared after Trp treatment (Figure 4.1B, zoom box). These are as expected, 
because inhibition of P-TEFb is known to inhibit escape from pause, but not Pol II 
initiation nor productively elongating Pol II6,29. In contrast, Trp prevents melting of 
DNA at the promoter, thereby preventing transcription initiation, but not the 
downstream steps. 
To assess the global effects on total Pol II and phosphorylation levels of the 
CTD in the cell, we fractionated the insoluble chromatin from the soluble fractions of 
untreated mESCs and cells treated with 300 nM FP, 500 nM Trp, or Trp-vehicle 
DMSO for 50 min, and performed western blots with antibodies against N-terminus of 
Rpb1, and Ser5 or Ser2 phosphorylated CTD. Overall, chromatin bound Pol II is 
generally reduced after treatment with FP or Trp. However, phosphorylation of the 
CTD was reduced only after FP treatment, but not Trp, indicating that FP and Trp 
exert the intended effects. 
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P-TEFb Dependent Escape from the Pause Occurs at All Active TSSs 
The entry of Pol II into productive transcription for genes shown in Figure 
4.1B clearly are dependent on P-TEFb kinase activity. However, to assess if P-TEFb is 
utilized generally in Pol II escape from the promoter proximal region, we examined 
composite GRO-seq profiles of selected genes for all experimental conditions (Figure 
4.1B and C) or heat maps of gene-specific change in Pol II density around the TSS 
after 50 min treatment of FP or Trp (Figure 4.2).   
 After inhibiting the initiation step with Trp, levels of promoter proximal Pol II 
and Pol II downstream of the TSS dropped within 12.5 min, and depletion progressed 
in time for the majority of genes (Figure 4.1C). After 50 min of Trp treatment, Pol II is 
depleted to near background density at the promoter proximal region and up to 120kb 
downstream, showing that Trp effectively blocks Pol II transcription initiation but 
allows elongation. Treatment with FP does not reduce promoter proximal Pol II, but 
like Trp, it causes a rapid decrease of Pol II density immediately downstream of the 
TSS, and Pol II density was reduced farther into the gene body with increasing time 
(Figure 4.1D). Elongating Pol II forms an ‘inhibition wave’ that is very similar after 
Trp or FP treatment (Figure 4.1C and D, lower panels). The reduced Pol II density 
region expands in a time dependent fashion, while the region where the inhibition 
wave has not yet passed remains at equal Pol II density levels throughout the time 
course, indicating that Pol II in the gene body at the start of treatment is not affected.  
These results indicate that Trp blocks transcription initiation and causes the time 
dependent clearing of Pol II from both the promoter and gene body, while FP’s 
prominent effect is to block escape from the pause, causing a time dependent gene 
body clearance but enhanced pausing of Pol II at the promoter. 
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Figure 4.2. (A) Left panel shows a density plot of the log10 of reads of the no Trp 
dataset, in 10 bp windows +/-1 kb around TSS of 6380 active genes. Genes are 
ordered by the maximum decrease after Trp treatment at the promoter proximal 
region. The two right panels show the log10 difference in 10 bp windows after 
treatment with Trp for 50 min on the sense strand (middle) and antisense strand (right 
panel) with decrease in blue and increase in red. Genes are ordered as in the left 
panel. The density scales and color code for each panel are depicted the bottom. (B) 
same as in A, log10 reads in 10 bp windows around the TSS of the no FP control 
dataset (left panel), and the log10 difference in reads after 50 min FP treatment on 
the sense (middle panel) and antisense strand (right panel). Genes are ordered by 
maximum increase after FP treatment at the promoter proximal region. This Figure 
was generated by Dr. Iris Jonkers. 
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Figure 4.3. (A) Scheme of the selection of genes used for analysis of FP or 
Trp effect. (B) Example of a ~200 Mb genepoor region used to establish 
background transcription levels. (C) Screenshots of two example genes that 
are defined as active but are excluded from general FP and Trp analysis as 
they are within the bottom 25% of expressed genes. (D) Log2 of change 
within the promoter proximal region on the sense strand (pause peak) or 
antisense strand (divergent peak) after 50 min FP treatment. Color scale is 
on the right and genes are ordered by the maximum to minimum of average 
change within the pause and divergent peak of the genes. (E) Quantification 
of the number of genes that have a pause (top) or divergent (left) peak that 
has a 1.5 fold decrease (down), 1.5 fold increase (up) or no change larger 
than 1.5 fold (same) of normalized read density after 50 min of FP treatment.  
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To facilitate the quantitative analysis of transcription, we selected the top 75% 
most actively transcribed genes that are long enough (over 3.5kb, to obtain a good 
measure of gene body transcription), and well resolved (>10kb from another tandemly 
oriented gene and not a member of a bidirectional pair of genes)(Figure 4.3A; 
n=6,380). The heat maps in Figure 4.2A display the Trp-induced changes on 
individual members of this gene set. The leftmost heat map shows the Pol II density in 
the absence of drug, while the center and right maps show a drug induced change in 
density on the sense and anti-sense strands after 50 min. Trp causes a reduction in the 
promoter and downstream regions of both the annotated gene (sense strand), and the 
upstream divergent region (antisense strand). This upstream divergent transcription is 
a well-documented feature of mammalian promoters8,32,33 (Figure 4.2A). These results 
indicate that Trp blocks the entry of Pol II on all promoters in both directions.   
The results of FP inhibition on the promoter regions are in sharp contrast.  
Figure 2B shows that while the Pol II density in the gene body is decreased after FP 
treatment, the Pol II at the promoter proximal region and divergently transcribed 
region increase at the majority of genes (Figure 4.2B and Table 4.2). This is consistent 
with FP blocking the entry of Pol II into productive elongation. Notably, a smaller 
fraction (~20%) of genes displayed an unexpected decrease in paused and divergent 
Pol II peaks (Table 4.2, and Figure 4.2B), indicating that FP can also affect initiation 
on a smaller subset of genes. Generally, the paused and divergent peaks at a single 
gene change in concert (both up or both down) after FP treatment (Figure 4.3D and 
4.3E), indicating that levels of paused and divergent Pol II at promoters are regulated 
similarly. 
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Quantification of the decrease in read density in the gene body region from 1 
to 3.5 kb shows that 96% of genes are significantly decreased after Trp treatment, 
while 95% of genes are decreased after FP treatment (Table 4.2). This demonstrates 
that inhibition of P-TEFb causes a block in the transcription cycle that is as universal 
as inhibition of initiation. 
 
Measurement of the Elongation Rates and the Acceleration of Elongating Pol II in 
the Gene Body 
Upon the addition of FP to block Pol II entry into productive elongation, Pol II 
that are already transcribing generate a clearly distinguishable wave of elongation.  
We could track the rate of this wave’s progress at more than 1000 genes that are 
sufficiently long and actively transcribed (Figure 4.1D, 4.4A). Determining the 
distance traveled by the wave between two time points provides a measure of 
elongation rates. To do this in an unbiased and systematic way, we adapted a Hidden 
Markov Model (HMM) to detect the transition of the wave, i.e., the point in the gene 
where Pol II density changes (Figure 3B and S3B). Similarly, we tracked the wave in 
the time-course following Trp addition to ESCs as an independent strategy for 
blocking Pol II entry into elongation. 
Significantly changed genes (p < 0.05) 12.5min Trp 25min Trp 50min Trp 2min FP 5min FP 12.5min FP 25min FP 50min FP
gene body decrease 4013 (62.9%) 5849 (91.7%) 6101 (95.6%) 4065 (63.7%) 5425 (85.0%) 6047 (94.8%) 6118 (95.9%) 6071 (95.2%)
gene body increase 178 (2.8%) 28 (0.4%) 7 (0.1%) 270 (4.2%) 25 (0.4%) 44 (0.7%) 40 (0.6%) 85 (1.3%)
pause peak decrease 4684 (73.4%) 5500 (86.2%) 5689 (89.2%) 1948 (30.5%) 1726 (27.1%) 1377 (21.6%) 1353 (21.2%) 1161 (18.2%)
pause peak increase 23 (0.4%) 8 (0.1%) 5 (0.1%) 499 (7.8%) 373 (5.8%) 1787 (28.0%) 3058 (47.9%) 3601 (56.4%)
divergent peak decrease 3733 (58.5%) 4735 (74.2%) 4914 (77.0%) 1373 (21.5%) 1512 (23.7%) 1358 (21.3%) 1848 (29.0%) 1629 (25.5%)
divergent peak increase 13 (0.2%) 9 (0.1%) 9 (0.1%) 524 (8.2%) 289 (4.5%) 1234 (19.3%) 2042 (32.3%) 2670 (41.8%)
pausing index decrease (no p-value) 5162 (80.9%) 4896 (76.7%) 4982 (78.1%) 2059 (32.3%) 1174 (18.4%) 431 (6.8%) 359 (5.6%) 320 (5.0%)
pausing index increase (no p-value) 1218 (19.1%) 1484 (23.3%) 1398 (21.9%) 4321 (67.7%) 5206 (81.6%) 5949 (93.2%) 6021 (94.4%) 6060 (95.0%)
Table 4.2. Number of genes with significant changes in GRO-seq profiles  
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Figure 4.4. (A) Three representative genes used for measurement of transition 
points with the HMM. In green, the affected region after FP treatment as established 
by the HMM, the transition point being the endpoint of this region. (B) General 
scheme of the Hidden Markov Model: The ratio of the read sums of the normalized 
control and treated data in windows are taken, where a ratio near 1 is unaffected. 
The HMM runs from 5’ to 3’ through the gene and defines the most probabilistic point 
of transition from Affected (grey bins) to Unaffected (white bins). (C) Average of 
HMM derived transition points of the FP timecourse (blue) or Trp timecourse (red) 
plotted against the time of drug treatment. Error bars are standard deviation from the 
mean. (D) Elongation rates derived from the FP timecourse. Elongation rate is the 
ratio of the distance traveled in the time spanning 5 to 12.5 min (top; n=141), 12.5 to 
25 min (middle; n=937) and 25 to 50 min (bottom; n=245). 
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Figure 4.5. (A) Three representative genes used for measurement of transition 
points with the HMM. In green, the affected region after Trp treatment as established 
by the HMM, the transition point being the endpoint of this region. (B) Scheme of the 
Hidden Markov Model (HMM). (C) Elongation rates derived from the Trp timecourse. 
(D) Average of HMM derived transition points of the FP timecourse (blue) or Trp 
timecourse (red). (E) Average of HMM derived transition points of all the transition 
points in the FP timecourse (blue) or of genes (n=91) that had three consecutive 
transition points (green) plotted gainst the time of drug treatment. (F) Boxplot of the 
12.5-25 min and 25-50 min elongation rates of genes that had both elongation rates 
(n = 91; same genes as in E).	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Although the inhibition wave using Trp was not as robust (Figure 4.5A), and 
the HMM produced transition points for fewer genes than with the FP time-course 
(Figure 4.4C), the resulting clearing wave of Pol II had kinetics indistinguishable from 
the FP treatment (Figure 4.5C and D). 
On average, the wave of Pol II travels about 100 kb during the 50 minutes of 
FP treatment. This corresponds to an elongation rate of about 2 kb/min, which is 
within the range of Pol II rates from previous studies27,28. The average Pol II inhibition 
wave travels equally far after Trp or FP treatment, indicating that inhibition of P-TEFb 
does not have a significant effect on elongation rates downstream of the promoter 
proximal region (Figure 4.4C). Also, the average transition points of genes with 
distinctive inhibition waves at three different time-points behaved the same as those of 
the genes that the HMM derived only one or two time-point data (Figure 4.5E), 
indicating that average transition points were not biased by how the groups of the 
genes were selected. 
 Interestingly, we found that the Pol II wave did not propagate linearly, but in 
an accelerating manner, both in FP and Trp time-courses (Figure 4.4D). Subsequently, 
elongation rates derived from different regions within the same gene increased further 
downstream (Figure 4.5F; p-value = 6.6×10-5), showing that the increase in elongation 
rates happens within most genes and is not a consequence of elongation rate variation 
between genes. The mean elongation rates increase from 0.5 kb/min to 1.8 kb/min and 
then 2.4 kb/min for the intervals 5-12.5 min, 12.5-25 min, and 25-50 min respectively. 
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Figure 4.6. The apparent increase in elongation rate can be described by two 
models. (A) Acceleration model; Pol II becomes more transcriptionally competent and 
accelerates (B) Termination model; Population of Pol II consists of a relatively slow, 
poorly active fraction and a relatively fast, highly active fraction, and termination of the 
slow fraction leads to an apparent increase of elongation rate. (C) Composite profile 
of the no FP GRO-seq of genes >60 kb from the TSS until 20 kb from the TSS. Note 
that density remains constant after ~15 kb. (D) Inverse plot of the density composite 
profile in C (D-1 plot), scaled by the density of the constant downstream region. The 
red line indicates the projected average elongation rates considering parameters in 
line with a termination model; the blue line depicts the projected average elongation 
rates when the acceleration model is more likely. In black, the actual mean elongation 
rates at the average distance traveled are depicted, with error bars indicating the 
standard deviation. 
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Figure 4.7. Modeling of the acceleration and the termination hypotheses. (A) Scheme 
of the elongation simulation. (B) Simulation time-course for an acceleration model 
and a termination model. (C) D-1 plot for the two models in panel B. (D) Scatterplot of 
the slope of v and the slope of D-1 for multiple acceleration models and termination 
models with varying parameters. The observed datapoints fit to the distribution of the 
acceleration models. (E) Elongation rate parameters for the acceleration models. (F) 
Elongation and termination rate parameters for the termination models. (G) 
Elongation rate parameter as a two dimensional function of position and activity in a 
mixed acceleration model. The scale of the v axis is 0-40 bp/s. (H) Termination rate 
parameters as functions of the position and activity in regional termination models. 
The scale of the kt axes are 0-0.1s-1, 0-0.125s-1, 0-0.125s-1 for each subpanels. The 
scale of the x axis is 0-100kb, and A axis is 0-100% for all 2D subpanels. 
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Modeling Acceleration of Pol II in the Gene Body 
The apparent acceleration of Pol II in the gene body can be interpreted in two 
ways. The total population of elongating Pol II transcribes slowly at the 5’ end of the 
gene, but increases in speed along the gene body, ramping up to ~2.4 kb/min on 
average after traveling approximately 30 kb downstream of the TSS (Figure 4.6A). 
Alternatively, elongating Pol II could consist of different populations, fast, 
transcribing at maximum speed throughout the entire gene body, and slow. It has been 
recently shown that termination of Pol II in the gene body can have regulatory roles34, 
and if the slow population terminates prematurely leaving the fast Pol IIs, then the 
overall apparent elongation rate at the 5’ end of the gene would be slower than at the 
3’ end (Figure 4.6B). To distinguish between these two models, we compared the 
measured elongation rates vs. inferred elongation rates from the steady-state GRO-seq 
density within the gene. This comparison allows one to address whether premature 
termination of Pol II plays a significant role in the apparent elongation rates.  
In the first model, because faster Pol II molecules will appear less dense on the 
GRO-seq profile, the elongation rate (v) will be proportional to the inverse of the 
GRO-seq density (D). Since D decreases to a constant level upon increasing distance 
from the TSS (x) (Figure 4.6C), the inverse of D (D-1) can be adjusted by a scaling 
factor to match the increasing trend of v (Figure 4.6D; blue dashed line). On the other 
hand, if termination takes place, D will decrease more than what is explained by the 
acceleration alone, and the slope of D-1 curve will not match but will be steeper than 
the increase of v (Figure 4.6D; red dashed line). In other words, if premature 
termination plays a major role at the 5’ end of genes, than the increase in elongation 
rates will be less steep than the increase of D-1 in the same region. While measured 
average elongation rates at 5-12.5 min and 12.5-25 min fall slightly below this curve, 
the increasing trend is consistent with D-1 curve pattern (Figure 4.6D). This indicates 
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that on average, the progressive increase in the elongation rate can largely explain the 
gradual decrease of the GRO-seq density and that termination of slowly transcribing 
Pol II populations plays a minor role in increasing the apparent elongation rate. 
The acceleration model is further supported by a thorough examination of 
parameter space using a Monte Carlo simulation describing the dynamics of Pol II 
movement through the gene body (Figure 4.7A). We simulated the time course of the 
inhibition wave of Pol II and used the same HMM to define the transition points of 
inhibition waves and the elongation rates under the two model scenarios (Figure 
4.7B). The relationship between D-1 and v shows a clear difference between the two 
models (Figure 4.7C and 4.7D). After scaling the simulated D-1 to converge to the 
simulated v, v falls right at the D-1 curve in the acceleration model, while v falls above 
the D-1 curve in the termination model. When we plotted the slope of v vs. the slope of 
D-1 in various simulated acceleration and termination models along with actual 
observations, the observation fits better with the distribution of the acceleration 
models than the termination models (Figure 4.7D). 
 
Correlations between elongation rates and transcription factors, histone marks and 
modifiers  
There is a wide variation in elongation rate of Pol II between genes (Figure 
4.4D), and we set out to find factors that contribute to this variation by looking at 
correlations between elongation rates and existing ChIP-seq data of transcription 
factors, chromatin modifiers, and histone modifications (see for full list of factors 
Figure 4.8D). We used 12.5-25 min elongation rates (n=937), and divided the genes 
into quartiles. 
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Figure 4.8. (A) Boxplots of the log10 of read density of ChIP-seq datasets in 
promoter region (-750 to 250 bp from the TSS) in green, or in the 12.5-25 min 
transition region in blue in elongation rate quartiles from low rates in light shade to 
fast rates in dark shades. Only the most striking correlations of ChIP-seq data and 
12.5-25 min elongation rates are shown. (B) Composite profile of H3K79me2 read 
density from -2 to 30 kb from the TSS in quartiles of 12.5-25 min elongation rates 
(left), or intron1 size quartiles (right). (C) As in C, but with H3K36me3 read density. 
(D) Table of ChIP-seq datasets and the associated references used to correlate with 
elongation rates. This Figure was generated by Dr. Iris Jonkers 
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Figure 4.9. (A) Boxplots of H3K79me2 (left) and H3K36me3 (middle) log10 read 
density within the 12.5-25 min transit (early) region of genes corresponding to 
quartiles of the 12.5-25 min elongation rates. The right boxplot shows the size of the 
first intron in kb of genes within quartiles of the 12.5-25 min elongation rates. 
Elongation rate quartiles increase in speed from left to right. (B) Histone mark and no 
FP GRO-seq read density composite profiles of genes with 12.5-25 min elongation 
rates and an intron1 and 2 of >5 kb (n=400). Profiles are centered on intron1-exon2 
or intron2-exon3 junctions. (C) The median of the subsampled no FP GRO-seq 
composite profile centered on intron1-exon2 and intron2-exon3 junctions, including 
0.75 and 0.25 confidence intervals after subsampling. This Figure was made by Dr. 
Iris Jonkers 
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Then we looked for enrichment of factors within the early region (the region from the 
12.5 to the 25 min transition points) of the individual genes, or in the promoter region 
(-750 to 250 bp around the TSS) and plotted the factor density between the quartiles 
(Figure 4.9A, 4.8A and data not shown). Although correlations between elongation 
rate and chromatin marks or transcription factors were modest in general (Spearman’s 
rho < 0.3), several factors showed intriguing correlations.  
 Specific histone methyl marks showed a reasonably strong positive 
(H3K4me1, H3K4me2, and H3K79me2) or negative (H3K36me3) correlation with 
elongation rates (Figure 4.9A and 4.8A). Although H3K36me3 has been shown to be 
enriched in the gene body of actively transcribed genes, the enrichment is not uniform; 
H3K36me3 increases at the intron1-exon2 junction, while H3K79me2 decreases at the 
junction35. Because the early regions often contain intron1, we addressed whether 
elongation rate correlations with these histone marks were a consequence of intron1-
exon2 position. Again, we divided the genes into quartiles based on the intron 1 sizes 
as well as the elongation rates. The composite profiles of the histone modifications 
between the quartiles reveales that the H3K79me2 (Figure 4.8B, right), H3K36me3 
(Figure 4.8C, right) and H3K4me1 and 2 (data not shown) distributions depend 
strongly on the size of intron1. Indeed, elongation rates and intron1 size correlate 
better than any of the histone modifications (Spearman’s rho = 0.31, Figure 4.9A).  
 Interestingly, we also observed that GRO-seq levels showed a similar drop at 
the intron1-exon2 junction (p-value = 0.008) that was not present at the intron2-exon3 
junction (p-value = 0.58)(Figure 4.9C). GRO-seq density within a gene is a measure of 
elongation rate, as slow moving Pol II will increase in density, while fast moving Pol 
II decrease. Therefore, we interpret the drop in GRO-seq density as an increase in 
elongation rate at the intron1-exon2 junction. The apparent speed-up could be a 
consequence of the abrupt changes in chromatin structure at the intron-exon junction, 
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or a conformational change of the transcription complex as a consequence of coupled 
cotranscriptional-splicing event at the first intron-exon.  
	  
Elongation Rates and Splicing 
Elongation rates have long been implicated in regulation of splicing21,22,26. 
However, most evidence supporting the hypothesis that Pol II slows down around 
exons has been measured indirectly by looking at accumulation of Pol II around 
individual exons with ChIP36,37. Our observation that 12.5-25 min elongation rates 
tend to be higher in genes with large first introns could point to a direct correlation 
between splicing and transcription speed, because genes with large first introns will 
have a lower exon density and fewer splicing events within the early region. To 
examine in more detail whether exons have a direct effect on elongation rates, we 
plotted elongation rates against exon density of the early region. We saw a striking 
negative correlation (Figure 4.10A), and calculated that adding an exon to the early 
region resulted in a reduction of elongation rate of 60 bp/min (roughly 3% delay of 
2kb/min) or a 20-25 sec delay (3% delay of 12.5-25min interval; p-value = 3×10-14).  
To further establish that elongation rates are directly related to splicing, and 
not to the presence of exons alone, we used RNA-seq data38 to map exons, and looked 
for alternatively spliced exons within the early regions. Exons were defined as 
‘skipped’ when read density in the exon was significantly (p-value <0.01) 3 fold lower 
than the average exon density of the gene, or ‘over-included’ when exon density was 
significantly 3 fold higher than the average. When looking at the splice sites of exons 
in active genes larger than 3.5 kb, we saw that over-included exons had a more 
conserved 3’ polypyrimidine tract, which interacts with splice factor U2AF and 
enhances splice site recognition39. 
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Figure 4.10. (A) 12.5-25 min elongation rates (n=937) are plotted as a function of 
exon density within the gene-specific 12.5-25 min transit region (grey points). Linear 
regression of the points is shown in black. (B) Same points are plotted as in A in grey, 
but linear regression is done over elongation rates taken over the transit region in 
which no exons were alternatively spliced (red; n= 759), exons were skipped (green; 
n=131), or exons were over-included (purple; n=50). (C) Composite profile of no FP 
GRO-seq centered on introns of > 20 kb (blue) and their surrounding exon start sites 
(red). (D) Skip ratio (skipped exon density /exon density) of all 12.5-25 min elongation 
rate genes (n=937) in the 12.5-25 min transit region (Early region; dark grey), or 
downstream of the 25 min transition point until 1 kb upstream of the stop 
(Downstream region; light grey). (E) Same as in D, but skip ratios are taken from 
12.5-25 min rate genes in quartiles of pausing index, with Early (E) and Downstream 
(D) region skip ratios of the least paused genes left, and 5’ and 3’ region skip ratios of 
the most paused genes right. (F) Box plots of 12.5-25 min elongation rates of genes 
in pausing index quartiles (shades of green, with dark green being the least paused 
quartile) or of all 12.5-25 min rate genes (white; n=937). (G) Box plots of intron1 size 
in kb of genes in pausing quartiles (shades of blue, with dark blue being the least 
paused quartile) or of all 12.5-25 min rate genes (white; n=937). 
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Figure 4.11. (A) Splice sites logo’s of exons of top 75% expressed genes longer than 
3.5 kb separated by all exons (top), skipped exons (middle), or over-included exons 
(bottom). (B) As Figure 6B, but with 25-50 min elongation rates and accompanying 
exon density in the region from the 25 to 50 min transition points. (C) Skip ratio in the 
early region of genes with a skip ratio > 0 plotted against 12.5-25 min elongation rate. 
Linear fit of the data points is plotted in red. (D) As Figure 6B, but with boxplots of 25-
50 min elongation rates in pausing index quartiles of genes (n=245). (E) Splice site 
logo’s of exons of 12.5-25 min elongation rate genes separated by all exons (top), 
exons located upstream of the 25 min transition point (middle, 5’ exons), or 
downstream of the 25 min transition point (bottom, 3’ exons). 
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On the other hand, skipped exons had a less conserved polypyrimidine tract (Figure 
4.11A).  Thus, splicing efficiency correlates generally with the quality of the splice 
sites in mESCs. 
If splicing has a direct negative effect on elongation rates, than intervals with 
one or more skipped exons should have faster elongation rates, while over-included 
exons should have slower elongation rates. Indeed, effects of exon skipping and exon 
over-inclusion significantly contributed to elongation rates (p-value < 0.05; Figure 
4.10B). Furthermore, elongation rates positively correlated with the extent of exon 
skipping within the early region as measured by the skip ratio (skipped exon density / 
exon density)(Figure 4.11B, R2 = 0.13). These correlations could be found clearly 
within regions transited in the 12.5-25 min interval, but also in the 25-50 min interval, 
although results were less significant as a consequence of fewer measurements 
(Figure4.11C). Overall, these results show definitively that elongation rates directly 
correlate with splicing. 
Reduced elongation rates as a result of splicing should also be reflected on the 
GRO-seq profile as an increase of read density at the exons. To measure the GRO-seq 
density of the introns that is not affected by adjacent exons, we selected the midpoints 
of the introns >10 kb. We compared these intronic GRO-seq density profiles to GRO-
seq densities at the exons that are adjacent to these introns. As expected, the GRO-seq 
densities are increased around the exons compared to the introns (Figure 4.10C). Not 
only did we observe a local increase right at the exon-intron junction, but also a 
regional increase (~10%) in the ± 2kb region surrounding the exons. Together the 
increased Pol II density corresponds to about 12 seconds of delay (10% of the 2 min 
interval for Pol II to pass the 4 kb region) per exon, which corroborates reasonably 
well with the observed reduction of elongation rates as a result of transcription through 
an exon.  
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Pausing Increases Splicing Efficiency 
Because slow elongation rates are associated with less exon skipping (Figure 
1.10B and 4.11B and C), we hypothesized that fewer exons would be skipped at the 5’ 
regions of genes, as elongation rates are significantly slower in this region (Figure 
4.4D, 4.5E and F). Surprisingly, significantly more exons were skipped in the early 
region than further downstream in the gene (p-value = 3.4×10-5; Figure 4.10D), 
pointing to less accurate co-transcriptional splicing close to the TSS.  
To address this apparent paradox, we searched for factors near the TSS that 
correlate with improved splicing accuracy. We hypothesized that pausing could have 
an effect, as capping is thought to be facilitated by pausing14,15,40. The 5’-methyl-
guanidine cap interacts with CBC, which has been hypothesized to improve splicing 
by recruiting splice factors16-18. To see if pausing has an effect on splicing fidelity, we 
looked at skip ratios in pausing index quartiles of genes with 12.5-25 min elongation 
rates (Figure 4.10E). Interestingly, the skip ratio in early regions of poorly paused 
genes is significantly higher compared to those of the highly paused genes (p-value = 
0.003), and to those in the downstream regions (p-value = 5×10-4). Nevertheless, 
skipping in downstream regions in genes of all pausing index quartiles is constant 
(Figure 4.10E). Thus, pausing correlates with fidelity of splicing of the first few 
exons. If splicing is more efficient in highly paused genes, elongation rates should be 
slower due to the reduction of Pol II speed at spliced exon regions. Indeed, the 12.5-25 
min elongation rates in the highly paused gene quartile are clearly slower than in the 
poorly paused genes (Figure 4.10F; p-value = 1×10-7). Furthermore, this effect of 
pausing on the elongation rate is reduced in downstream regions of genes (Figure 
4.11D), where skip ratios are lower and relatively constant between pausing quartiles 
(Figure 4.10D and E).  
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While pausing seems to facilitate splicing in 5’ regions of genes, another way 
to reduce splicing mistakes in this region could be by increasing splice site fidelity, or 
by moving exons out of the region close to the TSS. Indeed, 3’ splice sites are more 
conserved in the upstream region of genes compared to downstream regions (Figure 
4.11E). Furthermore, it has been shown that the first intron in mice is larger than 
average introns41, although no satisfactory reason for this phenomenon has been 
proposed previously. We show that poorly paused genes have significantly larger first 
introns than highly paused genes (Figure 4.10G), consistent with the idea that selective 
pressure caused by erroneous splicing in poorly paused genes has lead to exons 
residing farther downstream from the TSS. 
 
Discussion 
P-TEFb kinase activity has been known to be critical for release of paused Pol 
II into productive elongation. By using GRO-seq to map the amount and orientation of 
transcribing polymerase at high sensitivity, we show that not just genes with pausing 
as a rate-limiting step are dependent on P-TEFb, but that all active Pol II undergoes an 
intermediate, P-TEFb dependent step from initiation to productive elongation.  
Furthermore, analysis of GRO-seq signals at times following P-TEFb inhibition 
allows highly sensitive measurement of elongation rates at ~1,000 genes, and within 
different regions of genes. Analysis of elongation rates shows that Pol II accelerates 
while transcribing in the gene body, and that elongation rates are inversely correlated 
to splicing. Furthermore, we report a link between promoter proximal pausing, 
elongation rates and splicing efficiency at the 5’ region of genes. 
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Pol II undergoes a P-TEFb dependent pause escape step at all actively transcribed 
genes  
Previous studies have shown that promoter proximal pausing of Pol II is a rate-
limiting step at many genes in both Drosophila and mammals, and productive 
elongation depends on P-TEFb recruitment and its kinase activity6,8,42. Rahl et al., 
(2010) showed that about 75% of active genes show increased pausing after treatment 
with FP, and here we establish that at least 95% of actively transcribed genes undergo 
a P-TEFb regulated ‘pause’ step. In fact, inhibition of initiation by Trp has an effect 
equal to that of FP on gene bodies, showing that Pol II pausing and P-TEFb 
recruitment and kinase activity is an integral step of the transcription cycle of virtually 
all genes.  
  The widespread effect of FP on P-TEFb action is further exemplified by the 
dramatic loss of phosphorylation at the CTD after treatment with FP for 50 min. P-
TEFb has generally been proposed to phosphorylate Ser2 of the CTD; however, we 
also observed an equal loss of Ser5 phosphorylation. One explanation to this could be 
the cross reactivity of the antibodies to Ser2 and Ser5, underrepresenting the complex 
and dynamic profile of the phosphorylated CTD43,44. Another possibility is that 
specificity of the CTD kinases may not be simple one-to-one projections. Recent 
evidence has indicated Brd4 as well as Cdk12 also phosphorylate Ser2 of the CTD and 
may have a redundant role together with P-TEFb45,46. Moreover, studies of P-TEFb 
kinase specificity that do not rely on antibodies point to Ser5 as its primary target47,48. 
Overall, the prevalent theory that P-TEFb phosphorylates only the Ser2 residue of the 
Pol II CTD may be an oversimplification. 
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Molecular basis of differences in elongation rates within genes 
FP mediated inhibition of P-TEFb in a temporal fashion allowed us to measure 
elongation rates of Pol II. Because P-TEFb inhibition affects all active genes, we could 
determine over 1,200 individual elongation rates of Pol II in many long genes, often 
even at multiple regions within the same gene. Danko et al. (2013) has used GRO-seq 
following a rapid induction of transcription to examine the rate of movement of the 
Pol II wave front. Our elongation rates measured here after inhibition of P-TEFb led to 
slightly lower elongation rates in comparison and may point to a model in which 
lagging Pol II pushes leading Pol II thereby increasing overall elongation rates49. 
Indeed, elongation rates in highly expressed genes are faster compared to rates in 
poorly expressed genes in both studies (Figure 4.8B)28. 
Strikingly, both Danko et al. (2013) and we demonstrate that elongation rates 
of Pol II are apparently slower upstream compared to downstream in a gene. 
Furthermore, composite profiles of GRO-seq reads revealed that Pol II density is 
higher near the 5’ end of the gene, indicating more sluggish transcription within this 
region. A simple acceleration model of Pol II elongation rate could explain this, which 
was supported by our simulation models. It could do so by accumulating positive 
elongation factors, by post-transcriptional modifications that facilitate elongation, or 
by encountering a more preferable chromatin state as it transcribes through the gene. 
Indeed, an apparent increase Pol II elongation rate can be seen at the intron1-exon2 
junction, where dramatic changes in chromatin landscape take place, as well as the 
first co-transcriptional splicing event (Figure 4.9B and C).  This suggests maturation 
of Pol II occurs, which starts at the promoter proximal pause step and increases as it 
transcribes through the gene and completes its first co-transcriptional splice event.  
A recent study implies that Xrn2 mediated and decapping dependent 
termination takes place early on in the transcription of a gene50.  Our data is not 
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consistent with widespread Xrn2 mediated termination.  Instead, we postulate that 
Xrn2 executes termination of a fraction of Pol II that fails to meet checkpoints at the 
pause site for escape into productive elongation or fails to efficiently splice the first 
intron.  
 
Pausing, elongation rates and splicing  
It is a longstanding hypothesis that Pol II slows down at exons to facilitate 
splicing26. The most direct evidence for this hypothesis comes from studies that use 
slow mutant forms of Pol II, in which skipped exons are more likely to become 
included21,22. Other studies that indicate elongation rates have an effect on alternative 
splicing use ChIP of Pol II at exons to draw conclusions36,37. However, a direct and 
quantitative correlation between splicing, exon skipping, and elongation rates at 
multiple genes has not been demonstrated. Here, we show directly that Pol II slows 
when co-transcriptional splicing occurs by showing a striking inverse correlation 
between our kinetically measured elongation rates over specific regions of genes and 
the density of spliced exons measured within these regions.  
 We also show that despite relatively slow elongation rates near the TSS, 
splicing is less efficient in this region compared to downstream regions, as indicated 
by increased exon skipping (Figure 4.10D). Interestingly, genes that have a high 
promoter proximal pause can splice exons more efficiently regardless of their position 
within the gene, while poorly paused genes display less efficient splicing at the 5’ end 
of the gene. This coincides with a slower elongation rates in highly paused genes, and 
higher elongation rates and lower exon density in 5’ regions of poorly paused genes. 
Promoter-proximal pausing of Pol II might serve as a time interval or checkpoint to 
ensure phosphorylation of the CTD, capping of nascent RNA and recruitment of splice 
factors16-18. Capping occurs during pausing14,15, and the CTD is phosphorylated both 
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before the pause and during escape from the pause, thereby creating a pause dependent 
platform for the recruitment of splice factors. Recently, the SR protein class of splice 
factors has been reported to interact with the inactive 7SK-RNA P-TEFb complex, and 
it was proposed that these splice factors have a role in recruiting P-TEFb to paused Pol 
II51. Naturally, the SR proteins may also assist early spliceosome formation at highly 
paused genes.  
Together, we provide direct evidence that splicing and elongation rate are 
highly correlated. Also, we show that splicing is less efficient at the first few exons, 
especially in genes without a rate-limiting step at the promoter proximal region, 
providing a first link between pausing of Pol II and co-transcriptional splicing. By 
defining the elongation rates genome-wide, this study takes great strides to elucidate 
what processes can directly influence elongation rate. The collection of genome-wide 
data for various factors in mouse ES cell is growing. Analysis of our data in 
conjunction with these more comprehensive datasets in the future is warranted to 
identify the splicing and elongation factors and underlying mechanism that interplay 
with elongation rate of Pol II genome-wide. 
 
 
Material and methods 
Cell culture, nuclei isolation and GRO-seq library preparation (This part was carried 
out by Dr. Iris Jonkers) 
Cell culturing of the V6.5 mES cell line was done as described previously, and 
drug treatment was performed on pre-plated mES cells to remove irradiated MEF-
feeder cells, grown for one passage on 15 cm2 plates up to ~70% confluence before 
isolation of nuclei. Drugs were added to the cells by replacing ES medium with pre-
heated ES medium containing 300 nM FP, 500 nM Trp or 0.0125% DMSO as no Trp 
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control. Timed incubation of drug treatment was done at 37°C, after which cells were 
put on ice and rinsed twice with ice-cold PBS, pH 7.4, followed by immediate nuclei 
isolation. Nuclei isolation, nuclear run-on and nascent RNA library preparation was 
performed as described previously8. In brief, after rinsing the 15 cm2 plates with drug-
treated cells, 15 ml cell lysis buffer (10 mM Tris-Cl, pH 7.5, 300 mM Sucrose, 3mM 
CaCl2, 2 mM MgAc2, 0.5% NP-40, 5 mM DTT, 1 mM PMSF, protease inhibitors) was 
added to the plates and the cells were scraped off, and spun down at 4°C and 185 xg 
for 5 min in a GS-6R Beckman swing-bucket centrifuge, after which supernatant was 
discarded. 5 ml fresh cell lysis buffer was added and cells were dounced 50 times in a 
5 ml douncer on ice and spun down at 328 xg for 5 min, after which supernatant was 
discarded and nuclei were taken up in ~250 µl of glycerol storage buffer (50 mM Tris-
Cl, pH 8.3, 40% glycerol, 0.1 mM EDTA, 5 mM MgAc2, 5 mM DTT, 1 mM PMSF, 
protease inhibitors) and snap frozen.  
 For each nuclear run-on (NRO), 107 nuclei were used. An NRO master mix 
was added containing nucleotides ATP, GTP, CTP and nucleotide analogue bromo-
UTP, as well as sarkosyl and 300 mM KCl to remove all impediments that pause Pol 
II and prevent NRO and to prevent re-initiation of Pol II. The NRO was performed at 
37°C for 5 min, which results on ~100 nt addition to the nascent RNA. Immediately 
after the NRO, a population of in-vitro transcribed spike-in RNAs with and without 
Br-UTP was added to the nascent RNA as a way to assess experimental differences 
between each library, and to use as a normalization tool between timepoints within 
each timecourse.  The nascent RNA was fragmented to ~150 nts and NRO BrU-RNA 
was isolated 3 consecutive times with BrdU-antibody beads (sc-32323, Santa Cruz), 
with enzymatic TAP and PNK treatments to remove the cap and 3’-phosphate and to 
add a 5’-phosphate, as well as Illumina adaptor ligations between the BrU-RNA 
isolation steps. The three consecutive isolation steps lead to an approximate 500.000x 
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enrichment of BrU-RNA over background RNA. BrU-RNA was reverse transcribed, 
amplified, barcoded and sent for sequencing. Each dataset was done in replicate. 
 
Sequence alignments and normalization (This part was done by Dr. Iris Jonkers) 
All the GRO-seq libraries were sequencing in 50 nt runs on the Illumina HiSeq 
and split by barcode. Sequences that contained the Illumina adaptor were clipped with 
the cutadapt tool (https://code.google.com/p/cutadapt/) and remaining sequences were 
trimmed down to 32-mers, aligned to the ribosomal genome to remove rRNAs, and 
then aligned uniquely to the mm9 reference genome, with up to 2 mismatches with 
bowtie (http://bowtie-bio.sourceforge.net/index.shtml).  Replicates were highly 
correlated and were pooled for further analysis, with exception of one of the 25 min 
Trp-treated #1 replicate, which suffered from extensive RNA degradation during the 
library preparation, and was subsequently discarded. Spike-in RNA controls were 
aligned similarly to a spike-in reference genome.  The number of read counts of 
individual datasets differed significantly between timepoints and treatments, but 
instead of using total read counts to normalize between treatments within either the FP 
or Trp timecourse, we chose to normalize with the spike-in RNA read counts instead. 
This was done because we expect the overall Pol II transcriptional activity of cells to 
decrease significantly after treatment with either FP or Trp, resulting in an 
overrepresentation of Pol II activity in the 25 and 50 min timepoints if we would 
normalize to total reads. The general decrease in Pol II transcriptional activity is 
reflected in the increasing percentage of rRNA reads in each timecourse (Table 4.1). 
Sequencing and alignment information for each library is presented in Table 4.1. 
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Analysis of FP and Trp drug treatment effects in time on the genome-wide Pol II 
distribution (This part was done by Dr. Iris Jonkers) 
 
Calculation of gene activity, pausing index, pause peak locations and 
enrichment, divergent peak location and enrichment, and gene body enrichment were 
done largely as in Core e tal., with small modifications. The mm9 RefSeq genelist was 
used as reference genelist for all analysis and contained 29,699 unique gene entries 
mappable to specific locations on chromosomes. To assess the general pattern of Pol II 
distribution after drug treatment we made composite profiles. Composite profile plots 
were made by taking all genes >12.5 kb or >150 kb and taking the average read 
density from the coding strand in 50 bp windows in the region from -5,000 to +12,500 
bp, or +10 kb to +150 kb from the TSS, respectively. Profiles were plotted in R and 
smoothed with smooth.spline.  
To establish which genes were active and enriched above background, we 
mapped reads in genepoor regions (Figure 4.3B) of the mouse genome from the no FP 
and no Trp control datasets, took the average read density of these two datasets and 
multiplied it 10x as a safe threshold for background read density (5×10-4 reads/bp). 
Unmappable regions of the genome were identified and excluded by aligning the 
genome to itself in 30-mers and sequence reads mapping to these regions were not 
used in analysis. Genes were called active when they were enriched within mappable 
regions above the 5×10-4 reads/bp background cut-off with a p-value < 0.05. To 
ascertain whether these thresholds were reasonable we looked at screen shots of some 
of the least active genes and saw that most poorly transcribed genes could clearly be 
distinguished from background (Figure 4.3C). However, some genes that were 
characterized as active were the result of artifacts such as spurious peaks within the 
coding region, or read-through transcription of upstream tandem genes. To ensure that 
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we used a clean gene set for further analysis of changes at the pause and divergent 
peaks as well as changes within the gene body, we defined a genelist based on the 
following criteria (Figure 4.3A): The genelist for analysis of FP and Trp sensitive 
genes contains the top 75% of active genes larger than 3.5 kb present in both the FP as 
the Trp control dataset, from which genes that have a TSS within 1000 bp on the 
opposite strand of its own TSS (bidirectional genes) and genes that have a stop site 
upstream of its TSS within 10 kb (tandem genes) are excluded (Figure 4.3A). This 
stringently selected list contained 6,380 genes. 
 Pause peak locations were found by searching for maximum coding strand read 
density in 10 bp windows from -500 to +500 around the annotated TSS of the 6,380 
selected genes. The promoter proximal pause site was defined as a 250 bp region 
centered on the maximum 10 bp window. The same was done for the divergent region, 
but the search area was enlarged to -1000 to +500 bp from the TSS and only non-
coding sequence reads were taken into account. Gene body regions were defined as 
starting +1,000 bp downstream of the annotated TSS and ending at the annotated stop. 
The pausing index was calculated by taking the ratio of the read density in the pause 
region and the gene body region, and genes were called paused when read density in 
the pause region was significantly higher than in the gene body region (Fisher Exact, 
p-value < 0.01). Changes of the pause peaks and divergent peaks after treatment with 
either FP or Trp was established by counting the reads mapped within the promoter 
proximal pause and divergent regions at each timepoint, adding a pseudo-count, 
calculating the density in the mappable region at the promoter and taking the log2 of 
the ratio of the read density after treatment and the no FP or Trp control. The change 
was significant if the Fisher Exact p-value calculated over read counts within the 
pause or divergent regions before and after treatment was < 0.05.  
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 During the relatively short treatments with FP and Trp, the effects of the drugs 
could be observed close to the TSS, but not further downstream in the body of the 
gene (Figure 4.1B, C and D). The unaffected downstream regions would thus 
camouflage the effect the drugs have on the gene body and therefore deflate our 
analysis. Therefore we decided to look at gene body effects of the drug treatments in 
the region from +1,000 to 3,500 bp of the TSS of the 6,380 selected genes only, to 
ensure the results were not affected by the promoter proximal pause region, while still 
looking at the region where drug-related effects could be expected from as early as 2 
to 5 min onwards. Reads were counted within the 1-3.5 kb region for each dataset, a 
pseudo-count was added and read density and ratios within the mappable region were 
calculated as above. The change in gene body density was significant if the Fisher 
Exact p-value was < 0.05 for read counts within gene body regions between control 
and treated datasets.    
 Density plots in the -1 to +1 kb region around the TSS of the 6,380 selected 
genes were made by counting reads in 10 bp windows from -1,000 to +1,000 from the 
annotated TSS, adding a pseudo-count to each window and taking the log10 of the 
read count. This was done separately for the coding and non-coding strands for the no 
FP and no Trp controls as well as for the 50 min FP and Trp treated datasets. The 
overall Pol II distribution on both strands is the sum of the log10 read count of the 
coding and non-coding 10 bp windows. The increase or decrease of read counts within 
each 10 bp window was calculated by subtracting the no FP or Trp log10 read count 
from the 50 min FP or Trp read count. Genes in the density plots were ordered by the 
maximum decrease or increase after 50 min Trp or FP treatment in read density at the 
promoter proximal pause peak, respectively. The density in windows was plotting 
using heatmap.2 of the R packages gplots together with RColorBrewer.  
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Protein fractionation and western blot analysis (This part was done by Dr. Iris 
Jonkers) 
Extractions of chromatin bound and unbound proteins were done after 
treatment of pre-plated mES cells for 50 min with 300 nM FP, 500 nM Trp or 
0.0125% DMSO as no Trp control.  Cells were rinsed twice in ice-cold PBS, pH 7.4, 
scraped off the plates and spun down for 5 min at 1,000x g. Cells were resuspended in 
nuclei lysis buffer (20mM Tris-Cl pH 7.5, 3mM EDTA, 10% glycerol, 150mM KAc, 
1.5mM MgCl2, 1mM DTT, 0.1% NP-40, and phosphatase and protease inhibitors), 
dounced 60 times on ice and centrifuged at 13,000 rpm for 5 min at 4°C. Supernatant 
was snap frozen as the unbound fraction, while the remaining pellet was resuspended 
in the same volume of nuclei lysis buffer as above and sonicated to break up the 
chromatin and help solubilize the pellet. The chromatin fraction was also snap frozen 
until further use. Western blot analysis was done in triplicate with antibodies against 
the Ser5 (3E8, Millipore) or Ser2 (3E10, Millipore) phosphorylated CTD, or N-
terminal Pol II (N-20, Santa Cruz). 
 
Estimation of the inhibition wave-front and elongation rates using Hidden Markov 
Model (HMM) (This part was done by Hojoong Kwak) 
In summary, we selected genes that are long enough, start at the annotated 
TSS, and do not have interfering transcription in the middle of the gene bodies for the 
determination of elongation rates. Then we used an HMM to identify the position of 
the inhibition wave fronts at each time-point for individual genes. These positions of 
transition points are used to calculate the elongation rate between the time points. 
First, we selected genes that are longer than 30kb for 5min to 12.5 min, 60kb for 12.5 
min to 25 min, and 150kb for 25 min to 50 min analysis. Then we removed the genes 
that do not have corresponding transcription units at the annotated TSS or contain 
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intragenic transcription units defined by a genome-wide HMM (script named ‘tar2’, 
described below). Also, genes that have premature termination before the annotated 3’ 
ends and/or the 60kb/150kb mark are removed using a regional HMM (script named 
‘tar7’, described below). After filtering, the number of selected genes are n=4,461 for 
genes longer than 30kb, n=2,769 for genes longer than 60kb, and n=571 for genes 
longer than 150kb. 
We used a HMM algorithm (script named ‘hmm2’, described below) for each 
replicate of GRO-seq Flavopirodol (FP) and Triptolide (Trp) time courses and 
determined the transition points from the drug affected (inhibited) region to the drug 
unaffected (uninhibited) region of the gene body. We removed the genes that have the 
replicate transition points more than 20% different from the average of the two. For FP 
data after this filtering, we had 250 genes for 5min transition point and 1,798 genes for 
12.5 min transition points out of 4,461 genes that are longer than 30 kb. Similarly, 
1,389 genes remained from 2,769 genes longer than 60 kb and 387 genes out of 571 
genes remained from genes longer than 150 kb. For Trp data, the HMM worked less 
efficiently, and 183, 466, and 239 genes passed this filtering from the >30 kb, >60kb 
and >150kb gene lists. The elongation rates were calculated using the differences in 
the transition points. For FP, n=141 for rates between 5 and 12.5 min, n=937 between 
12.5 and 25 min, and n=245 between 25 and 50 min. For Trp, n=432 between 12.5 and 
25 min, and n=157 between 25 and 50 min. 
The followings are the descriptions of the HMM scripts. 
1. hmm2 
For the selected genes, GRO-seq read coverage from the TSS to 60kb or 150kb 
positions are binned for each time-point, and were divided by the untreated read 
counts at the same bins (Figure 3B). The bins sizes are 500bp, 1kb, 2kb, and 5 kb 
respectively for analyzing 5min, 12.5min, 25min and 50min time points. These sizes 
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were selected so that each gene will have approximately 30-40 bins throughout the 
gene body regions, which was the optimal number for the HMM results. For each 
gene, the ratios in individual bins were internally normalized, by dividing by the 
average ratios of last 5 bins at the 3’ ends. These bins are considered as the Markov 
process with the ratios as the observations (Figure 4.5B). For efficient HMM 
calculation, the normalized ratios were digitized, ranging from 0 to 2.0, with the step 
size of 0.05. Therefore, each binned position contains can have 20 observed states of 
the read ratio, and the probability of each state follows a binominal distribution of B(n, 
e), where n=20 and e is the emission probability. We assumed 2 hidden states 
‘inhibition affected’ and ‘inhibition unaffected’, with two emission probabilities e1 and 
e2. The transition probabilities between the ‘affected’ and ‘unaffected’ states are p11, 
p12, and p21 (Figure 4.5B), and are unidirectional. The Baum-Welch algorithm is used 
to estimate the transition and emission probabilities, by iterative calculations until the 
probabilities converge. If the iteration is over 200 cycles without convergence, we 
dropped the gene from further analysis. The transition point is calculated from these 
probabilities. 
2. tar2 
The untreated GRO-seq data is used similarly as hmm2 with some 
modifications. First, instead of using ratio relative to the reference dataset, we used 
binary observation values for each 200bp bin of the Markov process; 1 if there is a 
GRO-seq read within the bin and 0 if there are no reads. In this case, the binomial 
distribution becomes B(2, e). Second, the full length of each chromosome was used 
rather than individual genes. Third, the Baum-Welch algorithm was allowed to run up 
to 1,000 iterations. Finally, a Viterbi path was calculated to define transcriptionally 
active regions. 
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Using this de-novo transcription unit (TU) calling, we selected TUs that have 
both sense and divergent pairs starting within 2 kb from each other. These paired TUs 
can indicate annotated TSSs, unannotated TSSs, or other regulatory transcription 
activities such as lncRNA or enhancer transcripts. We compared these TUs to the 
annotated long genes and removed the genes that did not have paired TUs near the 
annotated TSS (<2 kb). Also, we dropped genes that contain divergent TUs within the 
gene body, since these paired sense TUs arising at the middle of the gene bodies can 
indicate alternative start sites that may interfere with the transcription signal arising 
from the annotated TSS of the gene. 
3. tar7 
Using untreated GRO-seq data, we generated binary bins from TSSs defined 
by tar2 to 50 kb downstream of the annotated 3’ end in each individual gene, and used 
these values to estimate the probability parameters of the HMM. This is similar to tar2 
in that it uses binary observation values, but also similar to hmm2 in that it is done in 
individual genes. One difference from hmm2 is that it starts from the active region and 
detects the transition point into the inactive region or in other words the end of the TU, 
which is opposite of hmm2. Genes that have the transition point before the 
60kb/150kb point are dropped, as this may interfere with detection of the inhibition 
wave by hmm2. 
 
Kinetic Monte Carlo simulation of the acceleration and the termination models (This 
part was done by Hojoong Kwak) 
The dynamics of elongating Pol II in gene body is simulated using a newly 
designed modeling program to describe Pol II transcription through a gene (Figure 
4.7A). First, we modeled a Pol II transcription complex entering the gene body region 
with an entry rate (r) as a function of time. For the steady state assumption, r is a 
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constant over time (t), while for the simulation of the inhibition wave, r is an 
exponential decay function of t. 
Each Pol II molecule was generated with the rate r, and has a randomly 
assigned activity parameter (A), from 0 to 100 as a percentile. This activity parameter 
A is an intrinsic value of each Pol II molecule that determines the efficiencies of the 
elongation and the termination rates. The termination constant (kt) and the elongation 
rate (v) are the functions dependent on the activity (A) as well as the position (x) 
within the gene body of the Pol II molecule. For instance, in a simple acceleration 
model where all Pol II molecules accelerate uniformly, kt = 0 for all A and x, while v is 
an increasing function of x but a constant function for A. In a termination model, 
intrinsically active polymerase molecules elongate faster while less active ones 
elongate at a slower rate and terminate more frequently. In this case, kt is a decreasing 
function of A, and v is an increasing function of A regardless of x. 
For running the simulation, entry, termination, and progression events are 
assessed after each time increment of Δt. For each event, a pseudorandom number 
between 0 and 1 is generated and compared to the probability of initiation as described 
by 1-exp(-rΔt), termination as described by 1-exp(-ktΔt), and processive elongation as 
described by 1-exp(-vΔt) respectively. If the number is less than the probability of any 
of the processes, the status of the polymerase changes accordingly. For the 
approximation of the progression event, the polymerase can move k bases following 
the Poisson distribution if the pseudorandom number is in the range [F(k; λ), F(k+1; 
λ)), where F is the cumulative Poisson distribution function and λ = vΔt. If there is a 
collision event between two polymerases, the leading polymerase terminates. 
The distribution of simulated Pol II in N=1,000 DNA templates are 
equilibrated for 10,000s. The average Pol II distribution at this point is recorded as D. 
Upon the simulation of the decay of entry, average Pol II distribution is recorded every 
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100s over 100,000 bp region. The average distribution at each timepoint is analyzed 
using the HMM, and the transition points are estimated. From the timecourse of 
transition points, the apparent elongation rates (va) are calculated as a function of the 
position (x). The slope plot (Figure 4.7D) is generated by calculating ΔD-1/Δx and 
Δva/Δx using linear interpolation between x=5, 15, 25, 35, 45, 55 kb or t=5, 12.5, 25, 
and 50 min. 
We tested the following parameter spaces for the simulation. Only two 
examples of the results from simple acceleration and simple terminations models are 
shown in Figure 4.7C. However, all the described models were used to generate the 
scatterplot in Figure 4.7D. 
1. Single component models 
1) Simple acceleration model 
v(x=0kb) = 5 bp/s, v(x=60kb)=40 bp/s ; Pol II starts at 5 bp/s (300 bp/min) and 
accelerates to reach 40 bp/s (2.4 kb/min) at the 60 kb position and downstream. The 
interpolating v(x) values are generated using cubic Bézier functions (Figure 4.7E). The 
termination rate kt is 0.  
2) Simple termination model 
v(A=0) = 5 bp/s, v(A=100)=40 bp/s; the interpolating v(A) values are made 
with the cubic Bézier functions (Figure S4F). kt(A=0)=0.002 – 0.0005 (/s), 
kt(A=100)=0; the interpolating kt(A) values are made with cubic Bézier functions 
(Figure S4F). The kt(A=0) values are chosen so that the simulated D curve reflects the 
observed D curve (Figure 4.7B) which gradually decreases in regions x<20kb and 
becomes nearly a constant where x>20kb. The less active (and slower) population of 
Pol II is mostly terminated within the first 20 kb region with selected kt parameters. 
Finally, combinations of v and kt functions are used. 
2. Complex models 
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1) Mixed acceleration model 
Models with mixed acceleration and termination are also tested. v(x,A) is 
generated as a combination of the v(x) of the acceleration model and v(A) of the 
termination model (Figure S4G). The kt functions of the simple termination models are 
used. 
2) Regional termination model 
The termination rate (kt) can also have an added dimension and can be treated 
as a function of both x and A (Figure 4.7H). The interpretation of this is that 
termination takes place at some preferred positions along the gene. We adjusted the 
shape of the function so that slower Pol II is relatively stable near the 5’ side of the 
gene to make the apparent elongation rate slower at the beginning. The increased 
termination at more downstream position leaves only the faster polymerase 
populations and the apparent elongation rates are higher. 
 
ChIP-seq correlation study (This part was done by Dr. Iris Jonkers) 
ChIPseq datasets listed in Figure 4.8D were downloaded and aligned to the 
mm9 genome when necessary. Reads were extended by 200 bp, and read density was 
derived in the mappable regions of interest. We correlated read density of ChIPseq 
factors in the promoter or elongation rate transition region with elongation rates and 
made boxplots of the elongation rate quartiles. For factors that correlated with 
elongation rates, we made additional composite profiles from -2 to 30 kb from the TSS 
in 25 bp windows of these factors in the elongation rate genes, and split the composite 
profiles up in quartiles of elongation rates or intron1 size. To further elucidate the 
relationship of intron1 size, histone modifications of interest and GRO-seq Pol II 
distribution, we made composite profiles centered on exon2 or exon3 start sites of 
genes with 12.5-25 min elongation rates, and introns 1 and 2 larger than 5 kb. GRO-
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seq distribution at these exon-intron junctions was further validated by subsampling 
1000 times over 10% of the genes at the time, and plotting the median of the 
subsampled composite profile, with confidence intervals at 0.25 and 0.75.   
 
Splicing analysis (This part was done in collaboration with Hojoong Kwak and Dr. 
Iris Jonkers) 
We aligned the RNA-seq dataset from Sigova et al.52 to the mm9 genome and 
established the read density within all exons of genes > 3.5 kb and expressed within 
the top 75% of activity, as well as the average read density in all exons of each gene. 
We next established whether read density within the individual exons is significantly 
different from the average read density in the coding region, and the fold difference of 
read density in individual exons compared to the average read density. We called an 
exon skipped when its read density was 3 fold less that the average density, and was 
significantly different with a p-value < 0.01. We also significantly different exons (p-
value < 0.01) with 3 fold increase in read density compared to the average and called 
these over-included exons, in other words, exons that are always present within the 
coding region and highly spliced. LOGO’s of splice sites for each of these exon 
groups were derived from the frequency matrix of the base compositions as described 
previously53.  
 Next, we specifically looked at genes with elongation rates associated with 
them, and calculated the exon density of all exons (exons/kb) within the transition 
regions of these genes. We plotted exon density against the elongation rates and did a 
linear regression between elongation rates and total exon density, or split up the linear 
regression fit analysis of elongation rates and exon density into elongation rate genes 
without alternative spliced exons, with skipped exons or with over-included exons 
within the transition region. We also calculated the skip ratio within the transition 
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region (skipped exon density/exon density) and plotted genes with a skip ratio > 0 
against elongation rates to see if increased skipping of exons correlates with higher 
elongation rates.  
 To investigate whether splicing is influenced by the position of exons in the 
gene, we looked at the skip ratio in the region from the TSS until the 25 min transition 
point of genes with 12.5-25 min elongation rates, and compared it to skip ratio in the 
same genes in the region from the 25 min transition point until the stop (excluding the 
last exon). We did this for all genes with 12.5-25 min elongation rates, or for quartiles 
of pausing index, to assess the role of pausing with respect to splicing. Both 12.5-25 
and 25-50 min elongation rates and intron1 size were also assessed with respect to 
pausing index quartiles. LOGO’s of splice sites for exons upstream of the 25 min 
transition point or downstream of 25 min transition point were derived as described 
above. 
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CHAPTER 5 
 
ANALYSIS OF THE ORGAN SPECIFIC NASCENT TRANSCRIPTOME FROM 
SOLID TISSUES 
Summary 
RNA polymerase (polymerase) mapping is an important strategy of measuring 
the activity of transcription at the level of RNA synthesis. The use of nuclear run-on is 
emerging as a prominent method to monitor genome wide transcription. One of the 
obstacles for the wide application of nuclear run-on is the requirement of efficient 
nuclei isolation procedure from cells or tissues. We solved this problem by performing 
run-on reactions directly on the suspension of pelleted chromatin without isolating the 
nuclei. Using this method, we first demonstrated the genome-wide nuclear run-on 
assays in tissues from mouse organs, and acquired high-resolution tissue specific 
transcriptional landscape of the nascent transcriptome that defines the tissue identity as 
well as novel potential regulatory elements. 
 
Introduction 
 Transcription can be measured in several ways. The simplest is to analyze 
the steady state total RNA within the cell1. However this preferentially detects 
processed forms of RNA, and not all of the transcriptional activity results in stable 
mature RNA. In contrast, transcription can be measured at the level of RNA synthesis 
by mapping the amount and the distribution of active RNA polymerases on the 
genome2. This has unique advantages over other transcription assays in that it detects 
all forms of transcriptional activity including long non-coding RNA, small regulatory 
RNA, and enhancer transcripts. Therefore, the application of the polymerase mapping 
method can become a valuable tool in both research and diagnostic purposes.  
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 Currently, Chromatin Immuno-precipitation by RNA polymerase antibodies 
(RNAP-ChIP) is the most widely used2. RNAP-ChIP uses the immuno-purification of 
RNA polymerase and extracts DNA fragments cross-linked to the polymerase 
molecules. It can be used in tissues, but ChIP has low genomic resolution, high 
background, and lacks the information about the direction of transcription on DNA2. 
 Nuclear run-on has been the method that uses the endogenous enzymatic 
activity of RNA polymerases to label the nascent RNA for genome-wide mapping. 
Coupling this to next-generation sequencing, Global Run-On sequencing (GRO-seq) is 
a powerful method that uses isolated nuclei from cells for the run-on reaction3. It 
shows the direction of transcription, has very low background, and only detects the 
polymerases that are actively engaged. However, the resolution is limited by difficulty 
in controlling the length of labeled-NTP incorporation. Precision Run-On sequencing 
(PRO-seq) is a variation of GRO-seq that improves the resolution problem by using 
only the biotin-NTPs for the run-on substrate4. Under this condition, the polymerase 
only incorporates one or at most a few biotin-NTPs, and the 3’ ends of these labeled 
nascent RNA represents the precise position of RNA polymerase. Since this method 
analyzes the portion of nascent RNA near the 3’ end that is protected by the 
polymerase molecule, the result is relatively less affected by RNA degradation than 
simple RNA-seq. These methods can in some cases be applied to tissues, but the 
nuclei isolation procedures require laborious optimization for each tissue and time 
consuming nuclei preparation. 
  Here we demonstrate the first use of the nuclear run-on method on mammalian 
solid tissues using a rapid efficient processing procedure. Analysis of the data shows a 
high-resolution tissue specific transcriptional landscape that defines the tissue identity 
as well as some novel potential regulatory elements. 
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The Chromatin Run-On Method 
 To establish a general cell or tissue preparation for nuclear run-on that does 
not include laborious nuclei isolation, we developed the Chromatin Run-On method. 
By coupling Chromatin Run-On with sequencing (ChRO-seq) in mouse liver and 
brain, we generated tissue specific nascent transcriptome data. Briefly, cells or frozen 
tissues are lysed in buffer containing urea and detergent followed by centrifugation, 
and pelleted chromatin is mechanically disrupted into suspension for biotin nucleotide 
incorporation (Fig. 5.1). This provides a method to label nascent transcripts engaged 
with active RNA polymerases for high specificity mapping in cultured cells or tissues 
without isolating the cell nuclei. 
  
Chromatin 
pellet 
Chromatin 
suspension 
Pol II 
Nascent RNA 
Biotin-NTP 
3’ biotin-nascent RNA 
Centrifuge 
Lysis 
Frozen 
tissue 
Run-On 
Brief 
sonication 
Figure 5.1. Scheme of the Chromatin Run-On method 
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Table 5.1. Sequencing and alignment statistics 
 Liver #1 Liver #2 Brain #1 Brain #2 
Total reads 24,510,462 25,212,384 27,703,805 24,587,514 
After adaptor clipping 22,623,570 16,997,599 21,394,140 27,876,076 
Mapped to rDNA 3,618,882 
(16.0%) 
4,124,860 
(24.3%) 
1,539,163 
(7.2%) 
2,697,042 
(9.7%) 
Uniquely mapped 12,480,668 
(55.2%) 
6,856,166 
(53.3%) 
11,019,407 
(51.5%) 
13,458,703 
(53.5%) 
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Figure 5.2. Correlation between the ChRO-seq libraries (A) Between liver 
repeats. (B) Between brain repeats. (C) Between liver and brain libraries. 
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We obtained sequencing results for two repeats (50mg and 200mg tissues) per 
each organ, and analyzed them (Table 5.1). To validate whether the repeats correlate 
well with each other, we generated scatterplots of the promoter proximal read counts 
and gene body read counts. The liver datasets generated from 50 mg and 200 mg 
tissues correlated well with each other (Figure 5.2A). However, we saw biased 
correlation between the promoter read counts of the brain datasets (Figure 5.2B). We 
speculate that this was due to the lack of sufficient complexity of the library; therefore 
we only used the 200 mg brain library for further analysis. Distributions between the 
liver and brain 200mg libraries were evenly dispersed, suggesting that the complexity 
of the brain 200mg library is adequate (Figure 5.2C). 
 We show examples of the ChRO-seq profiles at selected positions on the 
mouse genome. Figure 5.3A shows the UDP glucuronsyltransferase cluster where the 
genes are specifically expressed in liver tissues5. The distribution of Pol II is 
consistent with the ChIP-seq data in the same tissues6, demonstrating the validity of 
the ChRO-seq method. Compared to Pol II ChIP-seq data, ChRO-seq has higher 
resolution and shows the direction of transcription. The directionality is critical, not 
only to indicate the direction of the gene, but also to detect the positions where 
transcription arises. Gene promoters and some active enhancers are known to have 
characteristic signatures of initiating bidirectional transcriptions3,7-9. For example, 
Figure 5.3B shows a position where two convergent genes are expressed reciprocally 
between the two tissue types. Compared to Pol II ChIP-seq, ChRO-seq efficiently 
identifies the TSS of the Arhgap24 gene in the liver tissue by identifying the divergent 
peak of (-) strand Pol II near the start site (blue arrow). In the brain tissue, Arhgap24 
gene is not active and its pairing convergent Mapk10 gene is activated. Interestingly, 
we saw a pair of strong bidirectional peaks near the 3’ end of Arhgap24 gene showing 
an alternative TSS or an enhancer that might have a regulatory role (red arrow). 
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Figure 5.3. Examples of differential ChRO-seq profiles on selected genomic 
positions. Mouse tissue Pol II ChIP and mESC GRO-seq data are also shown. (A) 
UDP glucuronsyltransferase cluster. (B) Arhgap24 and Mapk10 genes. 
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Analysis of the Tissue Specific Nascent Transcriptome Data 
 We analyzed the expression level of genes from our ChRO-seq data, and 
classified the genes that are relatively more expressed in one tissue type versus the 
other. Using the list of these genes, we carried out a Gene Ontology analysis10 (Figure 
5.4). The genes more expressed in liver are related to wound healing, blood 
components and metabolism. This agrees well with the function of liver and its 
regenerative property11. On the other hand genes that are more expressed in the brain 
are involved in the neuronal signaling and differentiation. The tissue type prediction 
shows with high specificity that the ChRO-seq datasets are from the liver and the brain, 
respectively. 
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Figure 5.4. Gene ontology analysis based on the expression levels 
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 We further performed an analysis attempting to define tissue specific un-
annotated transcription units using a computational algorithm. Hidden Markov Model 
(HMM) is a widely used method to predict the unidentified statuses along a linear 
chain from probabilistic observations12,13 (Figure 5.5). We applied this method for the 
genome-wide de-novo identification of un-annotated potential regulatory transcription 
units. 
 For example, Srrm4 gene is a splicing regulator in neuronal cells that is not 
expressed in the liver14 (Figure 5.6A). It has an antisense non-coding transcript 
(2410137F16Rik) arising from the 3’ end of the gene. In the liver cells, there is a 
characteristic bidirectional peak indicative of a TSS or an enhancer located about 10 
kb downstream of the annotated non-coding transcript start site (Figure 5.6, black 
arrow). This was detected by the HMM algorithm as two bidirectional transcription 
units (tar#10229 and tar#11065; red and blue arrows) that arise at a similar location. 
This transcription activity is not observed in the brain tissue where Srrm4 transcription 
is dominant. Therefore, we suggest that the current annotation does not accurately 
reflect the transcriptional landscape in the liver tissues, and the novel ChRO-seq based 
transcription unit may have be associated with regulating the expression of the Srrm4 
gene. 
Inactive Active 
Begin 
Hidden states 
Read counts 
Low High 
p12 
p11 
p22 
e1 e2 p21 
Figure 5.5. Scheme of the de-novo transcription unit calling using HMM 
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Figure 5.6. Identification of tissue specific re-annotated de-novo transcription units. A 
pair of liver specific transcription units are identified, of which the expression is 
reciprocal to Srrm4 gene expression. Black arrow is the start of the bidirectional 
transcription is ChRO-seq profile. Red and blue arrows point to the newly annotated 
transcription starts using HMM on the plus and minus strands of the reference 
genome respectively. (T.U.: transcription unit) 
mESC 
Brain 
ChIP 
ChRO 
GRO 
ChIP 
ChRO 
Liver 
Refseq 
annotation 
Liver T.U. 
Brain T.U. 
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Another example is the Slc2a13, which is a membrane transport protein 
expressed in brain15 (Figure 5.7). In the brain ChRO-seq data, a bidirectional peak is 
located about 40kb upstream of the TSS, which could potentially be an active 
enhancer (black arrow). With ChIP-seq, it would be difficult to assess this since the 
bidirectionality cannot be determined. This un-annotated transcription unit was also 
detected by the HMM algorithm in brain but not in liver (red arrow), demonstrating 
that the genome-wide transcription unit annotation can serve as a useful tool to detect 
and evaluate potential regulatory elements on the genome. 
 
Discussion 
  We have demonstrated that the genome-wide nuclear run-on can be performed 
in solid tissues using our new ChRO-seq variation of the nuclear run-on protocol.  The 
results demonstrate the differences in the transcriptional landscape between tissues. 
This method has several unique features compared to conventional genome-wide 
transcriptional analyses. 
ChRO-seq provides a direct instantaneous processing of cells without nuclei 
isolation. Unlike other methods, the cells are lysed instantly in a mild denaturing 
solution where RNA polymerase would not be active. Therefore, there is little 
possibility of secondary effects altering the polymerase distribution during the 
preparation step. For tissues, instantaneous freezing in liquid nitrogen can ensure that 
RNA polymerase distributions are not altered. The frozen tissues can be processed by 
grinding and lysed within a few seconds. This is a major advantage over other 
methods, because it is extremely simple and efficient. 
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Figure 5.7. Identification of tissue specific un-annotated de-novo transcription unit. A 
potential enhancer site of Slc2a13 gene expression in brain is identified. Black arrow 
is the start of the bidirectional transcription is ChRO-seq profile and the red arrow 
point to the newly annotated transcription start using HMM on the plus strand. (T.U.: 
transcription unit) 
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ChRO-seq detects endogenous enzymatic activity of RNA polymerase from 
pelleted chromatin. Chromatin fractionation method originally described by Wuarin 
and Schilber16 has been previously used to isolate nascent RNA associated with 
chromatin. However, it has never been shown that the RNA polymerase in the 
chromatin pellet contains the enzymatic activity after the pellet is re-suspended. Using 
this enzymatic activity for labeling nascent transcript is critical for the three reasons. 
First, it provides affinity handle to highly enrich for nascent RNA engaged with active 
polymerase and no other forms of RNA3. Second, identifying the sequences of the 
labeled nascent RNA from the 3’ end makes it possible to map where the RNA 
polymerase was positioned to a base-pair resolution4. Finally, it is possible to 
selectively ablate the undesired cells or parts of the tissues by inactivating the RNA 
polymerase molecule, for instance with UV laser. 
By using the PRO-seq scheme for making the library for high-throughput 
sequencing, ChRO-seq can still obtain the genomic resolution up to a single base-pair 
and has all the other advantages of PRO-seq4. Biotin affinity purification system is 
established from many available commercial sources with well-controlled nuclease 
contamination. Also, it is less affected by deteriorated sample quality and RNA 
degradation. RNA polymerase active sites are mapped by aligning the 3’ end of 
nascent RNA sequence to the reference genome. Typically in mammalian cells, this 
requires about 30 bases of RNA sequence from the 3’ end. Most of this length of 
nascent RNA is structurally protected by RNA polymerase complexes from the 
degradation by RNases17,18. Therefore, ChRO-seq can be less affected by the quality 
of the sample or RNA. 
  We expect that the nascent transcriptome analysis using ChRO-seq can be 
easily extended to the diagnostics. Previous methods to measure the genome-wide 
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distribution of RNA polymerases are practically limited to cultured cells or blood 
cells. But this method can be used as a diagnostic nascent transcriptome analysis in 
pathologic specimen from solid tissues. Excess surgical specimen after a pathologic 
diagnosis, as little as 100mg of fresh frozen tissue, can be used. Coupled to the clinical 
studies that associate the disease outcome and therapeutic responses to drugs, 
ultimately this method can serve as a predictive tool. Currently, possible diagnostic 
genomic analyses are DNA sequencing of the exomes (exome-sequencing)19, and 
mRNA sequencing (RNA-seq). Because of the impractical depth of sequencing 
required to identify mutations across the whole genome by DNA sequencing, DNA 
sequencing at this stage is limited to the exons of all annotated genes (exome)19. 
However, critical mutation can take place at other regions of the genome such as 
regulatory regions of introns. Exome-sequencing only detects the mutations that may 
have the potential for a mis-regulation, but not directly at the gene expression 
products. RNA-seq measures the gene expression products, but also is limited to 
mature mRNAs, and cannot detect transcriptional activity at regulatory regions. 
Therefore, measurement of the transcriptional activity across the whole genome by 
ChRO-seq can make it serve as an efficient tool for the disease diagnostics as well as 
for the studies of the transcriptional mechanism itself. 
 
 
 
Materials and Methods 
Chromatin Run-On sequencing (ChRO-seq) 
We used NUN (NaCl-Urea-NP40) buffer which is 20mM HEPES pH 7.5, 
1mM DTT, 7.5mM MgCl2, 0.2mM EDTA, 1M Urea, 0.3M NaCl, 1% NP-40, RNase 
inhibitor, Protease inhibitor cocktail (modified from Wuarin & Schibler16). We lysed 
 164 
 
cells or finely homogenized frozen tissues in NUN at 4°C by immediate re-suspension 
and vortexing. The volume of NUN buffer was at least 20 × w/v of the cell or tissue 
mass. Centrifuge for 20min at >15,000g, 4°C. A thin white pellet formed at the bottom 
of the vessel. For tissues with high extracellular matrix content (brain), an additional 
layer of solid pellet formed over the chromatin pellet. However, that layer could be 
easily disrupted with pipetting while the chromatin pellet remained solid. Then we 
wash the chromatin pellet at least twice with cold 50mM Tris-HCl pH 7.5 buffer, 
using caution not to break the pellet since the pellet sometimes adhered to the pipette 
tips. We removed all wash buffer and add 100 µl of storage buffer, typically per 
200mg of tissue or 2 × 107 cells. The storage buffer is 50mM Tris-Cl pH 8.0, 25% 
glycerol, 5mM MgAc2, 0.1mM EDTA, and 5mM DTT. Then the chromatin pellet was 
disrupted with tip sonicator with short bursts of < 2 sec each. Repeat sonication until 
the chromatin pellet is disrupted to white cloudy suspension. Then we instantaneously 
froze the chromatin suspension in liquid nitrogen. The material was stored at -80°C for 
at least a few months until run-on processing. For the run-on, we mixed the chromatin 
suspension with the equal volume of 2 × run-on solution (10mM Tris-HCl pH 8.0, 
5mM MgCl2, 1mM DTT, 300mM KCl, 1% sarkosyl, 40µM biotin-11-ATP, 40µM 
biotin-11-CTP, 40µM biotin-11-GTP, 40µM biotin-11-UTP, and RNase inhibitor). 
The reaction mixture was incubated at 37°C (mammalian cells) or 30°C (insect cells) 
for 3 min. Then the labeled RNA was extracted. The extracted RNA was processed in 
the same manner as described previously for PRO-seq. 
 
De-novo annotation of transcription units using Hidden Markov Model 
For the full length of each chromosome, ChRO-seq read coverage was used to 
make binary observation values for a bin of the Markov process, 1 if there is a ChRO-
seq read within the bin and 0 if there are no read. Therefore, each binned position 
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contains can have either active or inactive states, and the probability of the each state 
giving ChRO-seq read coverage is the emission probability e. We assumed 2 hidden 
states ‘transcriptionally inactive’ and ‘transcriptionally active’, with two emission 
probabilities e1 and e2. The transition probabilities between the ‘affected’ and 
‘unaffected’ states are p11, p12, p21, and p22. The Baum-Welch algorithm is used to 
estimate the transition and emission probabilities, by iterative calculations until the 
probabilities converge. Then the Viterbi path was calculated to define transcriptionally 
active regions for each chromosome. 
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CHAPTER 6 
 
CONCLUSION 
An integrative model of Pol II elongation 
RNA polymerase II (Pol II) is the key molecule of eukaryotic transcription. In 
this dissertation, I have described some aspects of the mechanisms of Pol II during 
early and productive elongation. Although these studies were carried out in different 
systems such as Drosophila and mouse cells or tissues, the findings could be 
integrated into a single model that gives a general picture of how Pol II elongates. 
First, after the initiation and promoter clearance, Pol II starts the synthesis of 
nascent RNA chains1. At this stage, a part of the initiating complex on the promoter 
may still remain associated with the promoter DNA elements and retain contact with 
very early elongating Pol II2. As shown in the figures in chapter 1, the 3 dimensional 
space within the promoter and Pol II is quite restricted, and the complexes are within 
proximity to each other for such potential interactions to occur. The Pol II at this stage 
has only some of its C-terminal domain (CTD) phosphorylated at Ser5 position3. This 
very early elongating Pol II less than ~20-60 nt experience backtracks and pauses due 
to the energy landscapes of the transcription bubbles4 and potential interaction with 
large promoter protein complexes such as TFIID or TFIIH. GAGA factor and 
appropriately positioned GAGA element might have a role in stabilizing this promoter 
protein complex. This stabilizing of the promoter complex may be closely related to 
the positioning of core promoter DNA elements5 as described in Chapter 2. 
Second stage is the consolidation of the transient pausing through the 
recruitment of pausing factors, NELF and DSIF. The precise mode of their recruitment 
is still not very well known, but is speculated to be through the cooperative effect 
involving the binding to nascent RNA chains6, promoter protein complexes such as 
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GAGA factor7, and Pol II itself8. Binding of NELF and DSIF may lock the nascent 
RNA chain from exiting and modify the structure of Pol II active site through 
allosteric interaction with clamp regions of Pol II9. At the same time, TFIIS may get 
recruited to the other side of Pol II near the secondary channel10, and rescue 
backtracked Pol II by cleaving protruded nascent RNA, putting the polymerase 
molecule back to the paused position4. 
Third stage is the maturation of paused Pol II complex. 5’ RNA capping can 
take place at this time, which may be a checkpoint for pause escape and productive 
elongation11-13. If this stage is prolonged, some of the paused Pol II molecules may 
terminate, as described in Chapter 3. At the same time, assembly of splicing 
component may also take place during this stage14,15, preparing Pol II for an efficient 
splicing of the first intron as proposed in Chapter 4. If this stage is short, Pol II will 
appear less paused, but at the same time, splicing of the first intron would be less 
efficient, causing more exon skipping. 
Fourth stage is the pause escape, triggered by the recruitment of P-TEFb3. P-
TEFb phosphorylates Pol II CTD at Ser2 and the pausing factors16. The modification 
and release of the pausing factors release the Pol II from pausing. Immediately after 
the pause escape, Pol II elongates but not at its full speed. Other functions Pol II may 
still be ‘immature’ right after the pause escape. For instance, splicing is less efficient 
and there are more exon skips in regions immediately downstream of the TSS relative 
the regions more into the gene bodies as shown in Chapter 4. Assembly of additional 
factors to the elongation complex may still take place at this stage. 
Fifth stage is the productive elongation. Pol II accelerates and reaches a 
constant maximum speed in the body of the gene. Pol II function is ‘mature’; splicing 
is efficient and there is undetectable amount of termination in the gene body unless 
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there are specific regulatory sites that cause alternative splicing or premature 
termination17. 
 
Perspective 
The results contained in this dissertation have two major implications. First is 
on the basic mechanisms of transcription. Pol II pausing and elongation is among the 
major topics in the study of eukaryotic transcriptional regulation. The newly 
developed technologies, detailed dissection of the mechanisms of the early Pol II 
kinetics, and in-depth analysis of elongation rates with its linkage to splicing which 
were presented in Chapters 2 through 4 broadens the perspective of studying how Pol 
II elongations. For instance, the role of the components of the initiation complex such 
as TFIID subunits can be extensively studied using high resolution Pol II mapping. 
Associations of co-transcriptional processing machinery - capping or splicing factors - 
with pausing, elongation rates, and termination can be another set of questions that 
remains to be answered. 
Second is on the possible application of the method and the basic mechanisms 
to more translational biomedical research. The methods described in Chapter 5 are 
expected to open up a new possibility of conveniently analyzing the statuses of Pol II 
regulation in a large scale. It may not be restricted to studying the mechanisms of Pol 
II elongation, but may also be applied to approaching the transcriptional identity of 
cells or tissues from a different perspective. For instance, we could identify novel 
transcriptional units that may have regulatory roles rather than protein coding function. 
The collection of these new genomic elements will make the analysis of 
transcriptional statuses deeper and more complete. Coupled to computational analysis 
and modeling, accumulation of the database may lead into a potential use of 
transcriptional analysis technologies for diagnostic purposes. 
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